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Abstract 
 
Abstract 
This thesis examines issues related to cervical cancer epidemiology and prevention 
through screening, with the aim of informing policy regarding setting up an organised 
cervical screening programme in Hong Kong.  
There are five studies described here. The first, a case control study, indicated that 
screening is effective in preventing invasive cervical cancer among Chinese women. 
In addition, the main risk factors identified in other studies, were confirmed as risk 
factors in this population.  
Secondly, a cross-sectional study examined the pattern of cervical screening in Hong 
Kong. The screening system at that time achieved poor coverage, was inefficient, 
inequitable and potentially harmful. 
Thirdly, a cross-sectional study of practitioners showed the diversity in provision of 
services and the lack of consensus among practitioners in the management of 
abnormal smears. 
Fourthly, the use of an industrial quality management technique in monitoring quality, 
using inadequate smear rates as an indicator is assessed. It demonstrated that this is an 
efficient and useful method that can be applied to monitoring a screening programme. 
The last study was a randomised controlled trial showing that when women are given 
balanced information on cervical screening, with information on both the harms and 
benefits, relatively fewer chose to attend. 
The implications of these studies in relation to setting up a screening programme are 
discussed. 
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Overview 
-1- 
INTRODUCTION AND OVERVIEW OF THESIS 
This thesis examines issues related to cervical cancer epidemiology and prevention 
through screening, based on studies completed in Hong Kong and England. It consists 
of a series of research study reports, all on the same theme: cervical cancer screening. 
These include a case control study and two cross-sectional studies in Hong Kong, and 
another cross-sectional study and pilot randomised controlled trial in the UK. Each 
study examines an aspect of cervical cancer screening, focusing on informing policy 
in Hong Kong. Hong Kong is a special administrative region in China, with relatively 
high cervical cancer incidence, and no organised centralised screening programme
1
. 
However, the government are currently discussing setting up such a programme in the 
near future (planned for 2004). 
 
When setting up any screening programme, certain principles must be considered. A 
comprehensive set of principles was suggested by Wilson and Jungner in the 1960‟s2 
and remains widely used to this day. In the UK, the National Screening Committee 
have adopted and added to these
3
. In brief, these relate to the condition for which 
screening is performed, the screening test applied, the treatment options for those with 
positive test results and aspects of the programme itself. In relation to the condition, 
this should be an important health problem, with a recognisable latent stage and the 
natural history of the disease should be understood. In relation to the screening test, 
this should be suitable and acceptable. The treatment should be based on an agreed 
policy, be acceptable to patients, and there needs to be adequate facilities for 
diagnosis and treatment. This dissertation examines most of these criteria (all except 
last two) in relation to cervical screening in Hong Kong, and these are discussed in the 
final chapter. The thesis is divided into 6 chapters as follows: 
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Chapter 1 
This background chapter describes the epidemiology of cervical cancer world wide, 
and within Hong Kong. It provides a summary of the pathology, incidence and 
prevalence, geographical variation and secular trends in disease occurrence. The 
major risk factors for disease and approaches to prevention are discussed. Finally 
there is an overview of cervical cancer screening, outlining the evidence of 
effectiveness, the components required for an effective screening programme and 
current screening policy in Hong Kong. The contents of the chapter are based on a 
review of the literature and summary of routine data sources relating to cervical 
cancer incidence and mortality. In relation to the overall aims of the thesis, it provides 
information on the importance of, and natural history of cervical cancer, the 
availability of the screening test and evidence on the effectiveness of screening. 
 
Chapter 2 
The chapter describes a matched case control study of cervical cancer in Hong Kong. 
The study consisted of 98 cases (women with incident invasive cervical cancer) and 
294 matched controls (matched for age, social class and district of residence). The 
aims of the study were to identify the major risk factors for disease among Hong 
Kong women and to assess the effectiveness of screening. The chapter includes a 
discussion of the role of case control studies in assessing the effectiveness of 
screening and discussion on risk factors for cervical cancer. In relation to screening 
policy, the contents of this chapter provide local data to contribute to the evidence on 
the effectiveness of screening. Identification and awareness of the major risk factors 
allows policy makers to institute primary preventive measures in addition to screening 
Overview 
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(e.g. smoking control programmes). It also identifies the population at higher risk, that 
could be targeted for screening. 
 
Chapter 3 
This chapter forms the main bulk of the thesis, being the largest and most resource-
intensive study reported in this thesis. It comprised a cross-sectional telephone survey 
of 1,826 women in Hong Kong, and examined the pattern of cervical cancer screening 
in this population. The main aim of the study was to assess the coverage of screening 
among women in different age groups in Hong Kong. In addition, it aimed to assess 
women‟s knowledge and attitudes towards screening, and sought factors associated 
with uptake and barriers to screening. The equity of screening uptake, in relation to 
epidemiological risk factors, and the relationship between risk perception and risk 
factors and screening were also examined. Finally, a model was developed to assess 
the effectiveness and efficiency of the current pattern of screening in terms of the 
number of cases of cancer potentially prevented, and the number of screening tests per 
case prevented respectively. The model was also used to compare the current system 
with the level of effectiveness and efficiency that would be expected if different 
policies for organised screening were applied.  
In relation to screening policy, this chapter enables policy-makers to compare the 
status quo – ad-hoc screening – with what could be achieved if a centralised organised 
screening policy were introduced. It also identifies what the main barriers currently 
are to women attending for screening, and what incentives could encourage and 
increase uptake. 
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Chapter 4 
This chapter gives a basic description of the way cervical screening is currently 
provided in Hong Kong. A cross-sectional study of practitioners involved in cervical 
screening in Hong Kong was conducted to determine the attitude of practitioners, and 
the way services are organised and provided. Given that Hong Kong has no 
centralised cervical screening programme, and there is a mixed medical economy, this 
chapter provides a summary of the main providers, their beliefs, and their clinical and 
administrative procedures for cervical screening. The chapter also cross-references 
with the cross-sectional study of women reported in chapter 3, comparing 
practitioners and women‟s views in relation to barriers and factors influencing 
screening uptake. Practitioners‟ reports of how services are provided were compared 
to the women‟s reported experience. In relation to policy, this chapter emphasises the 
potential problem of obtaining consensus and agreed policies, when there are multiple 
providers with no centralised programme. 
 
Chapter 5 
The focus of this chapter is the monitoring and quality control aspects of a screening 
programme. The chapter introduces the literature on continuous quality improvement 
and the use of these techniques in healthcare. In particular, the use of statistical 
process control (SPC) is discussed, and its application to monitoring one aspect of the 
cervical screening programme is demonstrated, using inadequate smear rates as an 
indicator of quality. This is based on a study of inadequate smear rates across general 
practices in Birmingham, UK.  The study involved the use of control charts to identify 
practices with persistently high or low inadequate smear rates, and an investigation of 
possible procedures contributing to these. In relation to policy, the chapter emphasises 
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the importance of monitoring and quality control, and suggests a method that could be 
used for achieving this. 
 
Chapter 6 
This chapter examines some of the ethical issues related to screening, namely, of 
obtaining informed consent. In countries with organised screening programmes, there 
has been much emphasis on achieving high coverage. The benefits of screening tend 
to be overemphasised, without much regard to giving participants full information on 
all outcomes of the screening process. Therefore information on screening has usually 
not been fully balanced. This chapter is based on a pilot randomised controlled trial. 
This compared the effects of the current information sheets on cervical screening 
provided by the NHS, with one containing more information on benefits and harms, 
on women‟s intended screening uptake. This chapter should encourage policy-makers 
to consider the consequences of having a screening programme, and to balance a 
utilitarian approach with one where the emphasis is on individual informed choice. 
 
Chapter 7 
This final chapter provides a summary of the previous chapters, drawing out the main 
findings and implications in relation to developing a cervical screening programme in 
Hong Kong. 
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Aims and objectives of thesis 
The aim of the thesis was to review the current state of cervical cancer screening in 
Hong Kong and to consider the pros and cons of introducing a centrally organised 
cervical screening programme, instead of the current ad hoc system. 
 
In each chapter specific objectives for the study are described. However, for the 
overall thesis, the main objectives included: 
 To review the epidemiology of cervical cancer in Hong Kong (chapters 1 & 2) 
 To review the effectiveness of cervical cancer screening (chapters 1 & “) 
 To assess the pattern of cervical cancer screening in Hong Kong (chapter 3) 
 To determine the way cervical cancer screening services were organised and 
provided (chapter 4) 
 To assess the use of statistical process control for monitoring cervical 
screening (chapter 5) 
 To consider the information needs of women invited for cervical screening, 
and assess the effects of information on intended screening uptake (chapter 6) 
 To use the above information in suggesting pros and cons of introducing an 
organised cervical screening programme in Hong Kong (chapter 7) 
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1 CERVICAL CANCER EPIDEMIOLOGY 
1.1 Summary 
Cervical cancer is an important preventable cause of morbidity and mortality among 
women worldwide. This chapter briefly reviews the epidemiology of cervical cancer, 
focusing on Hong Kong and explores the evidence on the effectiveness of cervical 
screening. 
 
Epidemiology of cervical cancer 
Cervical cancer is the third most common female cancer worldwide. It progresses 
from pre-invasive cervical intraepithelial neoplasia, through to invasive disease over a 
period of about 10 years. Disease incidence increases with age, reaching a peak 
around 60 years. Incidence varies widely in different countries, ranging from around 3 
to over 40 per 100,000. The higher incidence rates are seen mainly in developing 
countries, particularly in Africa, and the lowest rates occur in western Europe and 
west Asia. Overall, there has been a declining trend in cervical cancer incidence over 
time in most countries. However, this trend is less obvious in some developing 
countries. Furthermore, some regions in developed countries have seen an increase in 
rates in younger women.  
 
Risk factors 
The main risk factor for cervical cancer is infection with human papilloma virus 
(HPV). Thus, other behaviours that increase risk of this sexually transmitted agent 
also increase risk of disease. In addition, use of the oral contraceptive pill and 
smoking have also been shown to increase risk. Cancer incidence has also been shown 
to be higher among women in lower socio-economic groups and in those with lower 
levels of education. 
 
Screening 
There is good evidence from observational studies that screening is effective in 
reducing incidence and mortality from cervical cancer. Countries with centrally 
organised screening policies with good coverage have seen significant reductions in 
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disease incidence since their introduction. A 3-yearly screening programme is 
estimated to reduce incidence by over 90%. 
 
Cervical cancer and screening in Hong Kong 
Hong Kong has a relatively high incidence rate of cervical cancer (10 to 15 per 
100,000) compared with most developed countries (1 per 100,000) and over half the 
cases occur in women under the age of 65. There is no organised screening 
programme, though screening is offered on an ad hoc basis. There have been few 
studies of the effectiveness of the current system of screening in Hong Kong. 
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1.2 Introduction 
Cervical cancer is an important public health problem, being the third most common 
female cancer (9.8% of all cancers) world-wide
4
. There are almost 400,000 new cases 
of cervical cancer diagnosed each year, about a third of which occur in southeast and 
central Asia
4
, which includes the region of interest in this thesis. There is some 
evidence that effective prevention can be provided by organised health screening 
services
5
 and death from the disease, particularly in younger women, should be 
avoidable
6
. Yet for several reasons (discussed later), this potential has not been 
achieved.
7
 This chapter will review the basic epidemiology of cervical cancer, 
focusing on the descriptive epidemiology of the disease in Hong Kong, and provide 
an overview of risk factors and strategies for prevention. 
  
1.3 Pathology and natural history  
There are two main types of cervical cancer: squamous cell carcinoma (SCC) and 
adenocarcinoma (ACC). SCC is the more common type of cancer, accounting for 
about three quarters of all cases
8
. Long term studies suggest that invasive disease 
arises as a consequence of progression from mild dysplasia through severe dysplasia 
to carcinoma in situ
9; 10
. These precursor lesions are also known as cervical 
intraepithelial neoplasia (CIN), and represent various degrees of disordered cell 
maturation in the cervical epithelium. A definitive diagnosis of CIN can only be made 
by biopsy of suspicious lesions and histological examination. However, cervical 
cytology, first proposed by Dr. George Papanicolaou in the 1940‟s11, is a screening 
tool for identifying abnormalities initially.  There are several systems for classifying 
cervical cytology, all derived from the original Papanicolaou system
7
. The original 
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classification consisted of five classes, ranging from normal, to invasive carcinoma 
(Table 1). The Reagen system, later adopted by the WHO, divides abnormalities into 
mild, moderate and severe dysplasia, and carcinoma-in-situ (CIS)
12
. Richart 
introduced a classification system which used the same terminology as the 
histological changes, with different grades of cervical intraepithelial neoplasia (CIN I 
to III)
13
. More recently, the Bethesda system classifies lesions as low- or high- grade 
squamous intraepithelial lesions, LGSIL or HGSIL
14
. It also includes one group of 
lesions characterised by “atypical squamous cells of uncertain significance” 
(ASCUS).  These cytological findings are associated with a variety of histological 
abnormalities on subsequent biopsy.  
 
There is little information on the natural history of cervical cancer. Few cohort studies 
offer useful information because of treatment offered following diagnosis of CIN, 
short follow up and poor methodologies. However there are few well-conducted 
studies. These show that mild dysplasia (CIN I) frequently regresses to normal, as do 
half of those with moderate dysplasia, whereas CIN III once established, is less likely 
to undergo spontaneous regression
15
. Most regressions occur within 2 years of 
diagnosis of the dysplastic smear. One study found that about one in ten (9.9% [95% 
CI 8.2 – 11.6]) women with mild dysplasia on cytology, progressed to severe 
dysplasia or worse within 10 years, whereas almost a third (32.0% [95% CI 29.0 – 
34.9]) of those with moderate dysplasia did so
10
. In another study, up to three quarters 
of cases of CIN I or II progressed to CIN III and 10-16% of all cases progressed to 
invasive cancer after 9 years follow-up
16
. As in the other study, those with more 
advanced lesions were more likely to progress to invasive cancer, whereas those with 
CIN I mainly did not. The number of cases of dysplasia diagnosed, far exceed the 
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number of cases of invasive cancer
17; 18
. For every case of invasive cervical cancer, 
there are approximately four cases of in situ carcinoma and more than 10 cases of pre-
invasive dysplasia
19
. This supports the idea that not all cases progress, and suggests 
that the natural history of disease is not fully understood. 
1.4 Presentation, clinical features and staging 
The pre-cancerous lesions, CIN, are asymptomatic and usually detected through 
screening or a pelvic examination. Invasive disease can also be asymptomatic, but the 
first and most common symptom is abnormal vaginal or post-coital bleeding
20
. There 
may also be increased vaginal discharge. Symptoms of more advanced stages of the 
disease include pelvic pain resulting from tumour extending into the pelvic wall, 
incontinence or haematuria resulting from pressure on the bladder, or constipation 
from pressure on the rectum.  
The most common diagnostic test for cervical cancer is cervical cytology, the same 
test that is used for screening. If the cytology result is abnormal, or if there are other 
indications, other more invasive investigations may be carried out to confirm the 
diagnosis. These include colposcopy, endocervical curettage and directed biopsy. For 
CIN, treatment is almost 100% curative and is usually carried out as an outpatient 
procedure
21
. The main forms of treatment for CIN include cryotherapy, laser 
vaporisation and laser electrosurgical excision procedure (LEEP)
21
.  
If invasive disease is diagnosed, staging is based on various features such as tumour 
size, spread, and type of cells (Table 2)
21
. Prognosis varies according to stage and 
extent of spread. Five year survival for stage IA disease exceeds 95%, whereas for 
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stage IV disease it is less than 20%
21
.  Treatment also varies according to stage, and 
includes hysterectomy, radiotherapy and chemotherapy (Table 2). 
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Table 1: Classification schemes for cervical cytology 
 
 
Classification 
system 
 
Cytology classification 
 
Bethesda 
system 
Normal Infection 
Reactive 
repair 
 
ASCUS Squamous intraepithelial lesions (SIL) Invasive carcinoma 
Low grade (LSIL) 
 
High grade (HSIL)  
Richart   Condyloma Cervical Intraepithelial Neoplasia (CIN)  
 
CIN I CIN II CIN III  
 
Reagen 
(WHO) 
Negative Atypia Mild dysplasia Moderate dysplasia Severe 
dysplasia 
Carcinoma 
in situ (CIS) 
 
Papanicolaou 
 
I II III IV V 
 
Source: Adapted from reference 
22
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Table 2: Staging system for invasive cervical cancer and recommended treatment 
Stage Treatment 
Stage 0 Carcinoma in situ - abnormal cells only on surface epithelium of cervix, not yet 
invaded deeper tissue. 
See text 
Stage 1 Cancer strictly confined to the cervix.                                                                                                         
Stage IA Invasive cancer identified only microscopically. 
Simple hysterectomy  
Stage IB Clinical lesions (lesions that can be seen without a microscope) confined to cervix.  
Stage II Cancer extends beyond cervix, but not extended onto pelvic wall.                                                                                                                                                    
Stage IIA Cancer spread to upper part of vagina, but no obvious parametrial involvement.                 
Radical hysterectomy with 
pelvic node dissection or 
external beam and 
intracavity radiotherapy 
Stage IIB Obvious parametrial involvement.  
Stage III Extended onto the pelvic wall or to the lower third of the vagina.                                                           
Stage IIIA No extension onto the pelvic wall, but involvement of lower third of vagina                              
Stage IIIB Extension onto the pelvic wall or blocked urine flow.  
Pelvic radiotherapy 
Stage IV Extended beyond true pelvis or clinically involved mucosa of bladder or rectum.            Chemotherapy with or 
without pelvic radiotherapy 
 
Source: reference 
21
 
1.5 Incidence and prevalence  
There is wide variation in the reported incidence and mortality from invasive cervical 
cancer between populations (Figure 1). Reported incidence ranges from 67/100,00 in 
the African population of Zimbabwe, to 3/100,000 for the non-Jewish population of 
Israel, during the same time period
23
. The incidence of invasive cervical cancer is 
highest in Central America, Sub-Saharan Africa and Melanesia
24
, whilst in most 
developed countries, the rate is around 11 per 100,000
4
. Apart from differences in 
diagnostic and reporting patterns, the two major factors contributing to this variation 
are considered to be differences in sexual practices, and differences in access to 
organised cervical cancer screening programmes. There is good evidence that sexual 
behaviour patterns such as the age at first intercourse and the number of lifetime 
sexual partners of the woman and of her husband, play an important role in the 
aetiology of cervical cancer (see section 1.7.2 on risk factors). These practices 
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determine the woman‟s risk of acquiring sexually transmitted disease and customs 
vary over time and between population groups. Thus certain population sub-groups, 
such as nuns and groups with strict practices of abstinence and monogamy have long 
been noted to have very low rates of cervical cancer
25
. In contrast populations with 
higher rates of sexually transmitted diseases, reflecting a greater level of extra-marital 
sexual activity, have higher mortality from cervical cancer
26
.  
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Figure 1: Incidence and mortality rates (per 100,000 women) of invasive cervical cancer 
Adapted from Ferlay et  al
24
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1.6 Trends 
Comprehensive studies of international trends in the incidence of cervical cancer 
during the period 1973 to 1991 have shown that there has been a general decline in 
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incidence over time in most countries (based on 60 population based cancer registries 
in 25 countries) 
8; 27
. Similarly, in the last few decades the overall mortality from 
cervical cancer has been falling in many countries
28
. This decline in both incidence 
and mortality, which is almost confined to developed countries, is generally attributed 
to the introduction of cervical cancer screening in these countries. However, changes 
in exposure to sexually transmitted diseases (STDs) may be another explanation. For 
example, in parts of China, where there has been a decline in mortality from cervical 
cancer over two decades, there is some evidence (based on an ecological study) that 
this was strongly related to a fall in risk of exposure to STDs after 1949
29
.  
However, if we examine trends in relation to histological type, the picture is even 
more complicated. For SCC, while manycountries have seen a general decline in 
incidence over time, there were a few exceptions, including the UK, Slovakia and 
Jews born in Israel. In these populations, an increase in incidence of SCC of the 
cervix was observed, predominantly in the younger age groups
8
. This was thought to 
be related to changes in sexual practice, and an increase in exposure to STDs and poor 
screening services
8
. In the UK, the increasing trend has started to stabilise and reverse 
in the last few years (see section 1.8.1 on screening for further discussion). For ACC, 
there has been a significant increase in the cumulative incidence in women born in the 
mid-1930s and in successive cohorts thereafter (age 25 – 49) in many parts of the 
world, including the United States (whites and Hispanic women), Australia, New 
Zealand, UK, Denmark, Slovenia, Slovakia and Japan (Osaka) and among Chinese 
women in Singapore
27
. At the same time, there has been a general decline in the 
incidence in women born in earlier periods. The reasons for this increase are not clear, 
but it may be partly attributed to an increasing prevalence of STDs, and hence human 
papillomavirus infection, to improvements in screening, which is less effective for 
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detecting ACC (see discussion on screening below – section 1.8.1) and to increasing 
use of the oral contraceptive pill. 
1.7 Risk factors 
There has been extensive epidemiological research to determine the factors 
underlying the aetiology of cervical cancer and CIN. Most studies do not differentiate 
between histological types when assessing risk factors. A geographical comparison 
across 60 cancer registries worldwide has shown high correlation  (r = 0.60, p<0.001) 
between the age-adjusted incidence rates for SCC and ACC, despite large differences 
in overall rates in different countries
27
. This suggests similar risk factors for both 
pathological types, and this is confirmed in some epidemiological studies
30; 31
.  
However, other studies have suggested that the aetiology of ACC may differ to some 
extent from that of SCC
30; 32-35
.  The main risk factors that have consistently been 
shown to be associated with invasive disease in various studies are discussed below. 
The primary aetiological factor in cervical cancer and CIN, based on both 
epidemiological and molecular studies, is thought to be infection with human 
papillomavirus (HPV)
36; 37
. HPV is implicated in the aetiology of both squamous and 
adenocarcinoma of the cervix
38; 39
. Almost every case of invasive cervical cancer 
worldwide contains HPV DNA
40
. The time lag between infection and development of 
invasive cervical cancer is thought to be about 15 years
15
. Of over 70 types of HPV, 
four (particularly HPV 16, 18, 45 and 56) are associated with 75% of cancers
41
. 
However exposure to HPV in young sexually active women is very common and 
infection with oncogenic viral types (lifetime risk is around 79%)
42
 exceeds the 
number of cases of invasive cancer. Therefore other co-factors must play a part in 
cervical carcinogenesis.  
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1.7.1 Sociodemographic factors 
The incidence of cervical cancer increases with age, starting to rise in women between 
the age of 30 and 35 in most countries, and reaching a peak at about 50 to 60 years. 
Both pathological types show the same pattern of age-specific incidence
27
. The 
disease is more common amongst women from lower socio-economic groups
30; 34; 43-45
 
and low levels of education
46
. This may be partly explained by a higher rate of HPV 
infection in this group
47
.  
Initial studies suggested that unlike SCC, adenocarcinoma was more common in 
women of upper socio-economic groups
48
. However, later studies have not confirmed 
this, and have shown that AC is also associated with lower social class and with lower 
levels of education
30; 34; 45
. 
 
1.7.2 Reproductive and sexual risk factors 
Some of the risk factors discussed below are now thought to be proxies for HPV 
infection, though others are likely to be co-factors in HPV progression.  
The lifetime number of sexual partners 
Behaviours that put women at risk for sexually transmitted diseases, also increase the 
risk of HPV and therefore of cervical cancer
49
. Thus, women who report three or more 
lifetime sexual partners have a two to three fold increased risk of developing cervical 
cancer compared to those with only one partner. The risk increases to nine fold for 
women reporting 10 or more partners. The relationship between cervical cancer and 
the number of sexual partners is seen for both histological types.  
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Use of oral contraceptives  
Several studies have shown a relationship between use of the oral contraceptive pill 
(OCP) and both CIN and cervical cancer
50
, particularly with increased duration of use 
(more than 5 years). Recent use of OCP (within 10 years) has shown to increase the 
risk of cervical cancer 2.5 fold in a large cohort study of 46,000 women followed up 
for 25 years
51; 52
. However, not all studies have consistent results. One case control 
study showed an increased risk among women taking the OCP
53
 which was 
significant and positive for adenocarcinoma, but only weakly positive for SCC. The 
observed association weakened after adjusting for HPV and screening, though 
remained for ACC in situ. Another study showed that after adjusting for HPV, the 
association between OCP and cervical cancer disappeared
54
. The majority of studies 
suggest that the increased risk is for ACC only
35; 55
.  This is suggested as an 
explanation for the increasing incidence in ACC among young women in many 
developed countries 
27; 30; 56-58
. 
 
Other hormones and cervical cancer  
Use of non-contraceptive hormones may also be associated with the risk of 
developing cervical cancer. In one case control study including 645 women aged 40-
75 years, with invasive cancer in Italy, use of hormone replacement therapy (HRT) 
was associated with a reduced risk of cervical cancer
59
. However, a study that 
differentiated between the histological types of cervical cancer showed that risk was 
increased for adenocarcinoma, whereas there was a weak negative association with 
squamous carcinoma
60
.  
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Other sexual and reproductive factors 
Sexual history, including high parity, early age at first birth and at first sexual 
intercourse have all been shown to be related to cervical cancer. Studies that have 
adjusted for HPV show that some of these associations lose significance after 
adjustment
61
, suggesting that they are confounders. The evidence on the association 
between ACC and reproductive risk factors, such as high parity, early age at first birth 
or number of abortions is conflicting
30
. Studies that have examined these associations 
have generally been small and not always adjusted for other confounding factors. 
1.7.3 Lifestyle factors 
Smoking and cervical cancer 
The association between invasive and pre-invasive cervical cancer and smoking has 
been debated for over 20 years. A review of observational studies concluded that there 
was sufficient evidence to support a causal association
62
. This was based on the fact 
that such an association was found in almost all published studies, particularly among 
heavy smokers. A formal meta-analysis based on all published case-control studies in 
English from 1977 to 1990, estimated a weighted OR for cervical cancer of 1.4 (95% 
CI  1.33 – 1.51) for ever smokers compared to never smokers63. Generally, smoking 
increases the risk for cervical cancer one and half to two-fold, the risk increasing with 
the amount and duration of smoking
62
. Furthermore, there is evidence that smoking 
cessation facilitates regression of CIN, supporting a causal mechanism
64
. There are 
several plausible biological mechanisms to support a causal association between 
smoking and cervical cancer.  Researchers have postulated that smoking has an 
immunosuppressive effect, as shown by a lower numbers of Langerhans‟ cells in the 
cervical epithelium of smokers with cervical cancer
65
. This could potentiate the effect 
Epidemiology 
-22- 
of HPV in cervical carcinogenesis. Furthermore, high levels of smoke derived 
cotinine and nicotine have been found in the cervical mucus of smokers
66-69
. 
Some researchers have suggested, however, that the observed association between 
smoking and cervical cancer may be due to residual confounding, particularly due to 
HPV infection
70
. Indeed, one case control study showed that the association between 
smoking and cervical cancer was weakened after adjusting for infection with HPV
43
.  
Another showed that the association between smoking and cervical cancer 
disappeared after adjustment for age and social class
71
. More recent studies however, 
have found that even after adjusting for HPV and other factors, smoking remains a 
significant risk factor for squamous carcinoma of the cervix
54; 72
. Smoking has also 
been shown to be an independent risk factor for high grade CIN, after adjusting for 
HPV
73
. 
Smoking is generally more strongly associated with squamous cell carcinomas than 
with adenocarcinomas for numerous cancer sites
74
. Most studies have found no 
association between smoking and ACC
30; 32; 34; 45; 75; 76
.  
With SCC, many of the aetiological studies have included women with carcinoma-in-
situ as the only or predominant group, rather than those with invasive cancer. One 
study that compared risk ratios for the two groups, found that the association with 
smoking was slightly stronger for invasive SCC (OR for current smoking = 3.0) 
compared with carcinoma in situ (OR = 2.6)
72
.  
Some studies suggest that smoking is a risk factor for cervical cancer only in younger 
women
42; 77
. A study of women in Utah, found that the risk estimate for cervical 
cancer among young smokers was greater than among older smokers (OR 6.81 for 
women under 30, compared with 2.30 for those over 40)
77
. Similarly a Swedish study 
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showed higher risk estimates for women under the age of 45 years (OR 2.61 
compared with 0.81 for older women)
42
. A possible hypothesis for this difference in 
age-related risk is that smoking has an anti-estrogenic effect
42; 78
. However, two other 
case control studies undertaken in Italy and the UK, to examine risk factors for 
cervical cancer in young women under the age of 40 and 45, showed that smoking 
was not related to disease in this age group
79; 80
.  A possible explanation for the lack 
of association in this younger age group is that smoking may act at the start of the 
process of carcinogenesis and therefore require a longer time to have a measurable 
impact on cervical cancer risk. This is supported by the finding of increased risk with 
increasing pack years of exposure
72
. Another view is that smoking facilitates HPV 
effects, particularly for less aggressive viral strains. Cervical cancer in young women 
is more likely to be due to more aggressive viral strains, and therefore the effect of 
smoking would be negligible argues against increased risk in young women. 
Although there is much evidence on the association between smoking and increased 
risk of cervical cancer, little has been published on the association between passive 
smoking and disease. A case control study exploring the relationship between passive 
smoking and CIN, found no effect
81
. This study, based on 103 cases and 268 controls 
in the US, showed a strong relationship between active smoking and high grade CIN, 
but no relationship between exposure to passive smoke and disease among smokers 
and non-smokers. However, 70% of the cases in the study were active smokers, 
leaving relatively few never smokers. Another study in the US, based on 212 cases 
(30% of whom smoked) and 330 controls, did show an increased risk with increased 
exposure to passive smoking
77
. This was a well-conducted case control study, but 
limited to white women, predominantly with CIS and some with invasive squamous 
cell carcinoma of the cervix. The study showed a significant dose-dependent 
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relationship between exposure to passive smoking and disease, which diminished, but 
persisted after adjusting for age, education, number of sexual partners and church 
attendance. The strength of this study was its‟ fairly robust exposure assessment, but it 
was limited in its study population. 
Nutritional status 
Studies about nutritional factors and both cervical cancer and CIN are conflicting. 
Some have shown that micronutrients such as folic acid, vitamins A, E, C and β-
carotene confer a protective effect
82-86
, while other studies have not
54; 87-89
. Other 
factors that have been suggested as risk factors include coffee drinking and a high 
intake of dairy products
54
. 
Weight gain 
Unlike SCC, adenocarcinoma is associated with weight gain in early adult life, a risk 
factor for endometrial carcinoma
30
. However, it differs from endometrial carcinoma, 
in that OCP use is protective in the latter, but increases risk in the former. 
 
1.7.4 Summary 
Many sociodemographic, sexual and lifestyle factors have been implicated as 
potential risk factors for cervical cancer. However, much of the evidence is 
conflicting. In general, there is consistent association between low socio-economic 
status and increasing number of sexual partners, and increasing risk of cervical 
cancer. There is also a consistent and strong association between smoking and SCC 
and use of the OCP and ACC. However some of the risk factors (e.g. low socio-
economic status or smoking) may be at least partly acting as proxies for HPV 
infection. 
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1.8 Prevention 
Primary prevention of CIN and therefore cervical cancer could theoretically be 
achieved, primarily through interventions to prevent or treat HPV infection. However, 
HPV infection is asymptomatic, and easily transmitted and therefore usually not 
detected.  Furthermore, there are currently no treatments to eliminate the infection 
once it is established. Some researchers are working on developing vaccines against 
HPV, which may be a primary preventive strategy in future
20; 90
. However, even when 
a vaccine is developed, issues such as safety, effectiveness and programme 
implications would have to be clarified. These approaches to primary prevention are 
therefore not feasible in the foreseeable future. Nevertheless, several features of 
cervical cancer make it an ideal target for a screening programme. It has a long pre-
invasive phase that may extend 10-15 years
91
. A safe, widely acceptable and 
inexpensive test, the Papanicolaou (Pap) smear, is available to detect early stage 
disease and effective treatment of early stage lesions can be accomplished with 
minimally invasive techniques
91
. When setting up any screening programme, the 
importance of considering both the scientific validity and overall benefits, and 
establishing cost-effective, ethical and equitable policies for population screening are 
increasingly recognised. Although insufficient evidence is available to support the 
provision of most screening procedures at a population level, cervical screening is one 
which has been shown to be highly effective and is well established in many 
countries
91
.  
1.8.1 Screening for cervical cancer  
Cervical cancer screening programmes usually screen using the Pap smear. This 
involves scraping cells from the cervix, fixing and staining them on a glass slide and 
having them evaluated by a trained cytologist. Other screening methods are possible, 
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but are either less effective (e.g. visual inspection with or without acetic acid
92
), or not 
yet evaluated. There has been growing interest in the use of HPV testing as a primary 
screening tool. However, a comprehensive review of the evidence by the Health 
Technology Assessment Committee of the UK DoH, suggests that further research is 
needed before this can be implemented
93
. HPV testing has been shown to be more 
sensitive than cytology screening, but it has low specificity, particularly in younger 
women.  
Evidence on screening for cervical cancer 
Although there have been no randomised controlled trials to determine the efficacy of 
the Pap smear as a screening test, there is much evidence of its value. This comes 
mainly form historic studies describing the effects of the introduction of well 
organised screening programs
94-97
, and case control studies. These clearly show that 
organised screening results in a reduction in both the incidence and mortality from 
invasive cervical cancer. Some of the Nordic countries (Finland, Iceland and Sweden) 
have had nation-wide “population based organised” screening programmes since the 
1960s. In these countries, the protective effect of two or more smears is clearly 
demonstrated
98
 and deaths from cervical cancer have reduced by 80%
91
. There is a 
strong correlation between increasing intensity of screening and reduction in the risk 
of cervical cancer
99-101
, lending support to a causal effect.  
Screening interval 
The extent of risk reduction is partly dependent on the screening interval. Data from 
large screening programs in European and North American centres has been analysed 
by a working group of the International Agency for Research on Cancer (IARC) and 
used to quantify the reduction in the probability of developing cervical cancer with 
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varying screening intervals
102
 (Table 3). These results agree very closely with 
estimated reductions in incidence from mathematical models
103
. The information is 
also adopted by other agencies, including the World Health Organisation Western 
Pacific Regional Office
104
, as a basis for some of their recommendations. The relative 
protection against cervical carcinoma in women with two or more previously negative 
smears have been estimated to be 15.3 after 0-11 months and 6.6 after 60-71 months 
when compared to women never screened. Protection was no longer apparent after six 
years however.   
 
Table 3: Percent reduction in cumulative rate of invasive cervical cancer in women 
screened from age 35 to 64 at different frequencies 
Interval between screenings 
(Years) 
Reduction in cumulative 
incidence (%) 
Number of tests 
1 93.5 30 
2 92.5 15 
3 90.8 10 
5 83.6 6 
10 64.1 3 
Assuming the woman has had at least one previous screen 
Source: reference
102
 
 
The table shows that screening in intervals of one to three years amongst women of 
35-64 years accomplishes about the same effect. Furthermore, even screening once 
every 10 years reduces the incidence of invasive cancer by almost two thirds. An 
analysis of the benefits of screening in the elderly, assuming there was no harm 
associated, found that 80% of the benefit for cervical cancer screening is achieved 
before the age of 65
105
. By the age of 75, non-attendance for screening will result in a 
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maximum of 3 days of life lost, whilst by the age of 80, a maximum of 1.5 days would 
be lost. 
There is much debate about the optimum screening interval, but several cohort
102; 106; 
107
 and case control studies 
108-110
suggest that intervals of one, two or three years offer 
similar levels of protection. Different countries have different screening policies, with 
organised programmes offering screening intervals of between 1 and 5 years. Annual 
screening is recommended as the optimum screening interval by some expert 
bodies
111
. Nevertheless, evaluation of a programme with 5 year screening interval 
showed that this was appropriate and effective in reducing the risk of invasive 
cancer
112
.  
Screening coverage  
There is some evidence that an organised programme with a wide coverage and range 
of ages is a more important determinant of risk reduction than a high frequency of 
screening
5
. At a population level, targeting women who have never had a Pap smear 
will have a much larger impact on reducing disease incidence and mortality, than 
screening more frequently those who have already been screened. There is evidence 
that older women and those with low socio-economic status, who have a higher than 
average risk for cervical cancer, are less likely to take up preventive health services
113; 
114
. This has several important implications. Increasing coverage by targeting will tend 
to attract these women more, and can therefore contribute to a reduction in health 
inequalities
115
. Furthermore, if most women attending screening are those at low risk, 
a higher proportion of false positive cases will arise, resulting in additional medical 
work, unnecessary anxiety and possibly iatrogenic disease. This also wastes scarce 
resources and reduces the cost-effectiveness of screening
116; 117
. 
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Elements of an effective screening programme  
In practice, despite the success of some screening programmes, others, such as the 
early ones in the United Kingdom and Norway, have not been successful
118
. The main 
reasons cited for such failures are poor programme co-ordination and non-
implementation of policy. In the United Kingdom resources were concentrated on 
more frequent screening of younger women, rather than trying to achieve regular 
coverage for the entire population
119
. In Norway, only a small proportion of the 
population were covered by an organised programme, and this is believed to account 
for their poor success. 
 
The essential elements of an effective cervical cancer screening programme, including 
organisation, accountability and commitment, are well documented
120
 and cases of 
invasive cervical cancer arising as a result of administrative and procedural failures 
cannot be justified in any developed country. In addition, the success of screening is 
dependent on other factors, including the provision of adequate resources and the 
adoption of quality control measures. Ensuring that smears are promptly examined 
and the results fed back accurately requires considerable resources, both in terms of 
laboratories and manpower. Amongst screening smears, over 90% of samples are 
expected to be normal, and a proportion of positive cases are likely to be missed. In 
order to minimise such false negative results independent re-screening and quality 
assessment must be an integral part of the programme
119
. Once abnormalities are 
detected, agreed guidelines for follow-up and clear lines of responsibility are 
essential. Several studies have highlighted incomplete follow-up as a problem, which 
is responsible for a proportion of cases of invasive cervical cancer
121
. Incomplete 
follow-up following screening has been reported in up to 40% of cases
122
. In one 
Epidemiology 
-30- 
study omission by clinicians and administrative errors accounted for over 90% of 
cases of documented incomplete follow-up, and only a small proportion of cases were 
attributable to the patients themselves
123
.  
Although financial and technical considerations are important, the main difference 
between effective programmes and those which fail, is in their level of organisation 
and management
118
. The recognition by the World Health Organisation that poor 
management and the implementation of inappropriate policies are responsible for the 
failure of some screening programmes, prompted the Western Pacific Regional Office 
to adopt managerial guidelines
124
. The purpose of these is to assist in the planning, 
development, management and monitoring of programmes for the early detection of 
cervical cancer.  
An organised screening programme is more likely to include women at high risk 
compared to one where screening is opportunistic
125
. There is a strong correlation 
between the organisation of screening programmes and changes in disease incidence
 
100; 101
.  
Screening and adenocarcinoma 
The aim of cervical screening is to prevent SCC, the more common histological type 
of cancer, rather than ACC. Evidence suggests that cervical smears are not sensitive 
for detecting ACC
126
. An evaluation of the screening programme in Iceland showed 
that the sensitivity of cervical smears for identifying pre-invasive SCC following a 3-
year interval was 81%, but only 42% for ACC
127
. Another case control study of ACC, 
based on screening in the 1970‟s and 1980‟s suggested that screening was ineffective 
in preventing cases
128
. This may also partly explain the increasing trend in ACC seen 
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in many countries where screening is established, whilst the incidence of SCC has 
reduced.  
1.8.2 Summary 
There is consistent evidence from observational studies across different countries on 
the effectiveness of cervical smear screening in reducing incidence and mortality from 
cervical cancer. However, there is no evidence from randomised controlled trials, and 
few studies have taken place in non-westernised countries. Effectiveness is increased 
with reducing screening interval, with over 90% risk reduction for 3-yearly intervals. 
However, at the population level, incrasing coverage of screening increases 
programme effectiveness most. Other outcomes of participation in cervical screening 
programmes (including potential harm) and considerations for setting up a screening 
programme are discussed in chapters 6 and 7. 
1.9 Descriptive epidemiology of cervical cancer in Hong Kong 
Hong Kong has had a population based cancer registry for the last 30 years. The 
registry is a member of the International Association of Cancer Registries (IACR), 
which means that it conforms to accepted standards for data collection and quality
129
. 
Each year the registry publishes information on cancer incidence in Hong Kong, by 
age and sex, though the publications are based on data that is approximately 5 years 
old.  In addition, the Hong Kong Department of Health (DH) publishes data on 
mortality from cancers, in their annual report each year. These reports have been 
published since 1989, and provide age and sex specific data for the current year. 
Therefore there is good, reliable information on cervical cancer incidence and 
mortality for at least 24 and 15 years respectively.  
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Cervical cancer is an important public health problem in Hong Kong. Compared to 
other developed countries, Hong Kong has a moderately high mortality rate for 
cervical cancer
130, and is cited as a “high risk” area for this by the International 
Agency for Cancer Research
131
 (Figure 2). In contrast, Hong Kong women are at 
lower risk of other common cancers, such as those of the breast and lung, compared to 
their counterparts in most of the Western countries
1
.  Mortality from cervical cancer 
increases with increasing age, though age-specific mortality rates have reduced over 
the last 15 years, and peak mortality has increased from around 55 in the early 1980‟s 
to over 70 years in late 1990‟s (Figure 3). Cervical cancer is the fourth most common 
cancer in Honk Kong. 
132
, in contrast to being ranked eighth in the UK in 1988
5
. There 
are about 450 to 500 new cases of invasive cervical cancer in Hong Kong each year, 
of which two thirds occur in women in the age group (15 to 64 years) where it could 
be considered “avoidable”6. Out of 159 deaths from the disease in 1999133, over half 
occurred in this age group. 
There has been little change in the overall rate of cervical cancer mortality in Hong 
Kong from the period 1982 – 1997 (Figure 4). This is mainly because rates in the 
older age group, with the highest mortality rate, have remained fairly steady, though 
there is a slight decreasing trend in recent years. In the 40 – 59 year age group, there 
has been a relatively sharp decline in mortality rate, particularly in the mid-1980‟s, 
which then levelled out. In the youngest age group (20-39 years), there are very few 
deaths in any one year to make meaningful interpretation of the trend. By calculating 
a 5-year rolling average in the mortality rate, there was a pattern of slow decline in 
mortality rate in the late 1980‟s, though there appears to be an upward trend in more 
recent years (Figure 5).  
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Figure 2: Age standardised incidence and mortality rates for cervical cancer in selected 
countries, 2001  
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Figure 3: Age-specific mortality rates for cervical cancer over three time periods 
in Hong Kong (Source: Hong Kong DH data) 
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Figure 4: Trend in age-standardised mortality rates (3-year rolling average) for invasive 
cervical cancer by age group (1982 - 1997), in Hong Kong (Source: Hong Kong DH data) 
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Figure 5: Trend in age-standardised mortality rates (5-year rolling average) for 
invasive cervical cancer for 20-39 year age group, in Hong Kong (Source: Hong 
Kong DH data) 
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The International Union Against Cancer (UICC) published a review of trends in 
cervical cancer mortality in 33 countries, over a 40-year period, based on WHO data 
(Figure 6). The mortality rates for the later years quoted in this study are slightly 
lower than those published in Hong Kong, and data prior to the 1980‟s is likely to be 
of poor quality. Therefore the graph should be interpreted with caution. Nevertheless, 
it suggests that the rate of decline in mortality in Hong Kong is similar to that seen in 
many developed countries, and steeper than that seen in developing countries such as 
Mexico.  
 
Incidence rates for cervical cancer also increase with increasing age, reaching a peak 
at around 60 to 65 years, and moderately declining thereafter (Figure 7). There has 
been a general decline in incidence rates over the last 24 years (Figure 7 and Figure 
8).  The decreasing tendency is apparent in all age groups to a similar extent. 
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Figure 6: Trends in age adjusted mortality rates for cervical cancer in selected 
countries, 1953 – 1992 
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Figure 7: Age specific incidence rates for cervical cancer, over three time periods in Hong 
Kong (Source: HK cancer registry data) 
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Figure 8: Trend in age-standardised incidence rates (3-year rolling average) for invasive 
cervical cancer by age group (1970 - 1994) in Hong Kong (Source: HK cancer registry data) 
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1.10 Cervical screening in Hong Kong 
This issue is topical and of increasing public interest in Hong Kong, as reflected by an  
article in both the Chinese and English daily press
1
. At present there is no centrally 
organised, systematic population-based cervical screening programme in Hong Kong. 
Most screening activity is either opportunistic or offered as a part of a general “well 
woman” check up by various health care providers, each with their own agenda. It is 
estimated that about two thirds of Pap smears are carried out by the Family Planning 
Association (FPA) and the Department of Health, whilst the rest are done mainly in 
the private sector (personal communication: Director of FPA).  The two main 
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providers have no locally developed policy on screening. There were also no 
guidelines from the major local medical organisations such as the Hong Kong 
Medical Association and the Hong Kong College of Obstetrics and Gynaecology 
(HKCOG) prior to this study. Subsequently, in 1999, the HKCOG has developed 
guidelines on the management of an abnormal cervical smear. In these guidelines, 
they recommend targeting screening at women with greatest risk, including those who 
have never been screened, or women not screened within 3 years.   
Health surveys by the Family Planning Association of Hong Kong in 1992, found that 
the one year coverage of screening amongst women under the age of 60 is around 
30%
135; 136
. One found that amongst women aged 15 to 60 years, 32% had a vaginal 
check up over a 12-month period
135
. The more detailed study showed that amongst 
married women of childbearing age (15 to 49 years), 30.2% had a Pap smear every 
year, whilst a further 27.7% have had a smear at some time in the past. The highest 
coverage was amongst the 30-49 year olds, whilst women over the age of 50, who are 
at highest risk of invasive tumours, had the lowest coverage (20%)
136
.  
Although these surveys contained some useful information, they had several 
limitations and there are still many unanswered questions. Neither study determined 
what proportion of cervical smears were done for routine screening, or for some other 
reason, such as investigation of menstrual symptoms. There is insufficient information 
on the frequency of screening or the equity of the present system in terms of access. 
The limited age range of the study populations means we do not know the coverage of 
screening amongst older women. In addition, there is no information on whether 
routine screening would be acceptable to women in Hong Kong, what factors affect 
the uptake and what barriers there are to screening. More research is needed to assess 
the technical and quality control aspects of screening. There is no local information on 
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the acceptability of the present arrangements for screening. Most important in terms 
of minimising the population impact of the disease, is the need to consider the most 
effective means of achieving high coverage of the population at risk. This is a major 
challenge because of the heterogeneous nature of Hong Kong‟s mixed medical 
economy. 
This thesis attempts to address some of these issues, based mainly on two studies 
conducted in Hong Kong during 1997 to 1998. 
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2 CASE-CONTROL STUDY OF CERVICAL CANCER IN HONG 
KONG 
 
2.1 Summary 
The aims of this case control study were to assess the effectiveness of screening and 
to determine the main risk factors for the disease in Hong Kong. 
 
Methods 
Cases included all women with newly diagnosed invasive cervical cancer presenting 
to three hospitals in Hong Kong over the two-year period 1997-98.  For each case, 
three matched controls were selected, from among responders to a random population 
survey on cervical screening. Controls were matched for age, social class and area of 
residence. All participants were interviewed and information was collected on 
sociodemographic factors, screening history and behavioural risk factors for cervical 
cancer. Cases and controls were compared in relation to screening history and risk 
factors for disease. Separate analysis was done for squamous and adenocarcinomas of 
the cervix.  
 
Results 
98 out of a possible 122 possible cases (80.3%) were interviewed, and 294 controls 
were selected (response rate 62.5% for controls). Over 70% of cases had squamous 
cell carcinoma, and most of the rest had adenocarcinoma. Cases were significantly 
less likely to have had a screening test in the last 3 years (unadjusted odds ratio for 
invasive cancer among unscreened population, 2.46 [95%CI 1.36 – 4.44]). Non-
participation in screening particularly increased the risk of squamous carcinoma (OR 
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3.8; 1.8 – 8.3) rather than adenocarcinoma (OR 1.2; 0.4 – 3.4). After adjusting for 
other factors using conditional logistic regression, other characteristics associated 
with squamous carcinoma included increasing number of lifetime sexual partners (OR 
2.3; 1.0 – 5.5 for two or more compared with one partner), having ever smoked (OR 
3.7; 1.6 – 8.6) and exposure to passive smoke (OR 2.9; 1.2 – 7.2 for exposure to two 
or more smokers compared with none). For adenocarcinoma, the most important risk 
factor was use of the oral contraceptive pill (OR 18.1; 1.7 – 188.7) and having ever 
smoked (OR 6.4; 1.1 – 38.2). 
 
Conclusions 
Case control studies are useful for examining screening effectiveness and risk factors 
for relatively rare diseases. The level of effectiveness for screening estimated from 
this study is similar to that found in other case control studies. Therefore a screening 
programme in Hong Kong is likely to be as effective as in other populations. The 
main risk factors identified in other studies were also important in this population. 
The findings suggest that separate risk factors play a part for different histological 
types. The study also supports the hypothesis that passive smoking contributes to the 
aetiology of squamous cell carcinoma of the cervix. 
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2.2 Introduction 
Case control studies offer an efficient method for evaluating the association between 
an exposure and disease, particularly where the disease has a long latency period and 
is rare
137
. They are also useful for examining multiple etiologic factors, and they are 
often used for exploring risk factors for disease. Increasingly, case control studies 
have also been used for evaluating the effectiveness of screening. This chapter focuses 
on a case control study that aimed to evaluate cervical cancer screening in Hong Kong 
and determine the main risk factors for cervical cancer in that region. 
 
2.2.1 Use of case control studies in evaluating the effectiveness of screening 
The gold standard method for assessing the effectiveness of any health care 
intervention is the randomised controlled trial (RCT). However, RCTs have practical 
difficulties that limit their use in certain circumstances. Where an intervention is 
already commonplace, such as in the case of cervical screening, and where the 
existing evidence suggest the intervention is beneficial there is an ethical dilemma in 
denying a control group the intervention. RCTs also require a large sample size and 
are generally a more expensive study design. Therefore observational studies are 
sometimes necessary to evaluate the effectiveness of preventive interventions. Case 
control studies have been used for assessing the effectiveness of screening since the 
1940s
138
.  
 
There has been much published on the principles behind using case control studies to 
evaluate screening efficacy
139-143
, but their appropriateness has been questioned
144
. 
There are two main arguments against their use. The first relates to the influence of 
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confounding factors, particularly as those who attend for screening may be at lower 
risk of disease, irrespective of screening. The second concern is that subjects with true 
positive screening results who are treated and do not subsequently develop the 
outcome that screening was intended to prevent, are excluded from the control 
population. However, these concerns do not invalidate the use of case control studies 
for assessing screening efficacy, rather they highlight the importance of attention to 
study design and the selection of cases and controls
145; 146
. The main issues that need 
to be considered in conducting such studies 
137; 147
 include: 
1) Definition of cases and controls147. Cases should be subjects with the stage of 
disease which screening aims to prevent. They should also be incident rather 
than prevalent cases
137
. For cervical cancer, the aim is to detect pre-invasive 
lesions and prevent invasive disease and death. Therefore appropriate cases 
would be women with newly diagnosed invasive cervical cancer. Controls 
should ideally be selected from the general population, and be representative 
of the population who would have been selected as cases had they developed 
disease.  
2) Handling of cases detected by screening147. If these cases are excluded, the 
benefits of screening are likely to be overestimated, whereas their inclusion, 
would tend to underestimate benefit. This is particularly a problem where there 
is no established screening programme, and coverage is low. 
3) Differentiating between “symptomatic” and “screening” smears147. Inclusion 
of symptomatic smears will underestimate benefit. Therefore studies should 
try to identify and exclude smears taken because of symptoms. Another way of 
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handling this is to exclude smears taken within six or 12 months of the date of 
diagnosis of the case. 
4) Selection bias. In situations where women at higher risk of cervical cancer are 
also those who are less likely to attend for screening, the case-control study 
would overestimate benefit
144; 147
. Some studies have tried to account for this 
by adjusting for risk factors, but residual confounding is still a possibility that 
must be considered. 
There have been few studies to compare the results of RCTs with those obtained from 
case control studies. However, Demissie et al did undertake such a comparison, in 
relation to screening mammography
138
. They found that the direction of effect was the 
same with both study designs. However, the case control studies consistently showed 
significantly more protective effect than RCTs. Selection bias in the uptake of 
screening may have been one explanation for this difference, though the authors did 
not find convincing evidence to support this. Another explanation is that case control 
studies may be assessing the efficacy of intervention, whereas RCTs assess 
programme effectiveness. If RCTs are analysed in relation to actual screening 
practice, rather than based on intention to treat, the risk estimate is lowered to a 
similar level to that found in case control studies, providing some support to this 
hypothesis
148
.  
For cervical cancer, case control methods have been used frequently for evaluation of 
screening
109; 110; 149-156
. Table 4 summarises the main characteristics of these studies. 
The table is ordered according to the number of cases included in the study.  
Most published studies have found screening to be protective, with a relative risk for 
ever versus never screening generally ranging from around 0.37 to 0.25
147
. The main 
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exceptions are a case control study from Taiwan
154
, which showed no difference in 
screening practice among cases and controls, and a study from Italy
153
, with an odds 
ratio of 0.1. The former study was based on a very small number of cases, and the 
authors attributed the findings partly to poor screening coverage and poor laboratory 
quality. In the latter study the percentage of women (cases and controls) who had 
screening was also generally very low, compared with other studies, suggesting that 
factors other than screening were contributing to the observed difference. Another 
study with null findings was a relatively recent study in Sweden, in a region with an 
organised screening programme
157
. In this study, history of ever screening was similar 
in cases and controls, though significantly more cases had some form of abnormality 
recorded previously. Uptake rates were over 80% among all women (cases and 
controls) in the age group targeted for screening (20 to 59 years). This suggests that 
other factors, such as follow-up and treatment of abnormalities were likely to be 
responsible for the difference observed in this population.  
 
Presentation of cervical cancer  
The vast majority of cervical cancers are squamous cell carcinomas
8; 158
. Before the 
general use of cytological screening, 75-90% of women with invasive cervical cancer 
presented with abnormal vaginal bleeding at a later stage of disease
158
. In countries 
where screening is widespread, the pattern has changed so that more women are 
diagnosed on the basis of abnormal pap smears, before the onset of symptoms. 
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Table 4: Features of case control studies to evaluate cervical screening (adapted from Moss
147
) 
 
Study Diagnosis 
of cases 
Matching and 
source of controls 
Total cases  
(% screened) 
Total controls  
(% screened) 
OR  
(ever vs. never) 
Other notes 
 
Herrero
152
  
Latin America 
1990 Hospital and 
community 
759 (50) 1,430 (71) 0.33 Not modified by risk factor adjustment 
Hernandez
159
  
Mexico 
1990 - 92 Age, district 233 CIS (38.6) 
397 invasive 
(28.2) 
1005 (76.1) 0.68 (CIS) 
0.38 (invasive) 
OR adjusted for age, age at first coitus, 
parity, number of sex partners and socio-
economic group 
La Vecchia
153
 
Milan 
1981 – 3  Age 145 with CIN 
191 with invasive 
(31) 
145 age-matched 
191 hospital 
control (64) 
0.26 After adjusting for SE status & sexual 
habits, RR for screening intervals: 
< 3 years = 0.10,      3 – 5 years = 0.18 
> 5 years = 0.36 
Clarke
151
 
Toronto 
1973 – 6  Age, neighbourhood, 
type of dwelling 
212 (32) 1,060 (56) 0.37 Stratification by age, income, education, marital 
history, smoking and employment not affect 
result 
Aristozabel
150
 
Cali  
1971 – 81  Age, neighbourhood, 
health centre 
attendance 
204 (4) 408 (31) 0.1  
Raymond
160
 
Geneva 
1970 – 6  Age, nationality, 
civil status 
186 (18) 186 (38) 0.31 Information only from abstract. Article not 
in English 
Celentano
161
 
Maryland 
1982 – 84  Age, race, 
neighbourhood 
153 392 0.29 Adjustments for education, ever treated for 
a sexually transmitted disease, smoking, 
age at first sexual intercourse, number of 
pregnancies & lifetime contraceptive use 
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Andersson-
Ellstrom
157
 
Sweden 
1990 – 97  Age (first woman after 
case on population 
register) 
112 (61)    
All ages 
69 (82.6)   
Age 20 - 59 
112 (65)    
All ages 
69 (88.4)   
Age 20– 59  
0.83  No significant difference in screening 
history between cases and controls. 
However, cases had significantly more 
atypia on smears. 
 
Sato
109
  
Japan 
1984 – 90  Age, area 109 (55) 218 (85.5) 0.16 Only significant for squamous cell 
carcinoma 
Chaplain
162
 
France  
1987 – 97  Age, date of last 
screening, 
residence 
104 (41.4)  208 (67.8)  0.32 Cases had CIS 
Shy
110
 
Washington  
1978 – 83  Geographical area 92 (*) 178 (*) 0.26 Not modified by risk factor adjustment 
 
Lai
154
 Taiwan  1979 – 84  No information on 
matching in 
abstract 
56 (*) Number of 
controls not given 
in abstract 
No effect Information based on abstract only (rest of 
article not in English) 
Oleson
156
 
Denmark 
1983 Age, area 45 (*) 67 (*) 0.25  
Van der 
Graffe
155
 
Netherlands 
1979 – 85  
(cases < 70 
years) 
Age, district 36 (47) 120 (68) 0.32 Adjust for age at first coitus  RR = 0.22 
Smear within 2 – 5 years  RR = 0.18 
Smear > 5 years previously  RR = 0.38 
*Data on proportions screened not provided
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2.2.2 Use of case control studies in determining risk factors 
Case control studies are useful and efficient for indicating disease aetiology. Several 
case control studies have examined risk factors for cervical cancer. Some factors have 
consistently been demonstrated to increase risk, though their relative importance may 
vary. Others are still controversial. Differentiating between epidemiological risk 
factors in different age groups can help us to better understand the mechanisms in 
cervical carcinogenesis. In general young women share the same risk factors for 
cervical cancer as older women. However, some studies suggest that smoking and use 
of the OCP have different effects in different age groups
42; 77; 79; 80
. The main risk 
factors were discussed in detail in chapter 1. 
There has been one other published case control study of cervical cancer in Hong 
Kong, focusing on reproductive and sexual risk factors 
163
. This hospital based study 
included 68 cases, of whom 20 had invasive disease and the others cervical dysplasia. 
The study showed that cases and their spouses had significantly more sexual partners 
than controls, and that they tended to have been younger at first sexual intercourse. 
However, this study did not examine other risk factors nor screening practice among 
cases and controls.  
2.2.3 Unanswered questions 
There have been no studies to confirm the protective effect of screening amongst the 
Hong Kong population.  The extent to which the classical risk factors for cervical 
cancer in other populations contribute to disease in this population is also not known. 
Also, given the paucity of studies examining the relationship between cervical cancer 
and passive smoking exposure, this study provided the opportunity for further 
examining this risk factor.  
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2.3 Aims and objectives: 
The primary aim of this study were to assess the effectiveness of the current system of 
screening in Hong Kong, in preventing invasive cervical cancer and to investigate the 
importance of previously identified risk factors for cervical cancer, in Hong Kong.  
Research questions: 
1. What is the level of screening activity amongst women with cervical cancer? 
2. How does this compare with screening activity among women in the general 
population? 
3. To what extent do the classic risk factors for cervical cancer explain disease 
among women in Hong Kong?  
4. Is passive smoking associated with an increased risk of cervical cancer? 
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2.4 Subjects and methods: 
This case-control study was based on Hong Kong Chinese women recruited over a 
two-year period (1997 – 1998), to examine the effectiveness of cervical screening, 
and the main risk factors for disease in this population.  
2.4.1 Selection of cases 
Given that the objective of cervical screening is to reduce the number of invasive 
cases of cervical cancer rather than reducing mortality, we defined cases as Hong 
Kong Chinese women with incident diagnoses of invasive disease. Women with 
newly diagnosed invasive cervical cancer who presented to Queen Mary Hospital 
(QMH), Queen Elizabeth Hospital (QEH) or Caritas Medical Centre (CMC) from the 
beginning of January 1997 to the end of December 1998 were included in the study. 
Recruitment started in QMH, and all women presenting here during this period were 
included. In QEH, women with newly diagnosed disease who had radiotherapy were 
included, and recruitment started from mid-June 1998. In CMC, all new cases 
diagnosed since March 1998 were included. The recruitment period was based on the 
time at which approval for the study was obtained from the respective hospitals‟ 
ethics committees.  
Informal discussion with the gynaecologists, suggested that almost every woman with 
cervical cancer would be referred to a hospital initially. Therefore, by targeting 
hospitals, we were unlikely to miss incident cases, unless the case was so advanced 
that they were directly referred to a hospice. QMH is the main oncology centre in 
Hong Kong, and women are referred here from all parts of the region. QEH is 
predominantly a tertiary referral centre, so is likely to have a higher proportion of 
more advanced cases. CMC is a relatively small hospital, with referrals from primary 
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care only. Limitation of resources did not allow us to include other hospitals in the 
study, but those included are major providers for Hong Kong and Kowloon. 
At the end of the study, a search of hospital records was made to identify any cases 
that may have been missed during the study period. For these cases, as much 
information as possible was obtained from the case records. 
2.4.2 Selection of controls 
Controls were randomly selected from among women interviewed for a different 
study to assess the pattern of cervical cancer screening in Hong Kong. This study is 
described in detail in chapter 3, but briefly, it was a population survey of 1,700 
women conducted by telephone. Participants for the study were predominantly 
selected through random digit dialling, though some were recruited through 
convenience sampling in order to obtain equal numbers of women in three broad age 
bands (20-39, 40-59 and 60 or over). The study included one women from each 
household contacted, who was 20 years old or more and who had not had a 
hysterectomy.  
For each case in the current study, all participants from the telephone survey who 
matched in terms of age (+/- 2 years), social class (based on own or husband‟s 
occupation) and geographical district of residence were identified. From amongst 
these, three controls were randomly selected per case. The controls would have been 
expected to be referred to the same hospital as the case, had they been cases. 
2.4.3 Study instrument and measurement 
The same research assistant, using a structured questionnaire (Appendix 1) 
interviewed all cases face-to-face. These were all conducted in Cantonese in the 
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respective hospitals, usually in the clinics. The interview questionnaire had four main 
parts: 
A)  Background information on patient‟s socio-demographic details  
B)  Screening history, including when and the reason for testing and regularity of 
previous tests  
C)  Personal history to assess other risk factors (smoking history, number of years of 
education, number of years of oral contraceptive use, age of first sexual contact 
and the number of lifetime sexual partners) 
D)  Patient‟s understanding of problem and satisfaction with care (not presented in 
this thesis) 
The questions for sections A to C were adapted from two other questionnaires used 
for similar studies elsewhere
164; 165
, with permission of the authors. In addition, for 
each patient, information was collected from the hospital records on the date of 
diagnosis, histopathology of the tumour, stage of disease at diagnosis and treatment 
received. 
The questionnaire used for controls was similar to that used for cases, except that 
other questions were used instead of section “D”(Appendix 1). For both 
questionnaires, we asked specifically about the reason for any Pap smear done, and 
when this was taken. Any smear test associated with prior symptoms was classed as a 
“diagnostic test”, whereas those initiated by the patient, or where there were no 
previous symptoms were classed as screening tests. Women who had a screening test 
were asked when they had their last test, and whether they attended for screening 
regularly. Those who said they did attend regularly were classed as “regular 
attendees”. 
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2.4.4 Sample size estimation 
There is no reliable estimate of the extent of screening for cervical cancer in Hong 
Kong, but two studies from the Hong Kong Family Planning Association estimate a 
coverage of 30% amongst selected groups of women
135; 136
. In order to detect a 
relative risk of at least 2 for invasive cancer without screening, with 95% confidence 
and with a power of 80%, we needed at least 75 cases, using 3 controls per case 
(based on tables for calculation of sample size in unmatched case-control studies)
166
. 
2.4.5 Data management and analysis 
The same research assistant, who also supervised data entry and the interviewers 
undertaking telephone surveys, collected all data for the cases. Analysis was done 
predominantly using SPSS, except for conditional logistic regression analysis, which 
was done using STATA. Cases and controls were compared regarding their cervical 
screening histories. The odds ratio for invasive cervical cancer in women who have 
been screened in the past 5 years compared to women with no prior screening was 
obtained. Logistic regression was also used to take account of possible confounding 
factors during analysis, and to identify any other factors associated with invasive 
cervical cancer. 
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2.5 Results 
All cases that the study team were informed about agreed to be interviewed. In 
addition, 24 cases were identified that presented to the hospitals included in the study 
within the study period, but failed to be interviewed because the study team were not 
informed about them (Table 5). Therefore overall 80.3% of potential cases were 
included in the study. The response rate for the survey from which controls were 
drawn was 62.5%. A total of 98 cases and 294 controls were included in the matched 
study. Where available, information regarding their age, method of presentation, 
screening history, stage of presentation and treatment were obtained from the relevant 
hospital notes. Analysis was repeated whenever possible, to include these women. 
Table 5: Characteristics of cases (including cases not interviewed) 
 Cases interviewed (%) Cases not interviewed (%)  All cases (%) 
Hospital 
Caritas Medical Centre (CMC) 
Queen Elizabeth Hospital (QEH) 
Queen Mary Hospital (QMH) 
n=98 
6 (6.1) 
28 (28.6) 
64 (65.3) 
n=74 
6 (25.0) 
 0 
18 (75.0) 
 n=122 
12 (9.8) 
28 (22.9) 
82 (67.2) 
Stage of disease 
I 
II 
III & IV 
Not known 
 
52 (53.1) 
27 (27.6) 
18 (18.4) 
1 (1.0) 
 
13 (54.1) 
3 (12.5) 
8 (33.3) 
- 
 
65 (53.7) 
30 (24.8) 
26 (21.5) 
1 (0.8) 
Histology 
Squamous cell carcinoma 
Adenosquamous 
Adenocarcinoma and other 
Not known 
 
69 (70.4) 
6 (6.1) 
22 (22.4) 
1 (1.0) 
 
18 (75.0) 
1 (4.2) 
5 (20.8) 
- 
 
87 (20.9) 
7 (1.7) 
27 (6.5) 
1 (0.8) 
Treatment received 
Radiotherapy 
Hysterectomy 
Radiotherapy and surgery 
Other 
Not known 
 
53 (54.1) 
36 (36.7) 
8 (8.2) 
1 (1.0) 
1 (1.0) 
 
13 (54.2) 
7 (29.2) 
0 
4 (16.7) 
- 
 
66 (54.1) 
43 (35.2) 
8 (6.6) 
5 (4.1) 
1 (0.8) 
Screening history 
Ever screened 
Never screened 
Not known 
 
38 (38.8) 
60 (61.2) 
- 
 
3 (12.5) 
9 (37.5) 
12 (50.0) 
 
42 (34.4) 
48 (39.3) 
12 (9.8) 
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Information on screening was only available for half of the cases that were not 
interviewed. These cases tended not to have had screening in the past, to have 
presented with more advanced disease and consequently fewer had hysterectomy as 
the only form of treatment (Table 5). 
The median age for all participants (cases and controls) was 52 years (mean 53.6), 
with a range from 27 to 75 years. Although the cases were recruited from only three 
hospitals, they came from all districts in Hong Kong.  Cases and controls were similar 
in terms of age, social class and district of residence (Table 6). The mean age for 
controls was 53.5, and for cases 53.7 (or 53.8 if we include those not interviewed). 
However, cases were more likely than controls to be single, divorced or separated, 
and generally tended to have had less education. 
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Table 6: Comparison of baseline characteristics in cases and controls 
 Number (%) 
 Controls (n=294) Cases (n=98) 
Social class   
I 72 (24.5) 24 (24.5) 
II 97 (33.0) 32 (32.7) 
III 86 (29.3) 29 (29.6) 
IV 39 (13.3) 13 (13.3) 
District   
Wan Chai, Eastern & Mid West 58 (19.7) 19 (19.4) 
Southern 48 (16.3) 16 1(6.3) 
Kung Tong, Won Tai Sin, Kowloon City, 
Sham Shui Po & Yau Tsim Mong 108 (36.7) 36 (36.7) 
Kwai Tsing & Tsuen Wan 17 (5.8) 6 (6.1) 
Tuen Mun & Yuen Long 18 (6.1) 6 (6.1) 
Sha Tin, Tai Po & Northern  45 (15.3) 15 (15.3) 
Age group   
20 – 39  37  (12.6) 12  (12.2) 
40 – 59  147  (50.0) 51 (52.0) 
60 + 110   (37.4) 35 (35.7) 
Marital status   
Single 1 (0.3) 1 (1.0) 
Married / cohabiting 240 (81.6) 72 (73.4) 
Divorced / separated 9  (3.0) 9 (9.2) 
Widowed 44 (15.0) 16 (16.3) 
Educational level   
Non/ primary 138 (46.9) 56 (57.1) 
Secondary 131 (44.6) 37 (37.8) 
Matriculation and above 25 (8.5) 5 (5.1) 
2.5.1 Knowledge and practice of cervical screening 
Overall, 67.9% (266/392) of women in the study had ever heard of a cervical smear, 
and 43.3% (175/404) had ever had a screening test. Information on screening history 
was available for 404 women, including all but 12 of those who were not interviewed.  
Comparison of cases and controls is described in more detail in later sections, but 
overall, a higher proportion of controls compared with cases had heard of a cervical 
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smear (before diagnosis of cancer for cases), had ever had a screening test and were 
regular attendees for screening (Table 7). Apart from having heard of the test, none of 
the differences were statistically significant. 
 
Table 7: Comparison of cases and controls in terms of screening knowledge and practice 
 Cases (n=98) Controls (n=294) Matched OR for control 
compared with case (95% CI) 
Heard of cervical smear 59 (60.2) 207 (70.4) 1.77 (1.03 – 3.05) 
Ever had screening smear 38 (38.8) 122 (41.5) 1.18 (0.69 – 1.99) 
Regular screening 20 (20.4) 69 (23.4) 1.26 (0.72 - 2.22) 
 
Among those who regularly attend for screening (n=89), over three quarters attended 
at least once per year, and the longest screening interval was 2-3 years. Women in the 
control group tended to have more frequent screening (Table 8) compared with cases 
(χ2 for trend = 13.65, p=0.009). 
 
Table 8: Frequency of regular screening among cases and controls 
  First smear ≥Once a year  Every 2 years Every 3 years No regular smear 
Controls (n=294) 11 (3.7) 57 (19.4) 6 (2.0) 6 (2.0) 214 (72.8) 
Cases (n=98)   11 (11.2) 3 (3.1) 6 (6.1) 78 (79.6) 
2.5.2 Comparison of risk factors between cases and controls 
Cases and controls were compared in relation to the prevalence of established risk 
factors. The comparison took account of matching, using conditional logistic 
regression, but no adjustments were made at this stage for other factors.  
Generally we found a greater prevalence of known risk factors among cases compared 
with controls (Table 9). Cases were significantly more likely to have had a greater 
number of sexual partners in their lifetime, to have ever smoked and to have used the 
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oral contraceptive pill (and for longer). Women in the control group tended to have 
been older at first sexual intercourse compared with cases. Since the cases and 
controls were matched on social class, the difference in educational level between 
groups will have been masked to some extent. Nevertheless, there was a tendency for 
cases to have had less education compared with controls. 
 
Risk factors were then examined separately by histological type of cervical cancer. 
Adenosquamous carcinomas were included together with adenocarcinoma (n= 27) 
and SCC was grouped separately (n = 69). The unadjusted matched odds ratio for 
cervical cancer was obtained for each risk factor (Table 10). The same risk factors as 
the combined analysis remained significant for SCC. However, the odds ratios for the 
sexual and smoking risk factors were higher and for use of the OCP lower than for the 
combined results. In contrast, most of the odds ratios for ACC reduced and were no 
longer significant. However, the odds ratio for use of OCP was much higher for ACC 
than for SCC and this remained statistically significant as a risk factor.  
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Table 9: Prevalence of risk factors for cervical cancer among cases and controls and 
matched odds ratio (OR) for being a ‘case’ for each risk factor 
 
Risk factor Number interviewed (%) Matched OR  
(95% CI)* 
p-value 
(based 
on χ2) 
Controls 
n=294 
Cases  
n=98 
Number of sexual partners 
One 
Two or more 
Not known 
 
238 (89.1) 
29 (10.9) 
27 
 
75 (76.5) 
23 (23.5) 
- 
 
1.00 
2.65 (1.42 – 4.95) 
 
0.002 
 
Age at first sexual intercourse 
19 or more years  
≤18 years 
Not known 
 
170 (90.9) 
17 (9.1) 
107 
 
79 (82.3) 
17 (17.7) 
2 
 
1.00 
2.27 (1.06 – 4.87) 
 
0.040 
Smoking history     
Never smoked 
Ever smoked  
Ex-smoker 
Current smoker 
Not known  
262 (89.1) 
32 (10.9) 
13 (4.4) 
19 (6.5) 
- 
69 (70.4)  
29 (29.6) 
15 (15.3) 
14 (14.3) 
-  
1.00 
3.51 (1.94 – 6.36) 
4.72 (2.06 – 10.84) 
2.84 (1.35 – 5.87) 
 
<0.001 
<0.001 
0.006 
0 – 5 pack-years 
5.1 – 15 pack-years 
15.1 – 30 pack-years 
30.1 or more pack-years 
277 (94.2) 
6 (2.0) 
6 (2.0) 
5 (1.7) 
83 (84.7) 
4 (4.1) 
3 (3.1) 
8 (8.2) 
1.00 
2.22 (0.58 – 8.49) 
1.61 (0.40 – 6.50) 
4.80 (1.57 – 14.67) 
 
0.245 
0.502 
0.006 
Per increasing pack-year of smoking   1.03 (1.01 – 1.05) 0.008 
Use of oral contraceptive pill 
Never or up to 5 years 
More than 5 years 
Not known 
 
261 (89.4) 
31 (10.6) 
2 
 
74 (76.3) 
23 (23.7) 
1 
 
1.00 
2.65 (1.42 – 4.96) 
 
 
0.002 
Educational level 
None / primary  
Secondary or above 
Matriculation 
Not known  
 
138 (46.9) 
131 (44.6) 
25 (8.5) 
- 
 
56 (57.1) 
37 (37.8) 
5 (5.1) 
- 
 
1.00 
1.83 (1.03 – 3.26) 
3.21 (0.99 – 10.51) 
 
 
0.040 
0.053 
Marital status 
Married/ cohabiting 
Single/ widowed/ separated 
Not known 
 
240 (81.6) 
54 (18.4) 
- 
 
72 (73.5) 
26 (26.5) 
- 
 
1.00 
1.86 (1.00 – 3.46) 
 
 
0.051 
* Odds ratios are unadjusted 
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Table 10:Risk factors for cervical cancer by histological type 
 Matched OR for cases vs. controls (95% CI)  
Risk factor SCC p ACC (inc. Adenosquamous) p 
Number of sexual partners 
One 
Two or more 
 
1.00 
3.34 (1.62 – 6.86) 
 
0.001 
 
1.00 
1.60 (0.47 – 5.47) 
 
0.45 
 
Age at first sexual intercourse 
19 or more years  
≤18 years 
 
1.00 
2.73 (1.07 – 6.97) 
 
0.04 
 
1.00 
1.56 (0.41 – 5.97) 
 
0.51 
Smoking history     
Never smoked 
Ever smoked  
Ex-smoker 
Current smoker  
1.00 
4.41 (2.15 – 9.04) 
6.29 (2.21 – 17.79) 
3.54 (1.50 – 8.34) 
 
<0.001 
0.001 
0.004 
1.00 
2.81 (0.68 – 11.67) 
1.85 (0.38 – 9.01) 
2.84 (1.35 – 5.87) 
 
0.14 
0.15 
0.04 
0 – 5 pack-years 
5.1 – 15 pack-years 
15.1 – 30 pack-years 
30.1 or more pack-years 
1.00 
1.19 (0.12 – 11.83) 
2.29 (0.50 – 10.43) 
10.50 (2.18 – 
50.56) 
 
0.88 
0.28 
0.003 
Numbers in categories too 
small to make meaningful 
comparison 
 
 
Per increasing pack-year of smoking 1.04 (1.01 – 1.07) 0.004 1.00 (0.95 – 1.05) 0.95 
Use of oral contraceptive pill 
Never or up to 5 years 
More than 5 years 
 
1.00 
2.13 (1.02 – 4.44) 
 
 
0.04 
 
1.00 
5.62 (1.46 – 21.46) 
 
 
0.01 
Educational level 
None / primary  
Secondary or above 
Matriculation  
 
1.00 
2.15 (1.06 – 4.38) 
3.64 (0.91 – 14.62) 
 
 
0.03 
0.07 
 
1.00 
1.42 (0.52 – 3.85) 
2.80 (0.27 – 28.78) 
 
 
0.49 
0.39 
Marital status 
Married/ cohabiting 
Single/ widowed/ separated 
 
1.00 
1.92 (0.92 – 4.05) 
 
 
0.08 
 
1.00 
1.96 (0.59 – 6.44) 
 
 
0.27 
* Odds ratios are unadjusted 
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Information on passive smoking exposure was obtained in relation to the place of 
exposure (home or at work), and the extent of exposure (number of people smoking at 
home or workplace). Cases were more likely to have been exposed to passive smoke, 
particularly at home. When we examined only women who were never smokers 
(n=331), the relationship remained with cases being more likely to have had any 
exposure (Table 11). Furthermore, for home exposure, there was a dose response 
relationship, with cases reporting a greater number of people smoking at home. The 
number of women reporting two or more smokers at work was relatively small, 
resulting in wide intervals for the risk estimates. 
 
When passive smoking exposure was examined according to histological type, the 
odds ratios were increased and significant only for SCC (Table 12). 
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Table 11: Exposure to passive smoking among cases and controls and matched OR for 
being a ‘case’, with a given level of exposure 
Passive smoking exposure Number (%) Matched OR   
(cases vs. controls) 
p 
Controls 
(n=294) 
Cases 
(n=98) 
Smokers and non-smokers  
Exposure at home 
No exposure (or live alone) 
Exposed to 1 smoker 
Exposed to 2 or more smokers 
 
203 (69.0) 
68 (23.1) 
23 (7.8) 
 
53 (54.1) 
32 (32.7) 
13 (13.3) 
 
1.00 
1.91 (1.11 – 3.27) 
2.42 (1.09 – 5.37) 
 
 
0.02 
0.03 
Exposure at work 
No exposure (or not work) 
Exposed to 1 smoker 
Exposed to 2 or more smokers 
Not known 
 
248 (91.2) 
8 (2.9) 
16 (5.9) 
22 
 
86 (87.8) 
6 (6.1) 
6 (6.1) 
- 
 
1.00 
2.10 (0.72 – 6.14) 
1.14 (0.41 – 3.07) 
 
 
0.17 
0.80 
Exposure from all sources 
No exposure 
Exposed to 1 smoker 
Exposed to 2 or more smokers 
Not known 
 
187 (63.8) 
66 (22.5) 
40 (13.7) 
1 
 
48 (49.0) 
30 (30.6) 
20 (20.4) 
- 
 
1.00 
2.23 (1.25 – 3.99) 
2.51 (1.24 – 5.11) 
0.006 
 
0.007 
0.010 
Never smokers only                                          (n=262)           (n=69) 
Exposure at home 
No exposure (or live alone) 
Exposed to 1 smoker 
Exposed to 2 or more smokers 
 
186 (71.0) 
58 (22.1) 
18 (6.9) 
 
38 (55.1) 
23 (33.3) 
8 (11.6) 
 
1.00 
2.24 (1.18 – 4.29) 
2.31 (0.79 – 6.71) 
 
 
0.014 
0.124 
Exposure at work 
No exposure (or not work) 
Exposed to 1 smoker 
Exposed to 2 or more smokers 
Not known 
 
222 (91.0) 
7 (2.9) 
15 (6.1) 
18 
 
58 (84.1) 
6 (8.7) 
5 (7.2) 
- 
 
1.00 
5.61 (1.39 – 22.61) 
1.21 (0.40 – 3.67) 
 
 
0.015 
0.734 
Exposure from all sources 
No exposure 
Exposed to 1 smoker 
Exposed to 2 or more smokers 
Not known 
 
171 (65.5) 
55 (21.1) 
35 (13.4) 
1 
 
33 (47.8) 
21 (30.4) 
15 (21.7) 
- 
 
1.00 
2.57 (1.25 – 5.28) 
2.75 (1.18 – 6.38) 
0.006 
 
0.010 
0.019 
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Table 12: Effect of passive smoking exposure on risk of cervical cancer, by histology 
 Matched OR for cases vs. controls (95% CI)  
Risk factor SCC p ACC (inc. Adenosquamous) p 
Smokers and non-smokers: 
No exposure 
Exposed to 1 smoker 
Exposed to 2 or more smokers 
 
1.00 
2.47 (1.27 – 4.79) 
3.35 (1.48 – 7.59) 
 
 
0.01 
<0.01 
 
1.00 
1.50 (0.46 – 4.94) 
0.87 (0.19 – 4.04) 
 
 
0.50 
0.86 
Never smokers only: 
No exposure 
Exposed to 1 smoker 
Exposed to 2 or more smokers 
 
1.00 
3.01(1.36 – 6.68) 
4.50 (1.64 – 12.34) 
 
 
0.01 
<0.01 
 
1.00  
1.03 (0.20 – 5.36) 
0.48 (0.07 – 3.15) 
 
 
0.97 
0.45 
 
 
The relationship between active smoking and invasive cervical cancer was examined 
in more detail, by age group. Generally, ever smoking was a more important risk 
factor for women aged 40 – 59 years, than for younger or older women (Table 13). 
The OR for increasing pack years of smoking was highest for the youngest age group, 
but only statistically significant for the 40 – 59 age group. 
 
Table 13: Odds ratios and (95% confidence intervals) of invasive cancer for smoking 
risk factors, by age group, using conditional logistic regression 
Age group Odds ratio (95% CI) compared with never smokers 
Ever smoking Per increasing pack-year 
<40 2.08 (0.48 – 8.41), p = 0.34 1.41 (0.81 – 2.44), p = 0.22 
40 – 59  6.55 (2.33 – 18.45), p < 0.001 1.05 (1.01 – 1.08), p = 0.02 
60 + 2.32 (0.96 – 5.62), p = 0.06 1.18 (0.99 – 1.04), p = 0.24 
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2.5.3 Effectiveness of screening: 
Case presentation: 
The majority of cases had squamous cell carcinoma (n=87, 71.9%), followed by 
adenocarcinoma (n=24, 19.8%) whilst the rest had adenosquamous (n=7, 5.8%) or 
other histology (n=3, 2.5%). The histology was not recorded or not known for the 
remaining woman. At presentation, stage I disease was most common (n= 63, 52%), 
but 31 (25.6%) had stage II disease, 23 (19.0%) stage III and the rest higher stage 
disease. 
The majority cases, presented with abnormal bleeding, and relatively few (10.7%) 
were detected through screening (Table 14). 
 
Table 14: Presenting symptoms for women with invasive cervical cancer 
 Presenting symptom Number (%) presenting 
 Cases interviewed Cases not interviewed TOTAL 
Abnormal vaginal bleeding 77 (78.6) 21 (87.5) 98 (80.3) 
Abnormal Pap smear 10 (10.2) 3 (12.5) 13 (10.7) 
Vaginal discharge 7 (7.1) -  7 (5.7) 
Pain 2 (2.0) -  2 (1.6) 
Other symptoms 2  (2.0) -  2 (1.6) 
   
 
As expected, women who presented following screening were more likely to present 
with early stage disease, compared with women presenting with symptoms (Figure 9). 
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Figure 9: Stage of disease at presentation, according to whether case was symptomatic 
or detected through screening 
 
0
10
20
30
40
50
60
70
80
Ia Ib II III IV
Stage
%
 o
f 
w
o
m
en
 (
n
)
Presented with symptoms
Detected through screening
 
Screening histories among cases: 
Information on screening history was available from 110 cases. Just over one third 
(42/110 = 38.2%) of these women had ever had a screening smear in the past. These 
were cervical smears that were unrelated to any gynaecological symptoms. Of these, 
20 women (50% of those ever screened) had a cervical smear within the last 3 years, 
and 29 (72.5%) within the last 5 years (Table 15). There were 20 women (50% of 
those ever screened) who were regular attendees for screening. A total of 6 of these 
women (6/20 = 30%) presented with invasive cancer of stage II or above, despite 
reporting a negative smear within the previous 5 years. Of these, 2 presented during 
their routine screen, whilst the remainder were interval cancers. 
Table 15: Stage of disease at presentation, according to screening practice  
Time since last screening smear Stage of cancer at presentation 
Ia Ib II or more 
Within 3 years (n=20) 6 (30.0) 10 (50.0) 4 (20.0) 
3 – 5 years (n=9) 2 (22.2) 5 (55.6) 2 (22.2) 
>5 years (n=11) 2 (18.2) 6 (54.5) 3 (27.3) 
Never been screened (n=69) 6 (8.7) 22 (31.9) 41 (59.4) 
(8) 
(9) 
(46) 
(2) 
(28) 
(23) 
(3) 
(2) 
*Stage information missing for 1 case 
*Stage information missing for 1 case 
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Screening practice among controls and comparison with cases: 
Among controls, 45.6% (134/294) had ever had a screening test, including 105 
(35.7%) in the last 3 years, and 113 (38.4%) in the last 5 years. There were 69 (51.4% 
of those ever screened) regular attendees. Generally, among controls that had ever 
been screened, the age at which they had their first smear was younger (mean age 
28.6), compared with cases (mean age 34.1), though the difference was not 
statistically significant (p = 0.21). When comparing time since last screening smear 
test, controls were significantly more likely to have had a test within the previous 
three years (Table 16). The risk of having invasive cervical cancer (being a case) was 
greatest for those not screened within 1 year of interview (OR 26.2), but screening 
remained protective even if we included screening within the last 10 years (though not 
statistically significant).  
 
Table 16: Risk of invasive cervical cancer according to time since last screening test 
Time since 
last 
screening 
test 
Number (%) 
cases screened 
(n=110) 
Number (%) 
controls screened 
(n=294) 
Matched OR (Unadjusted) 
Invasive cancer in non-
screened vs screened 
population (95% CI) 
Significance 
(p-value) 
for χ2 test 
< 1 year 1 (0.9) 63 (21.4) 26.25 (3.60 – 191.52) <0.001 
<2 years 12 (10.9) 92 (31.3) 3.90 (1.97 – 7.74) <0.001 
<3 years 21 (19.1) 105 (35.7) 2.46 (1.36 – 4.44) 0.003 
<4 years 29 (26.4) 108 (36.7) 1.58 (0.91 – 2.74) 0.104 
<5 years 30 (27.3) 113 (38.4) 1.61 (0.93 – 2.77) 0.086 
<10 years 34 (30.9) 122 (41.5) 1.63 (0.94 - 2.84) 0.080 
Ever screened 41(37.3) 134 (45.6) 1.42 (0.84 – 2.38) 0.190 
Each row represents a separate bivariate comparison of all cases and controls 
The relationship between screening history and risk of invasive cervical cancer was 
further examined by histological type. When only SCC was considered, screening 
appeared significantly protective at all screening intervals (Table 17). The protective 
effect was greater the more recently the last screening test took place. However, for 
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ACC, there was no apparent protective effect after 3 years, and only screening in the 
last one year significantly reduced risk. 
Table 17: Risk of invasive cancer in relation to time since last screen and histology 
 Matched Odds Ratio (Unadjusted) 
Invasive cancer in non-screened compared with screened population (95% 
CI) 
Time since last 
screening test 
SCC p ACC p 
< 1 year 1.36x10
1
5
 
(0 to infinity) 1.00 7.90 (1.0 – 61.5) 0.05 
<2 years 5.58 (2.27 – 13.69) <0.01 2.34 (0.78 – 7.04) 0.13 
<3 years 3.84 (1.78 – 8.28) <0.01 1.23 (0.44 – 3.45) 0.70 
<4 years 2.24 (1.13 – 4.46) 0.02 0.87 (0.32 – 2.40) 0.80 
<5 years 2.40 (1.22 – 4.72) 0.01 0.77 (0.28 – 2.10) 0.61 
<10 years 2.31 (1.18 – 4.54) 0.01 0.87 (0.31 – 2.43) 0.79 
Ever screened 2.03 (1.08 – 3.83) 0.03 1.54 (0.58 – 4.11) 0.39 
 
 
When screening effectiveness was examined separately for different age groups, the 
benefit appeared to be greatest among middle-aged women, although a higher 
proportion of controls compared with cases had attended for screening in all groups 
(Table 18).  
 
Table 18: Effectiveness of screening within last 3 years by age group 
Age group Number (%) 
screened among 
cases 
Number (%) 
screened 
among 
controls 
Matched OR (95% CI) for 
invasive cancer among 
controls compared with cases 
p-value 
20 – 40 
(n= 72) 
8 (47.1) 31 (59.6) 1.00 (0.32 – 3.10) 1.00 
41 – 60  
(n= 211) 
10 (17.9) 61 (41.2) 3.89 (1.64 – 9.22) <0.01 
61+ 
(n=137) 
3 (8.0) 13 (13.8) 1.56 (0.42 – 5.84) 0.51 
 
 
Case-control study 
-69- 
2.5.3 Factors associated with invasive cervical cancer (adjusted models): 
Conditional logistic regression was used to assess which factors were associated with 
invasive cervical cancer (being a “case”). Using the case/control variable as the 
outcome measure and the “enter method” for logistic regression, the influence of 
screening, number of sexual partners, use of the oral contraceptive pill, smoking and 
exposure to passive smoking were examined, as risk factors for developing invasive 
disease. After adjustment for the other factors, having had no screening test within 3 
years of interview was associated with a significantly greater risk of developing 
invasive cancer (Table 19). The other factors in the model also remained important 
predictors of being a “case”. Thus, having been a smoker, exposure to passive 
smoking and use of the pill for over 5 years were associated with increased risk. 
 
Table 19: Conditional logistic regression model for factors associated with invasive 
cervical cancer 
 Variables included in model (reference category) OR (95% CI) Significance 
(p-value) 
Cervical smear within last 3 years (screened) 
- Not screened 
 
2.22 
 
(1.14 
 
- 4.32) 
 
0.02 
Number of lifetime sexual partners (one) 
- Two or more 
  
2.43 
  
(1.12  
 
- 5.26)  
 
0.02 
Use of oral contraceptive pill (never used or < 5years) 
- 5 years or more 
  
2.16 
 
(1.03 
 
- 4.53) 
 
0.04 
Smoking status (never smoker) 
- Ever smoked 
 
3.61 
 
(1.76 
 
- 7.41) 
 
<0.001 
Exposure to passive smoking (not exposed) 
- Exposed to one person 
- Exposed to two or more persons 
  
1.99 
2.46 
 
(1.03 
(1.10  
 
- 3.81) 
- 5.47)  
 
0.04 
0.03 
 
 
The analysis was repeated to compare risk factors for different histological types. 
Cases were restricted to either those with squamous cell carcinoma (n=87), or those 
with adeno- and adenosquamous carcinoma (n=31), and for each case, the matched 
controls were included in the analyses. For ACC, the only significant risk factors in 
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the adjusted model were use of the oral contraceptive pill and history of smoking 
(Table 20), whereas the other factors were not associated with increased risk. On the 
other hand, after adjusting for other factors, use of the pill was not significantly 
related to squamous cell carcinoma, whereas increasing number of sexual partners, 
smoking, exposure to passive smoking, and no previous screening were all associated 
with increased risk (Table 20).  
 
Table 20: Conditional logistic regression models exploring risk factors associated with 
cervical carcinoma, by histology 
 
Variables included in model (reference 
category) 
Squamous cell carcinoma 
(n=252) 
Adenocarcinoma (n=80) 
OR (95% CI) p-value OR (95% CI) p-value 
Pap smear within last 3 years (screened) 
- Not screened 
 
3.84 (1.54 – 9.56) 
 
<0.01 
 
1.26 (0.35 – 4.54) 
 
0.72 
Number of lifetime sexual partners (one) 
- Two or more 
  
2.35 (1.01 – 5.47) 
 
0.05 
  
2.45 (0.31 – 19.65) 
 
0.40 
Use of oral contraceptive pill (never used 
or < 5years) 
- 5 years or more 
  
 
1.28 (0.52 – 3.15) 
 
 
0.59 
  
 
18.08 (1.74–188.68) 
 
 
0.01 
Smoking status (never smoker) 
- Ever smoked 
 
3.72 (1.61 – 8.63) 
 
<0.01 
 
6.37 (1.06 – 38.17) 
 
0.04 
Exposure to passive smoking (not 
exposed) 
- Exposed to one person 
- Exposed to two or more persons 
  
 
2.50 (1.15 – 5.45) 
2.91 (1.16 – 7.25) 
 
 
0.02 
0.02 
  
 
0.61 (0.13 – 2.87) 
2.43 (0.32 – 18.59) 
 
 
0.53 
0.39 
 
In the adjusted model for SCC, the OR for screening remained the same as in the 
unadjusted analysis, however, all other odds ratios reduced to a small extent. For 
ACC, almost all odds ratios increased, but particularly for use of the OCP and for 
smoking, which both remained statistically significant in the adjusted model. 
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2.6 Discussion 
Among participants in this study, screening coverage was generally low, with 39.4% 
of women having ever had a Pap smear for screening, and less than a quarter of 
women being regular attendees for screening. Generally, cases (women with invasive 
cervical cancer) were less likely to have ever had screening, particularly in more 
recent years. Just over 1 in 10 cases were detected through screening. Screening in the 
last three years was significantly protective against SCC. Risk factors for disease in 
this study were long-term use of the oral contraceptive pill (for adenocarcinoma) and 
increasing number of lifetime sexual partners, smoking and exposure to passive 
smoking (for squamous cell carcinoma).  
 
2.5.4 Strengths and weaknesses of study 
This was the first case-control study to assess the effectiveness of cervical cancer in 
Hong Kong.  
Role of bias 
We clearly differentiated women who had attended for a cervical smear as a 
diagnostic test, from those who attended for screening. This is important in order to 
minimise bias in estimating the effect size
167
. We assessed screening history by self-
report, though some studies suggest people over-report screening
168; 169
.  This would 
be important if there is a difference in recall between cases and controls, and it is 
possible that cases would have better recall of their last screening test. If this were the 
case, we may have overestimated the effect of screening.  
The selection of cases in this study was limited, as we were only able to recruit from 3 
hospitals, one of which was a tertiary referral centre. As most cases are referred to 
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hospital at diagnosis, however, we are likely to have identified a range of cases, with 
various stages of disease at presentation. The comparison of cases interviewed with 
those that we missed, suggests that the former tended to be those with less advanced 
disease, who were more likely to have attended for screening. This would mean that 
we might be underestimating the effect of screening, as a higher proportion of 
screened cases were interviewed.  
We selected controls from a random population sample rather than from the hospital, 
as they are more likely to be comparable to cases. However, almost all eligible cases 
were interviewed (>80%), whereas there was a moderate response rate to the 
population survey (62.5%). The controls may therefore be less representative of the 
general population. There is some suggestion that study responders tend to have 
higher screening rates
170
, be from a higher socio-economic group and be more likely 
to engage in a healthier lifestyle. Although in this study we matched for social class, 
the differential response rate between cases and controls is likely to bias the estimate 
of screening benefit to be greater than actual. We may also have overestimated the 
effect of behavioural risk factors.  
Role of confounding 
Although randomised controlled trials (RCT) are the gold standard method for 
evaluating the effectiveness of screening, case control studies provide an efficient 
alternative. It is likely, however, that the case-control study overestimates the 
protective effect of screening
138
.  The validity of case control studies in this respect is 
strengthened when adjustments are made for other risk factors for the disease under 
study
171
. We made adjustments for established risk factors, both by matching and in 
the analysis stage. Nevertheless, residual confounding is still possible. 
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2.5.5 Effectiveness of screening in preventing cervical cancer 
Several studies have shown that screening is protective for cervical cancer (Table 4). 
The most recent case control study in a French region with no organised screening 
programme, found that controls had a higher rate of screening within 3-years, 
compared with cases (OR 3.09)
162
.  Similar findings were reported in Mexico, where 
the risk of cancer was lower among those who had ever had screening (OR 0.4) 
159
.  
Other studies have shown risk reduction from periodic screening, ranging from 0.16 
for 3-yearly screening in Japan
109
 to 0.37 for 5-yearly screening in the UK
151
. The 
level of protection from 3-yearly screening demonstrated in this study (adjusted OR 
0.37) is in keeping with these.  
We did not find a significantly protective effect of screening for adenocarcinoma, 
though the number of cases with this histology was small. Nevertheless even the point 
estimate of benefit was lower than that for SCC, again in keeping with studies 
elsewhere
109; 126; 172
.  
2.5.6 Risk factors for cervical cancer 
Our findings were compatible with other studies in identifying the major risk factors 
for cervical cancer; namely increasing number of sexual partners, smoking and use of 
the oral contraceptive pill. HPV infection is a major risk factor, for which we were 
unable to adjust. Nevertheless, even after adjusting for HPV infection, smoking and 
use of the oral contraceptive pill have been shown to increase the risk of cervical 
carcinoma in situ in other studies
42
. A case control study in Sweden also showed that 
the relationship between smoking and increased risk of cervical cancer remained after 
adjusting for HPV infection, though the relationship with oral contraceptive pill use 
disappeared
54
. Conversely another case control study showed that among women 
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positive for HPV, use of the pill was a significant risk factor for cancer
43
. Most of 
these previous studies did not differentiate between ACC and SCC. 
Another case control study in Thailand showed that lower education, increasing 
numbers of sexual partners, interval since last screening test and smoking were all 
associated with invasive cancer, after adjusting for HPV
38
.  We found a trend for 
higher risk among those with less education, though this was not significant. 
However, any effect of education is likely to have been diminished in this study, 
given that we had matched with respect to social class.  
Initiation of an active sex life at an early age has been shown to increase risk in other 
studies
173
. We also found increasing risk with earlier age of starting sexual intercourse 
(under 19 years).  
Use of the oral contraceptive pill has particularly been shown to increase the risk of 
adenocarcinoma
35; 50; 53
 though it is weakly associated with an increased risk of 
squamous cell carcinoma in some studies. In this study, despite the small proportion 
of cases with adenocarcinoma, the use of the pill was significantly associated with 
risk in this group, whereas the risk of squamous carcinoma was not significantly 
increased. Conversely, the other risk factors were mainly significantly associated with 
squamous carcinoma of the cervix. Similar findings have been shown in other 
studies
32
. 
In addition to smoking being confirmed as a risk factor for cervical cancer in this 
study, we found that passive smoking was also an important risk factor, particularly 
among women who had never smoked. There have been few studies on this issue, and 
although a US study has shown passive smoking to be an important risk factor
77
, 
another study found no effect
81
. 
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2.6 Conclusion and implications 
The study suggested that cervical screening does offer protection against invasive 
cervical cancer, particularly SCC, among Hong Kong Chinese women. However, 
even among controls, screening coverage was low. This study therefore provides a 
strong case for introducing an organised cervical screening programme in Hong 
Kong. On the other hand, 30% of cases with more advanced disease reported that they 
had regularly attended for screening in the past, this implies a high false negative rate. 
This suggests an important role for monitoring, and for quality control measures 
among institutions currently offering screening to be reviewed. 
It was also confirmed that increasing number of sexual partners, active and passive 
smoking and long term use of the oral contraceptive pill increase the risk of invasive 
cervical cancer. These are important if a targeted screening programme is planned, 
rather than one that targets all women. In addition, these are important messages for 
health promotion. 
Finally, the finding of a significant increase in risk of cervical cancer with exposure to 
passive smoking among non-smoking women has important public health 
implications. The evidence on passive smoking as a risk factor has not been clear in 
the past, and this study provides more evidence to support this as a risk factor. 
Although smoking rates among women in Hong Kong may be lower than that among 
men
122; 174
, non-smokers may be exposed to passive smoke at home. This has 
important implications for health protection, and strengthens the argument for 
promoting non-smoking in public indoor places. 
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3 A CROSS-SECTIONAL STUDY OF THE PATTERN OF 
CERVICAL CANCER SCREENING IN HONG KONG 
3.1 Summary 
This cross-sectional study was undertaken to assess the pattern of cervical cancer 
screening in Hong Kong. In particular, the objectives included assessing the age-
specific coverage for screening, factors associated with screening uptake and barriers 
to attendance and the relationship between risk, risk perception and screening 
attendance. In addition, the results of the study were used to assess the effectiveness 
and efficiency of the current system of cervical screening in Hong Kong. The current 
system was compared with what could be achieved through an organised programme. 
Methods 
This was a cross-sectional study, interviewing a random selection of Chinese women 
in Hong Kong. The main outcome measure was coverage and frequency of Pap smear 
screening and the sample size was selected to allow coverage to be estimated in three 
main age bands (20 – 39, 40 – 59 and 60 and over). In addition information was 
obtained on socio-demographic and health behavioural characteristics, as well as 
perceived risk. The relationship between these and screening behaviour was 
examined. The coverage and screening frequency obtained was used to estimate the 
effectiveness (number of cases of invasive cervical cancer potentially prevented) and 
efficiency (tests per case prevented) of the current screening system. Potential 
effectiveness and efficiency of various organised programmes with different 
screening intervals and coverage were also estimated.  
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Results 
A total of 1,826 women participated in the study (response rate 62.5%). Ever 
screening coverage was 43.2% (95% CI 40.8 – 45.5) with regular attendance in 25.2% 
(95% CI, 23.1 – 27.2). Coverage was lowest in the oldest age group (47.3%, 54.7% 
and 20.6% for the 20-39, 40-59 and 60+ age groups respectively). Among those who 
reported attending for screening regularly, most attended annually or more frequently. 
 
Women who attended for screening tended to be in the higher socio-economic groups, 
to be married and to have better knowledge about cervical screening. They also 
tended to engage in other health protective behaviours, such as not smoking, attending 
for mammograms and for regular dental checkups.  
There was no relationship between overall epidemiological risk (based on a risk 
score) and attendance for screening, however attendees tended to have higher 
perceived risk and to express more worry about cervical cancer.  
The main barrier identified for non-attendance was not knowing what cervical 
screening was, and not wanting to attend (80% of non-attendees). Inconvenience and 
resource implications were also reasons given by about 15%, whilst a small 
proportion attributed their non-attendance to fear, anxiety, pain and finding the 
procedure humiliating. 
We estimated that the current system prevents about 40% of potential new cases of 
invasive cancer, with 2,192 tests per case prevented. In comparison we expect an 
organised programme with 5-yearly screening to achieve 80% coverage and to almost 
halve the number of incident cases with 70% fewer tests per case prevented.  
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Conclusions 
The current ad-hoc screening system in Hong Kong achieves poor coverage, whilst 
over-screening a minority of lower risk women. Thus the system is inefficient and 
may be resulting in unnecessary harm. At best, the effectiveness of the current system 
is equivalent to an organised programme with 10 yearly screening, but at much 
greater cost.  
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3.2 Introduction 
Cervical cancer is an important cause of morbidity and mortality among women 
world-wide
175
. However, despite good evidence that effective prevention can be 
provided by screening
5
, not all women attend. There has been much research to 
investigate the reasons for screening attendance and non-attendance in different 
communities (see section 3.2.1), and what factors are associated with uptake. 
However, few have been done in Chinese populations.  Although many industrialised 
countries have adopted organised screening programmes, this is by no means 
universal. Reported uptake of screening in regions with no organised programme, 
vary widely (see section 3.2.2) and there are few studies formally comparing ad-hoc 
with organised programmes. This study, funded by the Health Services Research 
Committee in Hong Kong, was an attempt to address some of these issues by 
providing information relating to the uptake of screening in Hong Kong. 
 
3.2.1 Factors associated with uptake and barriers to attending for screening 
Socio-demographic factors, knowledge, other health protective behaviour  
Many studies have shown that low socio-economic status is related to non-attendance, 
even where screening coverage is high
176-180
. However, this is not confirmed in other 
studies
181; 182
, based on regions with organised screening programmes. Other factors 
shown to be associated with non-attendance include low educational level
183; 184
, 
being single
177; 182; 184
 and older age
183-188
. These factors are reported in regions with 
and without organised screening.  
Poor knowledge about the purpose of screening has also been shown to be a risk 
factor for non-attendance
179; 180; 189; 190
. In a cross-sectional study of women in Canada, 
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of almost 9,500 women who had not had a recent screening test, over half reported 
they did not think it was necessary
184
. Another study including 2,510 women aged 35 
to 69 in Iceland, found that the most common reason given by non-attendees was that 
they did not want to participate
191
. Similar barriers have also been shown to be 
important in qualitative studies. One study in Mexico, where the incidence of cervical 
cancer is relatively high and there is no screening programme, used focus groups to 
explore barriers
192
. Lack of knowledge about cervical cancer and not knowing that a 
screening test exists were the main themes emerging as reasons for non-attendance. 
Other themes included problems in doctor-patient relationships, long waiting times 
and perceived high costs. Women with negative health protective and lifestyle 
characteristics are also generally less likely to attend for cervical screening
184
. In a 
survey of 843 women over the age of 50 years in the USA, those who attended for 
cervical screening
193
 were also more likely to have attended for mammography.  
The characteristics of women attending for screening in Hong Kong have not been 
previously examined, and we therefore sought to determine if the pattern observed 
elsewhere was also applicable to this region. 
 
Risk, risk perception and screening 
Perceptions of risk are thought to be important motivators of action, encouraging 
individuals to take part in preventive programmes such as screening
194
. Risk 
perception is the central construct within many theoretical models of health 
behaviour
195
, including the “Health Belief Model”196. Beliefs about disease risk and 
severity are thought to influence adherence to health promoting behaviours and aid in 
decision making for appropriate use of health services. Studies aimed at influencing 
risk perception lend some support to these theories, suggesting that behaviour can be 
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modified in this way
197
.  A meta-analysis of the relationship between perceived risk of 
breast cancer and uptake of mammography screening found a significant positive 
association
198
. However, reviews of studies of cervical or colorectal cancers showed 
no conclusive association between risk perception and screening behaviour 
195
. This 
was partly because of the small number of studies that have examined such 
relationships, particularly for cervical screening. Worry about cancer has also been 
shown to be strongly and positively associated with uptake of screening for 
colorectal
199
 and breast 
198; 200
 cancer. Although some suggest that worry is an aspect 
of perceived risk, the two measures are poorly correlated
201
. Previous studies have not 
reported the relationship between worry and uptake of cervical screening.  
In contrast to perceived risk, there is much evidence that women with higher objective 
risk for disease are less likely to access preventive health care
202-205
. In relation to 
cervical screening however, some studies suggest that women at higher risk are better 
screened, or no less likely to be screened than those at low risk
206-209
, particularly 
where there are organised programmes. Several studies have examined the 
relationship between perceived risk and objective measures of risk for breast 
cancer
195
. These have had mixed results, some showing no association, while others 
found some relationship between these measures. No previous published study has 
compared objective risk with perceived risk for cervical cancer. 
3.2.2 Effectiveness and efficiency of opportunistic screening compared with 
organised screening 
Evidence of the efficacy of Pap smear screening comes mainly from historic studies 
describing the effects of the introduction of well organised screening programs
94-96
 
and case control studies
151; 156
. These clearly show that screening results in a reduction 
in both the incidence and mortality from invasive cervical cancer. Two aspects of a 
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screening programme contribute to these benefits. First, there is a strong correlation 
between the extent of screening coverage and fall in mortality
99; 101
. Second, the 
screening interval is important in determining the amount of risk reduction. Analysis 
of data from large screening programmes in eight European and North American 
centres for a period of over 20 years has been used by the IARC to quantify the 
reduction in the probability of developing cervical cancer with varying screening 
intervals
102
 (adapted in Table 21). As discussed in chapter 1, these estimates are 
considered valid and credible (see page 18). 
Table 21: Percentage reduction in cumulative rate of invasive cervical cancer in women 
(age 35 to 64) screened at different intervals (source reference 
102
 
(Assuming the woman has had at least one previous screen) 
Frequency of 
screening (IARC 
data) 
Screening interval 
(months) 
Percentage reduction in 
cumulative incidence 
Percentage having 
screening test in 1 
year 
Number of tests in 
lifetime 
Yearly 0 - 11  93.5 100 30 
2-yearly 12 - 23 92.5 50.0 15 
3-yearly 24 - 35  90.8 33.3 10 
 36 – 47a 87.1 25.0 8 
5-yearly 48 –71b 83.6 20.0 6 
 72 – 119c 71.3 12.5 4 – 5 
10-yearly 120 64.1 10.0 3 
 ≥ 120 
d
 37.5 6.7 1 – 2 
No screening  0 0 0 
a
 Interpolated as square root [90.8 x 83.6] 
b 
Average benefit during interval assumed to be same as 5 years 
c 
Average benefit during interval assumed to be same as 8 years. The % reduction in cumulative 
incidence from a screening interval of 5 years (83.6%) compared to 10 years (64.1%) is equivalent to a 
reduction in benefit of 94.8% per year  
d  
Based on assumption that reduction in benefit continues at 94.8% per year for another 10 years 
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The incremental benefit achieved by reducing the screening interval from three years 
to one year is small. Furthermore, even screening once every 10 years reduces the 
incidence of invasive cancer by almost two thirds. Following one negative screening 
test result, a second test reduces the chances of false negatives, and therefore 
improves the sensitivity of screening
102
.   The IARC study was based on women with 
at least two negative screening test results, which probably explains why the level of 
risk reduction exceeds that expected from the relatively low sensitivity of cervical 
smear tests
22
. The IARC study also showed that the protection offered by screening 
was independent of age. In particular, women under the age of 35 were at no greater 
risk of developing fast growing tumours. The data on older women is sparse, but what 
is available suggests the same relative benefits would be expected
102
. 
A recent analysis of screening programmes in the European Union found that only six 
out of 15 countries have nationally organised programmes
210
. Seven others have 
regionally organised programmes some of which only cover parts of the national 
population. The 3-year population coverage of screening among these countries 
varied from 50 to 82%
211
. Furthermore, in some parts of North America and most 
low-resource countries, screening is offered opportunistically.  In the absence of an 
organised call and recall system, opportunistic screening tends to achieve a lower 
coverage 
55; 183
 although opportunistic screening rates as high as 91% have been 
reported
212
. Previous studies have not attempted to estimate the effectiveness and 
efficiency of opportunistic screening, and how this would compare with an organized 
system. 
This study aimed to explore a method for assessing the effectiveness and efficiency of 
opportunistic screening programmes, and using data from the cross-sectional study in 
Hong Kong. Hong Kong has no organized screening programme, though various 
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public and private providers offer opportunistic screening.  Information on age-group 
specific screening coverage and frequency is used to estimate the potential benefits of 
the current system and compare this with what could be expected from various 
screening policies within an organized programme.  
 
3.3 Aims and objectives 
The aim of this study was to examine the pattern of cervical cancer screening in Hong 
Kong.  The main questions addressed were: 
3.3.1 Coverage and pattern of screening 
1. What proportion of Chinese women living in households in Hong Kong had been 
screened for cervical cancer at least once in specific periods? 
2. What was the age specific coverage for cervical cancer screening (i.e. the 
percentage of women in each age group who had been screened at least once 
during defined periods) amongst women living in a household in Hong Kong? 
3. What was the screening interval for women who attended screening regularly? 
3.3.2 Factors associated with screening and barriers to uptake: 
4. What was the level of knowledge about,  and attitude towards,  cervical cancer 
and screening among Chinese women in Hong Kong? 
5. What factors were associated with the uptake of cervical cancer screening? 
6. What were the reasons for women not participating in screening? 
3.3.3 Risk, risk perception and screening behaviour 
7. What was the relationship between perceived risk, objective risk and screening 
behaviour in relation to cervical cancer in Hong Kong?  
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3.3.4 Effectiveness and efficiency of current screening system in Hong Kong 
8. How effective was the existing system of screening in Hong Kong, in terms of 
number of cases of invasive cervical cancer prevented? 
9. How efficient was the existing system, in terms of number of screening tests per 
case prevented? 
10. How did the existing level of effectiveness and efficiency compare with what 
could be expected in an organised system? 
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3.4 Materials and methods 
During 1997 to 1998, a cross-sectional study was completed, using telephone 
interviewing to contact Chinese women resident in Hong Kong. Telephone coverage 
in this population is close to 100%.
174
 The Health Services Research Committee of 
Hong Kong funded the study and approval was obtained from the ethics committee at 
the University of Hong Kong. 
3.4.1 Sample size estimation 
We sought to recruit equal numbers of women from each of three age groups: 20-39, 
40-59 and 60 or over. In order to estimate the coverage of screening in each age group 
with a precision of 4%, we calculated that at least 577 women would be required in 
each group.  
3.4.2 Subjects and sampling method  
Eligible subjects were Hong Kong Chinese women who were aged 20 years or more. 
Women who had a hysterectomy were excluded. Initially, telephone numbers were 
selected using a random digit dialling method. If there was no response, three further 
attempts were made over two weeks. Once contact was established, all eligible 
women in the household were identified, and one was randomly selected and invited 
to participate in the study. This method resulted in a greater proportion of women in 
the younger age group being identified, representing the distribution of age groups in 
the population. Once sufficient numbers in this group were recruited, sampling 
criteria were changed to include only women in the older age groups. Because very 
few women in the oldest age group responded, convenience sampling was used to 
complete recruitment in this group. Two researchers attended twenty elderly centres 
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in different parts of Hong Kong and conducted face-to-face interviews with women 
attending for health and social activities. 
3.4.3 Study Instrument:  
Trained researchers conducted all interviews according to a strict schedule, using a 
standard introduction, algorithm and questionnaire for selection and interviewing. The 
questionnaire was developed based on instruments used for a similar purpose in other 
published studies
164; 165
. Questions were adapted, and translated to Chinese from 
English. The final questionnaire was piloted and validated on a sample of 30 women 
and amended before the final version (Appendix 1). The main outcome measure was 
whether the woman had ever had a cervical smear and the reason for their last test. 
Women whose last smear was done because of a gynaecological symptom were 
classified as having had a diagnostic smear, whereas those who had this as part of a 
routine or opportunistic check up were regarded as having had a screening smear. The 
time of the last screening smear and the frequency of screening, for those who were 
regular attendees, were also determined. In addition, all women were asked about 
their intentions to attend for screening in the future. Other variables measured 
included:  
 Socio-demographic data 
 The individual‟s main risk factors for cervical cancer; 
 The reasons for non-attendance amongst those who have not been screened; 
 Other factors that may contribute to attendance or non-attendance; 
 Willingness to pay for cervical screening (not presented in this thesis). 
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3.4.4 Data collection and management  
A project manager supervised data collection,  monitored a sample of interviews 
conducted by interviewers and conducted a validation study by making a repeat call to 
5% of the women some days after the interview, to recheck key variables, including 
the date of last Pap smear. After data entry, coding, logical checks and data cleaning 
were carried out.  
3.4.5 Data Analysis: 
Data were analysed using the SPSS statistical software. Descriptive analysis was used 
to illustrate screening coverage and frequency, as well as the reasons for non-
attendance and the barriers to screening. In addition, the relationship between the 
uptake of screening, risk perception and risk factors for developing cervical cancer 
were examined. A combination of descriptive and multivariate analyses were used to 
address these objectives. 
Assessment of knowledge and attitude 
Women were asked whether or not they agreed with certain statements, which 
assessed knowledge, attitude and perceptions of their risk for cervical cancer (box 2). 
Box 2: Statements to assess knowledge attitude and perceived risk 
1) Permissive sexual behaviour will increase risk of cervical cancer 
2) Having regular smear test can help preventing cervical cancer 
3) A Pap smear can detect signs of pre-cancer before it develops 
4) If the result of Pap smear is abnormal, it means cancer has developed 
5) Women who get cervical cancer have only themselves to blame 
6) It's completely a matter of chance who gets cervical cancer 
7) I think I'm personally at risk of cervical cancer 
8) I'm less likely than average to get cervical cancer 
9) Women should have regular smears 
10) Diagnosis of cervical cancer would be worrying 
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Responses to statements 1 and 2 (knowledge) and 5 and 6  (attitude) completed were 
combined to form a knowledge score and attitude score respectively (Table 22). The 
total scores ranged from –2 to +2. Screening practice was compared with knowledge 
and attitude scores.  
Statement 3 was initially presented to all women, but interim analysis suggested that 
the question was badly worded and almost all women were agreeing with it. The 
statement was replaced by statement 4, part way through the study. 
 
Table 22: Scoring system used for assessing knowledge and attitude 
 
Statements 
Score according to whether agree 
Agree Disagree Unsure/ neutral 
Permissive sexual behaviour will increase risk of cervical cancer +1 -1 0 
Having regular smear test can help preventing cervical cancer +1 -1 0 
Women who get cervical cancer have only themselves to blame -1 +1 0 
It's completely a matter of chance who get cervical cancer -1 +1 0 
 
Objective and perceived risk assessment 
The objective assessment of risk was based on a validated risk scoring system
213
. This 
system categorises women to higher and low risk, according to their history of 
smoking, number of sexual partners, level of education and use of the oral 
contraceptive pill (Table 23). Using a cut-off value of score 3, gives the maximum 
sensitivity of 85% for risk of being diagnosed with pre-invasive cervical lesions. 
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Table 23: Basis for risk scoring system used in study 
Risk factor Risk level Score 
Educational level Matriculation or above 0 
 Other 1 
Smoking status Never smoker 0 
 Ever smoker 1 
Use of oral contraceptive pill <5 years 0 
 >5 years 1 
Number of lifetime sexual partners 1 0 
 2 1 
 3 or more 2 
TOTAL RISK SCORE  Range 0 – 5  
 
Using this risk score assessment,  women were categorised as being at higher risk (3-
5) or lower risk (0-2). Women were compared in relation to their screening history 
and their perceived risk, according to their risk factors and risk scores.  
For the subjective assessment, women were asked whether they considered 
themselves to be less likely than average to develop cervical cancer, and those 
responding affirmatively were categorised as having low perceived risk. Women were 
further categorised into four broad groups according to how their perceived risk 
compared to their objective risk (Table 24). The screening history and demographic 
characteristics of these women were compared. First, among women with lower risk 
scores, those who had low risk perception (low risk realists) were compared with 
those who overestimated their risk (pessimists). Next, among those with high risk 
scores, women who did not have low risk perception (high risk realists) were 
compared with those who underestimated their risk (optimists). Women‟s level of 
worry about a diagnosis of cervical cancer was assessed on a five-point scale, ranging 
from “extremely worrying” to “not at all worrying”. 
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Table 24: Perceived risk category according to objective and subjective risk assessment 
 
Perceive risk lower than average 
Objective risk 
Low (risk score 0-1) Higher (risk score 2-5) 
Yes Realist (low risk) Optimist 
No Pessimist Realist (high risk) 
 
 
 
Assessment of effectiveness and efficiency of screening 
Modelling was done using Excel, using the results of the cross-sectional study. The 
model was based on combining Table 21 with the data obtained on the screening 
coverage, frequency and the interval since the last screening test in our population. 
The effectiveness of the current screening system was estimated, in terms of number 
of cases potentially prevented and percentage reduction in incidence as a result of 
screening.  Details of the calculation are in Appendix 2. The calculations were 
repeated using different assumptions for age-group and interval-specific screening 
coverage, to obtain the most extreme estimates for the benefit derived from the 
current system. For the most pessimistic scenario, it was assumed that only women 
who currently attend regularly will continue to do so and their screening frequency 
was adjusted for when they had their last screening test. Thus, for example, if a 
woman said she attended regularly every 2 years, but in fact had not had a test for 5 
years, a screening interval of 5 years was used for the calculation. It was further 
assumed that for irregular attendees, and women who have only had one screening 
test, the benefit was the same as for screening every 10 years. For the most optimistic 
scenario, the stated likelihood of attending for screening in future was used, and what 
the women thought the screening frequency should be, whether or not they had 
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specific plans for attendance. This scenario was based on women following through 
with their stated intentions. 
For the basic model several assumptions were made. First, it was assumed that all 
women could derive the same level of benefit from screening, irrespective of age, 
screening attendance and other risk characteristics. Second, that compared with those 
who had never been screened, women who had their last test over 10 years ago still 
derived some benefit. Finally, it was assumed that the screening process in Hong 
Kong achieved the same level of benefit as that demonstrated in the IARC report (i.e. 
the test sensitivity and effectiveness of treatment offered to screen positives was the 
same).  A sensitivity analysis was performed by adjusting the key variables in the 
model, including the background incidence of disease among those screened, and the 
sensitivity of screening. 
It was estimated the efficiency of the current screening system by predicting the 
number of screening pap smears per case of invasive cancer potentially prevented per 
year (the number needed to screen). The number of screening tests per year was 
estimated from the proportion of women in each age group who were screened at 
various intervals and applied to the total number of women in the population. Thus for 
example, the proportions that were screened at 6-monthly, yearly and 2-yearly 
intervals would have 2, 1 and 0.5 smears per year respectively. Sensitivity analysis 
were also performed for the estimates of efficiency. 
The effectiveness and efficiency of hypothetical programmes in an organised 
screening system, which achieve high coverage, were predicted. The current system 
was compared with these predictions. 
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3.5 Results:  
A total of 1,826 women between the ages of 20 and 77 were interviewed during the 
period from September 1997 through December 1998. The majority completed the 
whole interview schedule, although 122 (6.6%) were only partially completed. 
Among those interviewed, 1,121 (61.4%) were sampled using random digit dialling. 
Once the minimum number of women in the 20-39-year age group sampling targeted 
women over the age of 40. A further 255 interviews were performed by telephone, 
and the remaining 450 women were recruited by convenience sampling from 20 
elderly centres situated in 14 different districts of Hong Kong  (Table 25 and Table 
26).  
The overall response rate for the study was 62.5%. For the telephone interviews, the 
response rate was 56.0% and for the face to face interviews 99.3% (Table 27). 
 
Table 25: Numbers of women recruited by each sampling method, by age group 
Age group Sampling method Number interviewed  
20 - 39 Random telephone survey 584 
40 - 59 Random telephone survey 
Targeted telephone survey 
461 
161 
60-77 Random telephone survey 
Targeted telephone survey 
Face to face interview at elderly centre 
88 
82 
450 
 
Cross-sectional study 
-94- 
Table 26: Sources used for recruiting older participants and numbers interviewed at 
each location 
Elderly Centre No. interviewed District 
Aberdeen Social Service Centre  12 Southern 
Yan Oi Tong Woo Chung Multiservice Centre  22 Tuen Mun 
St James' settlement Social Centre  26 Wan Chai 
Sha Tin Multi-service Centre  25 Sha Tin 
Lei Tung Social Centre  14 Southern 
Hong Kong Christian Service Multi-service Centre  12 Kwun Tong 
SAGE Chan Tseng Hsi Tsuen Wan Multi-service Centre  12 Tsuen Wan 
SAGE Fong Shu Chuen Social Centre  21 Eastern 
Mong Kok Social Service Centre 30 Yau Tsim Mong 
YWCA Sai Wan Estate Social Centre  28 Mid Western 
The Salvation Army Tai Po Multi-service Centre  26 Tai Po 
Asia Women's League, Yau Ma Tei Social Centre  44 Yau Tsim Mong 
Women's Welfare club Young Shu Cheung social Centre  38 Eastern 
SAGE Eastern District Multi-service Centre  28 Eastern 
Social Service Centre Wan Sing Mem. Social Centre 55 Yuen Long 
Oi Man Social Centre  5 Kowloon city 
Cheung Hong Baptist Church Social Centre  16 Kwai Tsing 
The Endeavourers Bert James Young Social Centre  11 Eastern 
Hong Kong Baptist Hospital Au Shue Hung Health Centre 16 Kowloon city 
Hong Kong YWCA Cheung Ching Social Centre  9 Kwai Tsing 
 
Table 27: Summary of response rates by survey method 
 Telephone 
survey 
Elderly centre 
interviews 
Successful completion of interview 1,253 450 
Partial completion of interview 123 0 
Interview refused 1,134 3 
Unable to contact*  3,051 - 
Non-residential telephone line 2,711 - 
No eligible women in household 
     Age or no women 
     Hysterectomy 
 
1,898 
73 
 
- 
- 
 
* Households where there was no response from telephone on at least 4 attempts over two weeks, at 
different times of day (includes households where a family member responded, but contact with the 
women eligible for the study was not possible on successive occasions, because she was not at home).    
Cross-sectional study 
-95- 
3.5.1 Validity and reliability of sampling 
The women interviewed using the random telephone survey were fairly similar to the 
census population of women in terms of social class, and district of residence. 
However, the study was designed so that the overall sample (including those 
interviewed by targeting and convenient sampling) had a different age structure from 
the census population. The overall sample had a different age and educational profile, 
but was similar in terms of residential location and social class compared with the 
census population (Table 28).  
Based on the 5% sample of women re-contacted, the overall repeatability of key 
responses was 95% and for the question on screening status it was 100%.  For the 
main variable in our estimates, coverage, we compared the women in the oldest age 
group recruited by telephone with those interviewed at elderly centres. Both groups 
were similar in terms of overall and interval-specific coverage.  
Table 28: Comparison of survey population with the Hong Kong Census population  
Characteristic Total survey population (%) 
N = 1826 
Random digit dial (%) 
N = 1113 
1996 HK Census (%) 
Level of education 
   None 
   Primary/ Lower secondary 
   Upper secondary / 6
th
 form 
   Tertiary 
 
314 (17.2) 
829 (45.4) 
493 (27.0) 
190 (10.4) 
 
790 (7.10) 
486 (43.67) 
395 (35.49) 
153 (13.75) 
 
9.49 
41.55 
33.79 
15.17 
Age group 
   20 – 34 
   35 – 44 
   45 – 54 
   55 – 64 
   65 – 74 
 
380 (20.8) 
477 (26.1) 
293 (16.0) 
203 (11.1) 
473 (25.9) 
 
376 (33.8) 
393 (35.3) 
213 (19.1) 
82 (7.4) 
47 (4.2) 
 
38.6 
26.8 
14.6 
10.8 
9.3 
District of residence 
   Hong Kong Island 
   Kowloon 
   New Territories  
 
447 (24.5) 
498 (27.3) 
875 (47.9) 
 
209 (18.8) 
317 (28.5) 
573 (51.5) 
 
22.2 
32.8 
44.4 
Social class 
I 
II 
III 
IV 
 
442 (24.2) 
526 (28.8) 
540 (29.6) 
318 (17.4) 
 
295 (26.5) 
341 (30.6) 
299 (26.9) 
178 (16.0) 
 
32.9 
23.1 
27.7 
15.4 
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3.5.2 Sources of information on cervical screening  
In general, more than two thirds of women (1250/1826 = 68.5%) had heard of 
cervical screening before the interview. The most common source of information 
about the test was health professionals, particularly GPs and family planning clinics 
(FPC). However, friends and family members and the media were also important 
sources of information (Table 29 and Figure 10). 
 
Table 29: Summary of reported sources of information on cervical screening  
Source of information Number (%) who heard from this source 
Health professionals  (mainly GP and FPC) 467 (25.6) 
Media (mainly TV and newspaper) 265 (14.5) 
Friends & family (mainly friends and neighbours) 131    (7.2) 
Health professionals and media 166 (9.1) 
Friends & family and media 79 (4.3) 
Friends & family and health professionals 53 (2.9) 
All sources 39 (2.1) 
Never heard 570 (31.2) 
Not sure or missing data 56 (3.1) 
 
 
Figure 10: Knowledge of cervical smear and main source of information  
 
 
Other
TV & radio
Newspaper 
or magazine
Not heard
Not sure
Heard about 
Pap Smear Health care 
worker
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family
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In terms of socio-demographic factors, those who had not heard of the test were more 
likely to be single, to be in the lower social classes (based on own or partner‟s current 
employment, whichever was the higher) and have a lower level of education. Women 
who were 30-49 years old were most likely to have heard of the test, and elderly 
women least likely (Table 30). 
 
Table 30: Logistic regression model for socio-demographic factors associated with 
having heard of cervical screening 
Woman’s characteristics Number (%) 
heard of test 
Adjusted OR for hearing 
about test (95%CI) 
Significance 
(p-value) 
Age (70+ years as referent) 
   20 – 29 years 
   30 – 39 years 
   40 – 49 years 
   50 – 59 years 
   60 – 69 years  
109 (15.0)   
0.003 
<0.001 
<0.001 
0.003 
0.014 
328 (17.4) 2.25 [1.31 – 3.85] 
385 (32.7) 4.90 [3.07 – 7.83] 
105 (44.0) 4.65 [3.03 – 7.12] 
202 (57.9) 2.07 [1.27 – 3.36] 
121 (38.9) 1.56 [1.09 – 2.21] 
Marital status (single as referent) 
   Married or co-habiting 
   Divorced / widowed / separated 
83 (49.7)   
<0.001 
<0.001 
980 (74.5) 5.05 [3.19 – 8.00] 
187 (54.4) 6.03 [3.48 – 10.46] 
Social class (4 as referent) 
   1 
   2 
   3 
339 (29.1)   
0.014 
0.005 
0.050 
370 (33.7) 1.64 [1.10 – 2.44] 
356 (42.7) 1.64 [1.16 – 2.31] 
181 (31.3) 1.37 [1.00 – 1.89] 
Highest level of education  
(No formal schooling as referent) 
   Primary / lower secondary 
   Upper secondary / matriculation 
   Tertiary 
    
 
<0.001 
<0.001 
<0.001 
132 (40.7)  
588 (70.9) 1.96 [1.44 – 2.68] 
384 (79.3) 3.07 [2.00 – 4.72] 
144 (77.4) 4.19 [2.31 – 7.58] 
 
3.5.3 Coverage and pattern of screening 
History of Pap smear screening (Objectives 1 to 3) 
Among responders, 111 (6.1%) claimed to have never had sexual intercourse, and 
were therefore at low risk of cervical cancer and not strictly eligible for screening. A 
further 87 (4.8%) did not want to answer this question. Excluding those with no 
previous sexual partners, 795 women (43.5%) had ever had a cervical smear test and 
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25 (1.5%) were unsure (22 of these reported having a gynaecological examination at 
some time, which may have been a smear). Among those who had a previous test, 54 
women (6.8%) had this as a result of gynaecological symptoms (classified as a 
diagnostic smear). Thus the proportion of women who have ever had a screening 
smear test in this population was 40.7% (95% CI 38.4 – 42.9).  This is equivalent to 
coverage of 44.5% in Hong Kong, after standardising to the age structure of women in 
the population. The screening history of responders is summarised in Table 31.  
 
Table 31: History of Pap smear testing according to sexual history 
  Had 
Diagnostic 
smear 
Ever had screening Pap smear Total 
Yes No Unsure Missing 
Ever had 
sexual 
intercourse 
Yes 52 706 843 23 - 1624 
No  3 108  - 111 
Prefer not 
to answer 
2 32 51 2 1 88 
Missing - 1 2 - - 3 
 Total 54 (3.0%) 742 (40.6%) 1004 (55.0%) 25 (1.4%) 1 (0.05%) 1826 
 
 
Among women who reported no previous sexual intercourse, 3 (2.7%) had attended 
for a screening test. One of these women was being screened regularly (3 tests in 
previous 5 years).  
Women who reported no previous sexual intercourse (n=111) were excluded for the 
remaining analysis on coverage, as they would not be eligible for screening within a 
programme. Screening coverage over the last 3 and 5 years (Table 32) was 33.8% 
(95% CI 31.6 – 36.0) and 37.8% (95% CI 35.5 – 40.1) respectively (equivalent to 
36.3% and 40.8% respectively when standardised to the Hong Kong population).  
When examined by age group, screening coverage was lowest in the oldest age group, 
where just over one in five women reported ever having had a screening test (Table 
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33).  Among women eligible for screening (n=1715) 104 (6.1%) had only had one 
such test and only 427 (25.0%, 95% CI 23.1 – 27.2 of all responders) attend for 
regular screening. The majority of regular attendees (345/427 = 80.8%) attended at 
least once per year and 99% (n= 423) attended at least 3 yearly.  The maximum 
screening interval was 3-4 years. A proportion (n= 94, 5.5%) attended for screening 
more than once per year. Smear tests taken for screening at intervals of less than three 
years are considered as “excess smears”212. Overall 24.7% of women (n=423) had 
attended more than 3-yearly, contributing to 780 excess smears over this period 
(calculation based on number of smears in excess of one every 3 years among 423 
women. Thus 94 had between 4 and 5 smears in 3 years (=433), 250 had between 2 
and 3 (=625), 54 had 2 tests (=108) and 25 had between 1 and 2 (=37). Of these 
smears, 780 [1240 – 423] were excess). 
Table 32: Time since last screening test by age group, for women with ≥2 previous tests, 
or one test but planning to re-attend  
Screening interval (months) Number (%) in each age group ALL 
GROUPS 
(n=1,712) 
20-39 
(n=497) 
40 – 59 
(n=609) 
60 + 
(n=606) 
0-11  139 (28.0) 168 (27.3) 38 (6.3) 343 (20.0) 
12-23  73 (14.7) 74 (12.2) 25 (4.1) 172 (10.1) 
24-35  23 (4.6) 25 (4.1) 15 (2.5) 63 (3.7) 
36-47  11 (2.2) 16 (2.6) 6 (1.0) 33 (1.9) 
48-71  12 (2.4) 19 (3.1) 5 (0.8) 36 (2.1) 
72-119  7 (1.4) 12 (2.0) 6 (1.0) 25 (1.5) 
≥ 120  0  14 (2.3) 14 (2.3) 28 (1.6) 
Only 1 test, no plans for future attendance 11 (2.2) 11 (1.8) 17 (2.8) 39 (2.3) 
Diagnostic smear only 13  (2.6) 23 (3.8) 18 (3.0) 54 (3.1) 
Never screened (or unsure) 208 (41.9) 249 (40.9) 461 (76.2) 918 (53.7) 
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Table 33: Screening coverage over the last 3years, 5 years, or in lifetime, by age group 
 Proportion (95% CI) screened in time period in each age band 
20 – 39  40 – 59  60+ 
Ever screened 47.3 (43.2 – 51.3) 54.7 (50.7 – 58.5) 20.6 (17.6 – 24.0) 
Screened within 5 years 45.4 (41.4 – 49.4) 48.9 (45.0 – 52.8) 15.5 (12.8 – 18.5) 
Screened within 3 years 41.1 (37.2 – 45.1) 44.1 (40.2 – 48.0) 14.0 (11.5 – 17.0) 
 
 
 
 
Consequences of screening 
Of the 795 women who had a previous cervical smear test, 21 (2.6%) had an 
abnormal result for their last test, and a further 17 (2.1%) probably did so. Among 
these 38 women without a normal result, 8 (21.1%) had a diagnostic smear, as a 
consequence of gynaecological symptoms, but the remainder had attended for 
screening.  This translates to an abnormal smear rate of 4% (30 of 741 routine smears) 
for all women attending for screening. Among those with an abnormal result, 18 
mentioned their treatment (Table 34). 
 
Table 34: Type of follow-up or treatment following last abnormal cervical smear 
Type of follow up treatment Number (%) with definite abnormal smear 
Repeat smear in 6 months 1 (4.8) 
Medical treatment (tablet or ointment) 13 (61.9) 
Invasive treatment (surgery/ radiotherapy) 5 (23.8) 
No response 2 (9.5) 
 Number (%) with probably abnormal smear 
Had treatment (not specified what) 9 (52.3) 
Not recall what type of assessment/ treatment 8 (47.1) 
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3.5.4 Factors associated with screening and barriers to uptake 
Knowledge and attitude towards screening (objectives 4 – 5) 
The majority of women had good knowledge about the risk of cervical cancer and the 
benefits of screening. For almost all statements, women who had previously attended 
for screening themselves were significantly more likely to be more knowledgeable 
and to have more positive attitudes favouring screening. However, over half of those 
responding to these questions, wrongly believed that if the test results are abnormal, it 
means cancer has developed. Women who had a previous screening test were more 
likely to have good knowledge (Table 35). 
 
Table 35: Knowledge, attitude and perceived risk in relation to cervical screening, by 
screening status 
 
Statements (number of responders) 
Number (%) who agreed  p-value for difference 
between screened and 
unscreened (based on χ2) 
Ever had a screening test 
No Yes Total 
Permissive sexual behaviour will 
increase risk of cervical cancer (1740) 
682 (67.5) 567 (77.8) 1249 (71.8) <0.001 
Having regular smear tests can help 
prevent cervical cancer (1740) 
811  (80.1) 620 (85.2) 1431 (82.2) 0.004 
A Pap smear can detect signs of pre-
cancer before it develops (736) 
262 (70.8) 288 (78.7) 550 (89.9) 0.009 
If the result of Pap smear is abnormal, 
it means cancer has developed (565) 
220 (53.7) 76 (49.0) 296 (52.4) 0.187 
Women who get cervical cancer have 
only themselves to blame (1742) 
425 (42.0) 174 (23.9) 599 (34.4) <0.001 
It's completely a matter of chance who 
get cervical cancer (1738) 
594 (58.8) 317 (43.5) 911 (52.4) <0.001 
I think I'm personally at risk of 
cervical cancer (1747) 
331 (32.5) 300 (41.2) 631 (36.1) <0.001 
I'm less likely than average to get 
cervical cancer (1739) 
433 (42.9) 239 (32.8) 672 (38.6) <0.001 
Women should have regular smears 
(1741) 
827 (81.7) 707 (97.0) 1534 (88.1) <0.001 
Diagnosis of cervical cancer would be 
worrying (1742) 
750 (73.8) 630 (86.8) 1380 (79.2) <0.001 
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In terms of attitude and perceived risk, the majority of women responded that they 
would find a diagnosis of cervical cancer worrying, particularly those who had 
previously had a screening test. About a third of women believed that those who get 
cervical cancer only have themselves to blame and half, that getting cervical cancer is 
completely a matter of chance. Those who had never been screened were more likely 
to have negative attitudes. These women were also less likely to perceive themselves 
to be at risk. The majority of responders  (88.1%) felt that women should have a 
regular smear, though women who had previously been screened were more likely to 
think this (OR 6.62, 95% CI 4.25 – 10.42). Among women who had not been 
screened before, those who expressed they were willing to attend for screening in 
future (406/983) were also more likely to say women should attend for screening 
(375/406) compared with those who were not willing to attend (430/577) [OR 4.09, 
95% CI 2.69 – 6.21].  
 
Women who had previously had a screening test compared with those never screened 
had significantly higher mean knowledge scores (1.44 and 1.30 respectively, p for χ2 
for trend = 0.003) and attitude scores (0.87 and 0.34 respectively p for χ2 for trend 
<0.001). 
 
Barriers to screening (objectives 5 and 6) 
Among 1,024 women who had never been screened before (or were unsure)  and 
responded, 40.6% (n=  416) stated they were willing to have a screening test, but have 
not yet been to do this, whilst 45.8% (n= 469) were not willing, and 13.6% (n= 139) 
were unsure. Two thirds of these (n =620/931, 66.5%) stated they did not know where 
they could have a screening test. This was more likely among those who would not 
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consider attending (n= 310, 71.2%) compared with those who were willing to attend 
screening (n=  227, 59.9%) [OR 1.65 (1.26 – 2.18)]. 
 
The reasons given for non-attendance were varied (Table 11). All women were asked 
whether or not they agreed with a number of statements, outlining various barriers. 
Relatively few women cited lack of time, fear of results or finding the test humiliating 
as barriers, whereas high proportions said they did not want or need a test, and over 
half believed cost was a barrier. They were then asked what their main reason was for 
non-attendance. The most common responses were that women did not think they 
needed to, or that they did not know what the test is for (Table 36).  
There were 420/1200 women (35%) who had heard of a cervical smear test, but had 
never had one. These women were less likely to say they didn‟t know what the test is 
for, but otherwise gave similar reasons to those who had never heard of a pap smear 
before (Table 36). Excluding those giving these two statements as their top reason for 
non-attendance, the next most common reason was lack of time.  
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Figure 11: Proportion of women who agree these reasons contributed to their non-
attendance for screening  
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Table 36: Main reasons given for non-attendance for screening 
Main reason Number (%) of women giving this reason 
 
All women never 
screened (n= 1007) 
Never screened, but 
heard of test  (n=460) 
Not need a test 526  (52.23) 249 (54.13) 
Not know what it is for 256 (25.42) 71 (15.43) 
(%) Giving this reason, excluding those who don‟t know what it is for or “don‟t need a test”  
                                                                                     (n = 225)                            (n = 140) 
Lack of time to attend 79 (35.11) 51 (36.43) 
Problems with accessibility 42 (18.67) 20 (14.29) 
Problems with affordability 31 (13.78) 21 (15.00) 
Psychological aspects (anxiety, fear, 
humiliation) 
31 (13.78) 25 (17.86) 
Don't want to have a test 22 (9.78) 13 (9.29) 
Other reasons 20 (8.89) 10 (7.14) 
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Women who perceived the test as unnecessary, did not want it or did not know what it 
is for, tended to be older, whilst fear, anxiety, pain and humiliation were relatively 
more common reasons among younger women (Table 37).   
 
Table 37: Main reason given by women for non-attendance for screening by age group 
  Main reason for no test in past 
 
Number (%) giving this reason 
Age groups Total 
  
n =1058 
20-39 
n=301 
40-59 
n=273 
60+ 
n=484 
Not know, not need, don't want 206 (68.4) 176 (64.5) 426 (88.0) 808 (76.4) 
Inconvenient, costly, timely 63 (20.9) 63 (23.1) 28 (5.8) 154 (14.6) 
Fear, anxiety, pain, humiliation 15 (5.0) 9 (3.3) 7 (1.4) 31 (2.9) 
Other 3 (1.0) 5 (1.8) 6 (1.2) 14 (1.3) 
Non-responders 14 (4.6) 20 (7.3) 17 (3.5) 51 (4.8) 
 
 
 
Stated intention of attending for screening in future 
Nearly two thirds (64.3%) of women responding to this section (n=1148 of 1785), 
whether or not they were previously screened, stated that they were likely or very 
likely to attend for screening in future (Table 38). Over half (54.8%) of all women 
who stated they were likely to have a test in future (n=1159) had specific plans for 
when they would attend; 40.4% (n= 468) within 11 months and 9.0% (n=104) within 
12 to 36 months. There was a decreasing trend for 20-39 (85.0%), 40-59 (77.2%) and 
60+ (33.8%) age groups in stated likelihood of attending (χ2 for trend = 324.8, p 
<0.001). Women who had previously been screened (n= 736) were more likely 
(n=649, 88.2%) to say they would re-attend compared with those never screened 
(n=515/1075, 47.9%) (RR 1.93, 95% CI 1.79 – 2.07). The main reasons given by 
those not intending to attend were, again, not knowing what the test was for, or 
Cross-sectional study 
-106- 
perceiving that it was not necessary. Accessibility, time and cost issues were the next 
most important, whilst fear, anxiety, pain and perceiving the test as humiliating were 
least important in determining intended uptake. Among women who had previously 
been screened (n= 736), 6.9% (n= 51) stated they definitely did not intend to attend 
for further tests.  The main reasons given by these women were, no longer needing a 
test, not wanting it and lack of time.  
 
Table 38: Women’s stated likelihood of attending for screening in future by screening 
status 
 
 Likelihood of attending for screening in future 
Number (%) 
 Ever been screened Very likely 
n=536 
Likely 
n=612 
Not likely 
n=242 
V. unlikely 
n=197 
Don't know 
n=198 
No      n=1050 103 (9.8) 397 (37.8) 206 (19.6) 182 (17.3) 162 (15.4) 
Yes     n=735 433 (58.9) 215 (29.3) 36 (4.9) 15 (2.0) 36 (4.9) 
 All      n=1785 536 (30.6) 612 (34.3) 242 (13.6) 197 (11.0) 198 (11.1) 
* There were 41 non-responders 
All women were asked about their perceptions of positive and negative aspects of 
attending for screening, based on statements that they could agree or disagree with. 
Women without a recent screening test significantly differed from those who had, in 
relation to their agreement with these statements (Table 39). Recent attendees were 
more likely to believe that screening would give them peace of mind and that the test 
results would be confidential. They were also significantly less likely to expect 
embarrassment or anxiety, though just as likely to expect pain. They generally had a 
more positive attitude towards the clinical services, and less likely to see time and 
expense as barriers. Also, they were more likely to fear that abnormalities would be 
found and to perceive themselves at risk. 
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 In terms of stated likelihood of future attendance, different factors appear important 
for screened and unscreened women. Among those without a recent screening test the 
most significant barriers were embarrassment and fears about confidentiality. Women, 
who stated they were likely to attend for a test in future, were more likely to expect 
anxiety and pain associated with the test, but also to believe they were personally at 
risk and expected screening to give them peace of mind. Among women with a recent 
screening test, anxiety and lack of time were the most significant barriers to re-
attendance. Those who intended to re-attend were more likely to believe the doctor 
would find something wrong, and that having a test would give them peace of mind.  
A logistic regression model was developed to examine socio-demographic factors, 
beliefs, knowledge and attitudes associated with screening uptake. In the adjusted 
model, women who said they were unlikely or very unlikely to attend for screening in 
future were significantly older, in lower social class groups and single (Table 40). 
They were also less likely to have had a previous smear test, had less knowledge 
about cervical cancer and screening, and less likely to believe they were personally at 
risk.  They were significantly more likely to think the test would be embarrassing and 
for the clinical atmosphere to be cold, and less likely to believe having a test would 
give them peace of mind. 
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Table 39:  Relationship between beliefs and expectations about screening and stated 
likelihood of attendance in future, by previous screening history 
Likelihood of attendance in future:  No. (%) screened 
within 5 years 
No. (%) not screened 
within 5 years 
p-value for 
χ2 test † 
Believe screening will give peace of mind  622 (95.7)  972 (87.3) <0.001 
Likely/ very likely 
Not likely/ very unlikely/ don‟t know 
579 (96.3) 
43 (87.8) 
514 (93.3) 
458 (81.3) 
 
p-value for χ2 test* 0.014 <0.001  
Believe results will be confidential
†
  561 (86.5)  903 (81.3)  0.005 
Likely/ very likely 
Not likely/ very unlikely/ don‟t know 
520 (86.7) 
41 (83.7) 
466 (84.6) 
437 (78.0) 
 
p-value for χ2 test* 0.556 0.005  
Believe test will be embarrassing
†
 155 (23.8) 407 (36.5) <0.001 
- Likely/ very likely 
- Not likely/ very unlikely/ don‟t know 
139 (23.2) 
16 (32.7) 
182 (33.1) 
225 (40.0) 
 
p-value for χ2 test* 0.134 0.017  
Believe will be very anxious
†
 289 (44.3) 639 (57.4) <0.001 
- Likely/ very likely 
- Not likely/ very unlikely/ don‟t know 
260 (43.3) 
29 (59.2) 
336 (61.1) 
303 (53.8) 
 
p-value for χ2 test* 0.032 0.014  
Believe the test will be painful 228 (36.0) 423 (38.9) 0.232 
- Likely/ very likely 
- Not likely/ very unlikely/ don‟t know 
208 (35.7) 
20 (41.7) 
225 (41.9) 
198 (36.0) 
 
p-value for χ2 test* 0.406 0.046  
Believe clinical atmosphere will be cold
†
 147 (22.6) 329 (29.6) 0.001 
- Likely/ very likely 
- Not likely/ very unlikely/ don‟t know 
132 (22.0) 
15 (30.6) 
171 (31.1) 
158 (28.2) 
 
p-value for χ2 test* 0.168 0.285  
Believe the clinical staff will be rude
†
  53 (8.1) 127 (11.4) 0.016 
- Likely/ very likely 
- Not likely/ very unlikely/ don‟t know 
49 (8.2) 
4 (8.2) 
61 (11.1) 
66 (11.8) 
 
p-value for χ2 test* 1.000 0.724  
Believe problems found will be curable 466 (71.9) 803 (72.3) 0.876 
- Likely/ very likely 
- Not likely/ very unlikely/ don‟t know 
431 (71.9) 
35 (71.4) 
399 (72.7) 
404 (72.0) 
 
p-value for χ2 test* 0.952 0.805  
Believe it‟s difficult to find the time to go 143 (22.7) 408 (37.4) <0.001 
- Likely/ very likely 
- Not likely/ very unlikely/ don‟t know 
125 (21.4) 
18 (37.5) 
208 (38.7) 
200 (36.2) 
 
p-value for χ2 test* 0.010 0.407  
Believe the test will be expensive 212 (33.5) 498 (45.8) <0.001 
- Likely/ very likely 
- Not likely/ very unlikely/ don‟t know 
193 (33.1) 
19 (39.6) 
243 (45.3) 
255 (46.4) 
 
p-value for χ2 test* 0.361 0.713  
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Likelihood of attendance in future:  No. (%) screened 
within 5 years 
No. (%) not screened 
within 5 years 
p-value for 
χ2 test † 
Fear that the doctor will find abnormalities 281 (44.4) 375 (34.7) <0.001 
- Likely/ very likely 
- Not likely/ very unlikely/ don‟t know 
266 (45.6) 
15 (31.3) 
189 (35.3) 
186 (33.9) 
 
p-value for χ2 test* 0.319 0.045  
Believe personally at risk of cervical 
cancer 
271 (41.6) 365 (32.6) <0.001 
- Likely/ very likely 
- Not likely/ very unlikely/ don‟t know 
256 (42.6) 
15 (30.0) 
225 (40.8) 
140 (24.7) 
 
p-value for χ2 test* 0.083 <0.001  
† 
Significance test for difference in level of agreement with statement between women recently screened and not-screened 
* Significance test for difference in likelihood of future attendance for screening, within subgroups of screened and not-screened  
 
 
Table 40: Logistic regression model for stated likelihood of uptake of screening in future 
 
 Unlikely or very unlikely to have pap 
smear in future:  
Odds ratio 
  
(95.0% C.I.) p-value 
  
Increasing age* 1.072 (1.06 -  1.08) <0.001 
Lower social class * 1.178 (1.04 -  1.34) 0.012 
Marital status (single as reference)           
- Married / cohabiting 1.621 (0.89 -  2.94) 0.113 
- Divorced / widowed / separated 0.731 (0.51 -  1.04) 0.085 
Believe personally at risk *** 0.513 (0.39 -  0.68) <0.001 
Increasing knowledge score *** 0.754 (0.66 -  0.87) <0.001 
Had previous screening test *** 0.214 (0.16 -  0.29) <0.001 
Believe screening will give peace of mind 
*** 
0.438 (0.28 -  0.68) <0.001 
Believe test will be embarrassing ** 1.498 (1.11 -  2.02) 0.008 
Believe the clinical atmosphere will be cold * 1.460 (1.08 -  1.98) 0.014 
Increasing attitude score 0.970 (0.88 -  1.07) 0.549 
Believe results will be confidential 1.067 (0.75 -  1.51) 0.712 
Believe will be very anxious 0.952 (0.71 -  1.27) 0.739 
Believe any problems found will be curable 0.833 (0.62 -  1.12) 0.229 
Believe the clinical staff will be rude 1.400 (0.91 -  2.15) 0.123 
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When asked about factors that would make attendance for screening easier, 393 
women (21.5%) gave a response. Tthe most common suggestions were increased 
publicity and education (Table 41). 
Table 41: Factors suggested by women that would encourage them to attend for 
screening 
Enabling factors Number (%) who suggested this 
Publicity / education 146 (36.2) 
Reducing the cost 43 (11.0) 
Advice from doctors 35 (8.9) 
Increasing accessibility 34 (8.7) 
Improved test attributes 24 (6.1) 
Other (personal factors) 110 (28.1) 
 
 
Factors associated with screening uptake (objective 5) 
The relationship between socio-demographic and lifestyle factors and screening 
uptake were examined (Table 42). In general, women who were younger, in higher 
socio-economic groups and married were more likely to have attended for screening 
within the past 5 years. About half of the responders (906/1815) were born in Hong 
Kong. The rest were mainly born in Mainland China, though 4.8% (n=87) were born 
in other Asian countries, and 0.2% (n= 4) in the west. Those born in Hong Kong were 
more likely to have attended for screening. Within Hong Kong, those living in 
Kowloon were least likely to have attended for screening. 
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Table 42: Socio-demographic and lifestyle factors related to screening uptake 
 Number (%) screened within 
last 5 years  (n=665/1826) 
OR (95% CI) for screening 
attendance 
Age group  
- 20 to 39 
- 40 to 59 
- 60+ 
 
265 (45.4) 
304 (48.9) 
96 (15.5) 
 
1.00 
1.15 (0.92 – 1.44) 
0.22 (0.17 – 0.29) 
Social class (1 missing) 
- IV 
- III 
- II 
- I 
 
81 (25.6) 
176 (32.8) 
201 (38.5) 
206 (46.8) 
 
1.00 
1.41 (1.04 – 1.93) 
1.82 (1.33 – 2.47) 
2.55 (1.86 – 3.50) 
Marital status 
- Single 
- Married/ co-habiting 
- Divorced/ widowed 
 
12 (7.2) 
603 (45.9) 
59 (14.5) 
 
1.00 
10.93 (6.02 – 19.87) 
2.20 (1.14 – 4.25) 
Country of birth (14 missing) 
- Hong Kong 
- Other place 
 
434 (65.3) 
231 (34.7) 
 
1.00 
0.36 (0.30 – 0.44) 
Area of residence (1 missing) 
- Hong Kong Island 
- Kowloon 
- New Territories 
- Outlying Islands 
 
172 (38.5) 
152 (30.0) 
333 (39.1) 
7 (36.8) 
 
1.00 
0.68 (0.52 – 0.90) 
1.03 (0.81 – 1.30) 
0.93 (0.36 – 2.41) 
Had attended for mammography 
(283 missing) 
146 (57.5) 3.07 (2.33 – 4.05) 
Had regular dental check-ups 
(282 missing) 
207 (53.5) 2.85 (2.25 – 3.61) 
Smoking history (2 missing) 
- Never smoker 
- Ex-smoker 
- Current smoker 
 
624 (37.3) 
19 (23.8) 
25 (30.1) 
 
1.00 
0.52 (0.31 – 1.20) 
0.72 (0.43 – 1.20) 
 
Women who had attended for cervical screening, were also more likely to have 
attended for a mammogram, to have regular dental check ups and to have never 
smoked. Attendees also had higher mean family income ($23,898 / month [exchange 
rate: £1 = $12 (HK)]) compared with non-attenders ($13,657 per month) (t-test for 
difference between means = 12.6, p<0.001). Logistic regression was used to obtain 
adjusted odds ratios for factors associated with screening uptake (Table 43). 
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Table 43:  Logistic regression model of factors associated with screening uptake in last 
five years 
  Adjusted OR (95.0% C.I.) 
  
p-value 
Increasing age 0.97 (.95 – 0.98) <0.001 
Decreasing social class  0.82 (0.72 – 0.95) 0.007 
Birthplace outside of Hong Kong 0.64 (0.48 – 0.86) 0.003 
Marital status (single as reference) 
- Married / cohabiting  
- Divorced / widowed / separated 
  
21.62 
9.72 
  
(10.83 – 43.17)  
(4.17 – 22.71) 
 
<0.001 
<0.001 
District of residence (Hong Kong Island as reference) 
- Kowloon 
- New Territories 
- Outlying Islands 
 
0.60  
0.92 
0.60 
 
(0.41 – 0.89) 
(0.65 – 1.29) 
(0.15 – 2.42) 
 
0.011 
0.616 
0.472 
Believe personally at risk of cervical cancer 1.32 (1.00 – 1.72)  0.052 
Increasing attitude score  1.17 (1.06 – 1.31) 0.003 
Increasing knowledge score  1.27 (1.08 – 1.48) 0.004 
Previously had mammograms 3.16 (2.21 – 4.53)  <0.001 
Previously had dental check ups 1.86 (1.36 – 2.53) <0.001 
 Having never smoked 1.83 (1.07 – 3.13) 0.028 
 
 
In the logistic regression model, previous screening was significantly associated with 
younger age, higher social class, being married, being born in Hong Kong, and not 
living in Kowloon. Better knowledge and more positive attitude were also associated 
with higher rates of screening, as was belief that they were personally at risk. 
Participation in other health protective activity was also significantly associated with 
screening.  
3.5.5 Risk, risk perception and screening (objective 7) 
Information on risk factors to allow a risk score to be constructed was available for 
1546 (84.7%) of women. The majority had a low objective risk score (median risk 
score =1), with just over 6% (n= 97) (95% CI 5.1 – 7.5) scoring greater than 3. There 
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were 1765 (96.7% of responders) who answered the question on perceived risk. In 
contrast with objective risk, only 38.4% (n=678) perceived their risk to be low. 
 
Objective risk and screening history 
History of screening within the last 5 years was compared among women with 
different risk factors for cervical cancer (Table 44). In general, women with higher 
risk score were no more likely to have been screened than those with lower risk. In 
relation to risk factors, women in the lower socio-economic groups, smokers and 
older women were all significantly less likely to have attended for screening. The only 
risk factor that was significantly positively associated with screening was long-term 
OCP use. 
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Table 44: Variation in having had a screening test within the last 5 years, by risk factor 
Risk Factor (number of 
non-responders) 
Number (%) screened 
within last 5 years 
Crude OR (95% CI) for 
screening 
Significance level 
Social Class (1)    
IV  75 (12.5) 1.00  
III  160 (26.6) 1.47 (1.09 – 1.99)  
II  183 (30.4) 1.85 (1.37 – 2.49)  
I  184 (30.6) 2.57 (1.89 – 3.50) P <0.001 
Level of education (0)    
Form 5 and below 509 (32.3) 1.00  
Matriculation and above 94 (37.7) 1.27 (0.96 – 1.67) P = 0.090 
Number of sexual partners (152) 
3or more 25   (37.3) 1.00  
2 42   (38.9) 1.07 (0.48 – 1.32)  
1 481 (32.1) 0.79 (0.48 – 1.32) P = 0.251 
Smoking Status (1)    
Ever smoker 32  (22.1) 1.00 P = 0.003 
Never smoker 571 (34.0) 1.82 (1.21 – 2.73)  
Age group (0)    
60+ 87 (14.4) 1.00  
40 – 59 years 271 (45.6) 4.78 (3.72 – 6.16)  
20 – 39 years 241 (40.0) 3.52 (2.73 – 4.55) P <0.001 
Use of oral contraceptive pill (0) 
Never or <5 years use 506 (31.2) 1.00 P <0.001 
Used OCP ≥ 5 years 97   (47.1) 0.52 (0.39 – 0.70)  
Total risk score (154) 
Higher (score 3-5) 35   (36.1)  1.00 P = 0.87 
Lower (score 0-2) 511 (35.3) 0.97 (0.63 – 1.48)  
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Perceived risk and screening history 
Perceived risk was also compared with screening history (Table 45). There was a 
significant positive association between higher perceived risk and screening. There 
was also a significant increasing trend in likelihood of having had a screening test 
with increasing levels of reported worry associated with cervical cancer. 
 
Table 45: Relationship between perceived risk and history of screening in last 5 years 
 Number (%) screened 
within last 5 years 
(n=665/1826) 
Crude OR (95% CI) for 
screening 
Significance level 
Perceived risk compared to average 
Less than average 191 (28.2) 1.00 P < 0.001 
Not less than average 401 (36.9) 1.48 (1.20- 1.82)  
Level of worry about a diagnosis of cervical cancer 
Not at all worrying 11   (11.0) 1.00 P < 0.001 
Not very worrying 60   (22.1) 2.29 (1.15 – 4.57)  
Fairly worrying 214 (37.7) 4.88 (2.55 – 9.33)  
Very worrying 150 (33.0) 3.98 (2.07 – 7.67)  
Extremely worrying 152 (40.6) 5.52 (2.86 – 10.68)  
 
Women who had a previous abnormal cervical smear result, were more likely to 
perceive themselves at risk of cervical cancer, compared to those with previously 
normal result and those who had never had a screening test (51.4% n= 12, 41.0% n= 
305 and 31.5% n= 333 respectively). They were also least likely to believe that their 
risk was less than average (24.3% n=6, 32.6% n= 243, and 43.4% n=459).  
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Relationship between objective and perceived risk 
The relationship between perceived risk and objective risk factors and risk score were 
compared. Women with risk factors were no more likely to perceive their risk to be 
higher, except for older women (OR 3.19 [95% CI 2.49 – 4.07] for oldest compared 
with youngest group) and those with lower levels of education (OR 1.41 [1.06 – 
1.88]). However, low risk perception was not related to low objective risk score 
(Figure 12).  
 
Figure 12: Variation of perceived low risk in relation to objective risk score 
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Among women with low objective risk score, pessimists (who overestimate their risk) 
were significantly younger than realists (mean age 47.8 and 55.6 respectively, t-test 
for comparison of means = 10.9 p<0.001), but were no different in terms of other risk 
factors. They were significantly more likely to have attended for screening in the last 
5 years. Among women with higher objective risk score, optimists (who 
underestimate their risk) were significantly older than realists (mean age 46.1 and 
36.0 respectively, t-test for comparison of means = 2.3, p=0.001) and more likely to 
have been long-term OCP users (46.9% compared with 25%, χ2=13.2, p=0.03). 
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However the two groups were similar in terms of other risk factors and screening 
practice. 
 
After adjusting for age and social class, realists with high risk were least likely to 
have attended for screening, and were not significantly different from those with high 
score and optimistic perception of risk. Those with a pessimistic perception of risk 
and realists with low risk were significantly more likely to have been screened (Table 
46). 
Table 46: Logistic regression model for screening behaviour according to risk 
perception 
 
 Adjusted OR (95% CI) for screening in 
last 5 years 
Level of significance 
Risk perception  
High risk realist 
 
1.00 
  
0.03 
Optimist 1.81 (0.71 – 4.63) 0.22 
Pessimist 2.34 (1.33 – 4.11) <0.01 
Low risk realist 1.94 (1.08 – 3.50) 0.03 
Increasing age 0.96 (0.95 – 0.96) <0.01 
Decreasing social class 0.80 (0.71 – 0.89) <0.01 
 
Screening behaviour in relation to subjective and objective risk, and level of worry 
about cervical cancer was then compared, adjusting for age and social class (Table 
47:). In the adjusted model, objective risk was significantly inversely associated with 
screening up to risk score 2, but not those with higher risk scores. Subjective risk 
perception remained just significant as a predictor of screening uptake. In addition, 
increasing worry was significantly associated with screening uptake. 
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Table 47: Logistic regression model of relationship between risk perception and other 
factors associated with screening uptake in last five years 
 
  OR (95% CI) for screening in last 5 years Level of significance 
Low perceived risk 0.80 (0.64 – 1.00) 0.05 
Objective risk score 
- 0 
- 1 
- 2 
- 3 to 5 
 
1.0 
1.64 
2.24 
1.37 
 
 
(1.13 – 2.38) 
(1.47 – 3.43) 
(0.80 – 2.35) 
<0.01 
 
<0.01 
<0.01 
0.26 
Level of worry about diagnosis of cervical cancer  <0.01 
- Not at all worrying 
- Not very worrying 
- Fairly worrying 
- Very worrying 
- Extremely worrying 
1.0 
1.98 
2.26 
2.67  
2.96 
 
(0.98 – 4.01) 
(1.14 – 4.48) 
(1.36 – 5.24)  
(1.49 – 5.89) 
 
0.06 
0.02 
<0.01 
<0.01 
Increasing age 0.97 (0.96 – 0.98) <0.01 
Decreasing social class 0.80 (0.71 – 0.89) <0.01 
 
 
 
3.5.6 Effectiveness and efficiency of screening (objectives 8 –10) 
Benefit of current screening system 
The potential number of new cases of invasive cervical cancer prevented by the 
current screening system in one year is 335 (Table 48). Given the observed number of 
incident cases, the present system is likely to have prevented 40% of all cases. Based 
on the pattern of screening observed in this study population, there would have been 
734,775 smear tests among women aged 20 or over per year in Hong Kong, or 2,192 
screening smears per case of invasive cancer prevented. 
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Table 48: Estimation of potential number of new cases of invasive cervical cancer 
prevented in one year, from the current system of screening in Hong Kong 
 
Age 
group 
Age-group specific incidence 
per 100,000 (based on 5 year 
average, 1990-1994)
214
 
Number of cases expected 
if no screening: 
Potential number of 
cases prevented 
20-39 6.1 146 73 
40-59 32.1 473 228 
60+ 52.1 214 34 
All groups 21.6 833 335 
 
Using the most pessimistic estimates of coverage and screening interval led to a more 
conservative estimate of benefit, suggesting that 31.6% of expected cases per year 
would be prevented, with 3,426 screening tests per case prevented. In the most 
optimistic scenario, we estimate a 65.1% reduction in the number of cases with 1,220 
screening tests per case prevented. 
 
A sensitivity analysis was performed based on the key variables in the model. We first 
tested the model by adjusting the expected incidence of cancer in each group. If 
women who attend for screening currently were at lower risk of cervical cancer than 
the general population, this would affect the incidence of disease. Reducing the 
expected incidence of disease in the screened population compared to those who 
rarely or never attend for screening made little difference to the outcomes of the 
model. If we assume those who attend for screening are at 10%, 20% or 30% lower 
risk, the percentage reduction in incidence as a result of the current screening pattern 
would reduce from 40.2% to 40.0%, 39.8% and 39.5% respectively. Correspondingly, 
the numbers of smear tests per case prevented would increase from 2,192 to 2,311, 
2,444 and 2,594 respectively.  
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We then adjusted the estimated effectiveness of screening. If we adjusted the 
effectiveness of screening at yearly intervals to 80% and 60% and at other intervals 
accordingly, the percentage reduction in incidence would reduce from 40.2% to 
33.9% and 24.1% respectively. The corresponding number of smear tests per case 
prevented would increase from 2,192 to 3,843 and 6,195 respectively. 
 
Benefits of screening in an organised system 
We considered the effectiveness and efficiency of screening under various policies 
within an organised screening system (Table 49). Generally, increasing coverage 
results in an increase in effectiveness as measured by the expected percentage 
reduction in incidence (Figure 13). Increasing coverage has no effect on efficiency 
under our assumptions, though the total number of tests would increase (Figure 14). 
Decreasing the screening interval also increases effectiveness but at the cost of 
reducing efficiency. Thus for a screening programme with 3 – 5 yearly interval (as in 
most organised screening programmes), increasing the coverage has more influence 
on effectiveness than any further decrease in screening interval, and this is achieved 
with no loss in efficiency.  
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Table 49: Effectiveness and efficiency of adopting various screening policies, targeting 
all or selected groups in the population & with varying screening intervals and coverage 
 
 
 
Screening interval 
(months) 
Percentage reduction in incidence of cervical cancer expected in organised 
screening (Number of smears per case potentially prevented) 
80% coverage 70% coverage Ad hoc <40,  
80% coverage  
40’s  
No screening <40, 
80% coverage  
40’s  
0 - 11  74.8 (2958) 65.5 (2958) 70.4 (2198) 61.7 (1723) 
12 - 23 74.0 (1495) 64.8 (1495) 69.7 (1457) 61.0 (871) 
24 - 35  72.6 (1015) 63.6 (1015) 68.6 (1222) 59.9 (592) 
36 - 47 69.7 (794) 61.0 (794) 66.2 (1134) 57.5 (463) 
48 -71 66.9 (662) 58.5 (662) 63.9 (1091) 55.2 (386) 
72 - 119 57.0 (485) 49.9 (485) 55.8 (1107) 47.0 (283) 
120 + 30.0 (492) 26.3 (492) 33.5 (1660) 24.7 (286) 
Present ad hoc system: 40.2 (2192)    [65.1 (1,220) to 31.6 (3,426)] 
 
 
Since the current system is predominantly screening women in the younger age 
groups, we considered the effects of adopting policies to target older women (over 40 
years), either whilst allowing screening in younger women to continue in an ad-hoc 
fashion, or by stopping all screening in under 40‟s. The former policy would be both 
less effective and less efficient than an organised system targeting the whole 
population. The latter would also be less effective, but far more efficient than a non-
targeted policy. 
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Figure 13: Expected percentage reduction in incidence of cervical cancer based on 
screening policies with different target coverage and screening intervals 
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Figure 14: Number of cervical smear tests (’00,000s) per year based on screening 
policies with different target coverage and screening intervals in Hong Kong  
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Comparison of current system with an organised system 
Using the most likely benefit estimates, the current screening system in Hong Kong is 
less effective and less efficient than would be expected in an organised screening 
programme. The level of effectiveness achieved is poorer than an organised 10-yearly 
programme achieving 80% coverage (Figure 13), though the numbers of screening 
smear tests are equivalent to a 2 to 3-yearly programme. Even the most optimistic 
estimate would mean the effectiveness of the current system is similar to an organised 
5 to 10-yearly programme, with 80% coverage, but at about twice the cost per case 
prevented (Table 49 and Figure 13). Compared with the most likely estimate of 
benefit (achieving 40% reduction in incidence), a 3-yearly or 5-yearly screening 
policy targeting the whole population and aiming for 80% coverage would prevent an 
extra 32.4% (equivalent to 267 new cases per year) and 26.7% (222 new cases per 
year) respectively.  This could be achieved with more efficient use of resources, 
reducing the number of tests per case prevented from 2,192 to 1015 and 662 
respectively.  
 
Cross-sectional study 
-125- 
3.6 Discussion 
This was a large study of a representative sample of Hong Kong Chinese women in 
different age groups, regarding their knowledge, attitudes and screening practice in 
relation to cervical cancer.   The modest overall response rate was 62.5%, with only 
56% of telephone contacts having been successful. Use of telephone interviews for 
assessing cervical screening coverage has been used in other countries
185
 and the 
response rate, although not high, was in keeping with those obtained in that (52%) and 
other telephone surveys
215; 216
. Responders to the random digit dialling part of the 
study were similar to the general Hong Kong population in terms of age, education 
and social class, suggesting that responders were representative of the population.  
Information was successfully collected on screening practice, reasons for non-
attendance and risk factors for cervical cancer. 
3.6.1 Screening coverage 
 Screening history was assessed by self-report. This is commonly used in 
epidemiological studies and is simpler than checking pathology reports. Although it 
was found reliability of this variable to be good, verification studies have 
demonstrated that self-report results in over-reporting of screening
168; 169
 and women 
believe they have had screening more recently than they actually have
217
. One study 
in Sweden, where women‟s self-report of screening was compared with information 
from their screening database, found that 99% of women screened within 5 years and 
95% of those who had a screening test over 5 years ago correctly reported this. 
However, half of those who had not had a screening test (based on n=42), falsely 
reported having had one
181
. Another study in the USA based on low-income minority 
women, found that 67% of women correctly reported a previous screening test, but on 
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average they believed they had the test 23 months earlier than they actually had
217
. 
Furthermore, non-responders to the survey are less likely to have ever been screened. 
Therefore our finding of 43% ever screening coverage, is likely to be an overestimate, 
and the proportion who are regular attendees are probably less than a quarter of all 
women.  
 
Other regions with no organised call and recall system achieve similar coverage. A 
study in Catalonia in Spain found coverage of 42% in the absence of a programme
183
, 
whilst a study in Italy showed a coverage of 52% ever screening, and 37% screening 
within 3-years prior to introduction of an organised programme
55
. However, higher 
coverage was reported in countries with central organisation. In the Netherlands 
where screening is both by organised and spontaneous screening, coverage in areas 
where there was an organised call and recall system was 91% compared with 68% 
where screening was spontaneous
186
. Similarly a study in Italy found that an 
organised programme with call and recall increased coverage, particularly among 
disadvantaged, previously poorly screened subgroups, and also reduced over-
screening among previously screened women
187
. There is a relationship between the 
level of reduction in cervical cancer incidence and mortality and the intensity of 
organisation of screening
99
. 
3.6.2 Age specific coverage and screening interval 
It was found that screening coverage was lowest among older women (over the age of 
60). Less than 10% of these women have regular screening, compared with a third of 
younger women. Other studies have also shown that the older age groups are least 
likely to have been screened
183; 185-188
. Even within organised screening programmes, 
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older women and those in lower social class groups tend to be less likely to be 
screened
177
.  
It was also found that most women, who are currently being screened regularly, attend 
annually. Annual screening has little benefit over 3-yearly screening and was not 
recommended in organised programmes. Such over-screening (at intervals less than 3 
years) is a common feature in other countries where there is no organised programme, 
particularly among younger women
55; 185
.  
3.6.3 Factors associated with screening uptake 
In this study population, screening uptake was higher among younger women, those 
in higher socio-economic groups, who engage in other health promoting behaviour 
and who perceived that they were personally at risk of cervical cancer. They had a 
better knowledge and attitude towards cervical screening and perceived cervical 
cancer as a worrying diagnosis.  
Few other studies like this have been done in Chinese populations in Asia. One study 
among Singapore Asian women (age 50 to 64) found that having a good social 
network, less fatalistic attitude towards health, belief that screening could improve 
outcome and higher education were related to screening attendance among women
218
. 
Another survey of 4,400 women over the age of 20 in Taiwan, found that age 
(younger than 30 and older than 65) was the strongest predictor of non-screening
219
. 
Low levels of education, being single and living outside of the city were also related 
to non-attendance.  
Engaging in other health protective behaviour (such as mammography) had also been 
shown to be associated with Pap screening in other studies
188
. Several studies also 
confirm that screening coverage tended to be lower among women with lower levels 
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of education or in lower socio-economic groups and women who were single
183; 185-
188
. 
 
3.6.4 Barriers to screening 
This is the first study in Hong Kong to explore potential barriers to screening among a 
large cross-section of women. The barriers to screening that were explored, were 
based on those identified in studies elsewhere. It was found that lack of knowledge 
about the Pap test and not perceiving it as necessary were the major reasons for non-
uptake of screening. In countries where there is organised screening; not wanting to 
attend; or believing that screening is unnecessary also accounted for a large 
proportion of non-attendance
191
. Lack of knowledge and not having heard of the Pap 
smear had been cited as important reasons for non-attendance in other countries
192; 220; 
221
. The most common source of information on the Pap smear screening in this study 
was health professionals. The media, friends and family were also important sources. 
Other studies have also shown that health personnel and the mass media are principal 
sources of information about the test
222
. This would suggest routes for promoting 
information on screening to other women. 
It was found that the majority of women who had been previously screened expressed 
their intention to have further screening tests. After adjusting for previous screening 
experience, women who were older, single and in lower social groups were 
significantly less likely to indicate they would want to have a test in future. Perception 
that the test would be embarrassing or that the clinical atmosphere would be cold were 
associated with negative views on future attendance. Similar findings were found in a 
Scottish study, where women in lower social classes and those who thought the test 
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was embarrassing were less likely to say they would attend in future
223
. However, in 
that study perceived pain associated with screening was also a barrier, which was not 
the case in our population. Embarrassment and discomfort had been suggested as 
barriers in other studies
224-226
, particularly among younger women
227
. The proportion 
reporting discomfort among women who had been screened in this study, is similar to 
those reported elsewhere
228
. 
3.6.5 Risk and risk perception 
Some studies showed that women with higher epidemiological risk (e.g. multiple 
partners, use OCP, smokers, sexual intercourse at young age) were better screened, or 
no less likely to be screened than those at low risk
177; 185; 229
. It was also found that in 
relation to epidemiological risk score, there was little difference in screening 
behaviour between women at higher and lower risk. However, when individual risk 
factors were examined, there was a significant inequality in screening, so that smokers 
and those in lower social classes were less likely to be screened. Those with multiple 
sexual partners were no more likely to have had screening, and the only group that 
were more protected were women taking the oral contraceptive pill. 
It was found that personal risk perception was an important factor in determining 
screening uptake. Similarly, stated intention to attend for screening in future was more 
likely among those who perceived they were personally at risk, or who thought 
screening would give them peace of mind. A community based study of beliefs and 
attitudes towards cervical cancer in Singapore, had similar findings, with belief in 
personal susceptibility being an important determinant of screening intentions
225
. 
Another study of low-income women in the USA, also found personal susceptibility, 
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belief in the efficacy of screening tests and benefits of screening to be associated with 
screening uptake
230
. 
There are several studies providing evidence to support the effectiveness of 
educational messages in changing risk perceptions
231-235
. Some
231; 236
, but not all of 
these showed an effect on screening behaviour. However, it was not clear whether 
increasing the accuracy of risk perception would necessarily influence screening 
behaviour according to risk. Other studies suggested that women who overestimate 
their risk (pessimists) may either over-screen
237
, or they may stop attending for 
screening
238
. Here it was found that women who overestimated their risk were 
significantly more likely to attend for screening, whereas women who underestimated 
or accurately perceived their risk as high, were less likely to have attended for 
screening. Further studies are needed to assess the impact of influencing risk 
perception on screening behaviour. 
3.6.6 Effectiveness and efficiency of screening 
Overall it was found that an organised screening programme, aiming to achieve at 
least 80% coverage across all age groups would be the most effective and efficient 
policy. Effectiveness was increased with increasing coverage, whilst reducing the 
screening interval had relatively less influence. It was found the current system of ad-
hoc screening in Hong Kong was likely to be less effective than would have been 
expected from an organised 10-yearly screening programme achieving a realistic 80% 
coverage. The current system was also inefficient, with 30% of women being over-
screened.  
The estimates of screening effectiveness were based on the estimates of screening 
interval-specific benefit demonstrated in the IARC study. The effectiveness of 
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screening depended partly on the sensitivity of the screening test, and partly on 
appropriate management of those who tested positive.  The IARC estimates suggested 
higher test sensitivity than demonstrated in other studies, mainly because sensitivity 
was improved after two negative tests. A meta-analysis of smear test sensitivity 
showed a wide variation in estimates, ranging from 30 to 87%
22
.  The sensitivity 
analysis showed that variations in the estimate can have a marked effect on the model 
results.  The calculation of the effectiveness of the current system was likely to be an 
overestimation. One of the features of organised systems of screening was an 
improvement in the quality of smear taking, cytology diagnosis and follow-up. This 
would allow programme effectiveness to approach more towards the findings in the 
IARC study. 
It was assumed that women who were not screened have the same level of risk as 
those screened. However, studies in populations where there is no organised screening 
suggest women who attended for cervical screening were at lower risk
55; 239
. The 
sensitivity analysis suggested that variation in background risk among those attending 
for screening has little effect on the benefits achieved. Therefore any overestimation 
of benefit as a result of this estimate is likely to be small. On the other hand, 
introducing an organised programme has been shown to reduce inequalities in access, 
and increase coverage in higher risk groups
187
.  
Given that actual coverage is likely to be lower than the study indicates, the true 
benefit achieved from the current system is likely be more towards a pessimistic 
estimate.  Among the responders, two thirds expressed their intention to attend for 
screening in future. This means that even if they follow through with their intentions, 
further effort is required if coverage is to be increased. Higher coverage is reported in 
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countries with central organisation and achieving 80% coverage is a realistic goal. In 
the Netherlands where screening is both by organised and opportunistic screening, 
coverage in areas where there was an organised call and recall system was 91% 
compared with 68% where screening was opportunistic
186
. Similarly in the UK, 
coverage has increased to 80%, since introduction of a national call and recall 
system
240
.  
We also found that most women (79%) who are currently being screened regularly 
attend annually. This has little benefit over 3-yearly screening and is not 
recommended in organised programmes. Such over-screening is a common feature in 
other countries where there is no organised programme, particularly among younger 
women
183; 185
. However this can be minimised with introduction of an organised call 
and recall programme
187
. Some studies suggest that screening has more benefit in the 
older age group, suggesting that an organised programme would actually be more 
effective than we have demonstrated. 
Apart from improving effectiveness, it was found that an organised system would 
improve the efficiency of screening in terms of Pap smears per case prevented. The 
estimates of the number of smear tests are based on the number of women attending 
for screening. However, this does not take account of the additional smear tests 
consequent to an initial false positive result. With over screening and non-targeting of 
high risk women, the risk of false positive results is high, and the estimates of 
efficiency of the current system are likely to be generous. Other studies have also 
shown that cost-effectiveness can be improved by introducing an organised 
programme instead of spontaneous screening
241
. The efficiency of the current system 
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is limited because of two reasons: poor overall coverage means that the effectiveness 
of the system is reduced, whilst over-screening and excess smears wastes resources.  
In conclusion, it was found that an ad-hoc cervical screening system achieves poor 
coverage, over-screening of a small group of women and was less effective and 
efficient than an organised programme was likely to be. Given that in many ad-hoc 
systems, screening activity was subsidised by public organisations, it was important to 
ensure that resources were used more efficiently. If any screening activity is carried 
out, particularly by public organisations, this should be within an organised system 
with call and recall and adequate systems for quality assurance. 
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4 PROVISION OF CERVICAL SCREENING SERVICES IN 
HONG KONG  
4.1 Summary 
Given the mixed medical economy in Hong Kong, there are many different providers 
of screening services. There have been no previous studies to try to describe the 
diversity of practices and to what extent these relate to current best evidence. The aim 
of this study was to identify the range and characteristics of practitioners providing 
cervical screening services in Hong Kong, and  to compare practitioners‟ and 
women‟s knowledge of risk factors for cervical cancer and views on factors 
influencing screening uptake. 
 
Methods 
A postal questionnaire was sent to a range of practitioners working in the private, 
government and non-government sector organisations that were likely to offer 
screening. These were identified through the relevant professional colleges, the 
Department of Health and Hospital Authority. Participants were asked about their 
professional background, details of screening services they offered,  their perceived 
training needs and their management of abnormal smears. They were also asked about 
what they perceived as the main factors encouraging or discouraging women from 
attending for screening. 
 
Results 
There were 384 practitioners responding to the survey (overall response rate of 22%). 
Responders came from a variety of organisations including the private sector, the 
Hong Kong Family Planning Association, Department of Health clinics and the 
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Hospital Authority. There were a wide variation in professional training, experience 
and service provided by responders. The age range for which screening was offered 
varied from a limited range (30 – 64) to having no limit and recommended screening 
intervals ranged from one to three yearly. Waiting times for screening, time allocated 
to the screening session, time to receiving results and charge for the service all varied 
between and among provider types. The most frequent charge was between $100 and 
$300, although one third of providers had no charge for screening, whilst over 2% 
charged over $500. Providers with a higher charge tended to have shorter waiting 
times, longer consultations and to use a private laboratory for analysing smears. They 
also were more likely to recommend a shorter screening interval.  
 
There was no clear consensus among responders on the management of abnormal 
smears. Early colposcopy for mild dyskaryosis was recommended by a third of 
responders from an obstetrics and gynaecology specialty, whilst most other 
practitioners would repeat the test within 6 to 12 months. On the other hand, a 
minority of practitioners (3%) did not recommend colposcopy even for severe 
dyskaryosis. 
 
Most practitioners mentioned sexual activity as a risk factor for cervical cancer, but 
relatively few recognised smoking as a risk factor. On the other hand among both 
practitioners and women responding to the telephone survey (chapter 3) a proportion 
believed that diet, exercise and stress reduction would reduce cervical cancer risk. 
Most practitioners recognised the main barriers to screening uptake among women, 
but over half underestimated the role of anxiety related to getting test results and the 
time needed for attending as barriers to uptake. 
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Conclusions 
The lack of a centrally co-ordinated screening system was apparent by the diversity in 
which screening services were offered. There is no uniform policy for training in 
smear taking and no clear management plan among practitioners for dealing with 
abnormal screen results. These issues need to be tackled as part of setting up an 
organised screening programme.  
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4.2 Introduction 
A range of factors influence whether or not women attend for screening. In chapter 3, 
factors related to the woman‟s socio-demographic characteristics, knowledge, 
attitudes and beliefs were examined. In addition, there was evidence that external 
influences, such as the way screening was organised and the qualities of providers of 
screening, were all important. Several studies suggested that the gender, discipline 
and skills of the practitioner, all influenced uptake 
242-244
. Both the technical and 
interpersonal skills of practitioners have had an effect on the woman‟s experience 
during screening and affect subsequent uptake
243; 245
.  The delivery and organisation 
of services, including their accessibility
246
 and cost, as well as methods used to notify 
women of their results
247; 248
, also influenced uptake and re-attendance.  
As an aid to planning screening services and to improve uptake, it is also important to 
explore the views of providers of screening services. The actions and motivation of 
health care providers are important factors for increasing screening uptake and 
promoting behaviour change among women
244; 249
. It is also important to understand 
perceived barriers to screening from the practitioners‟ point of view, and to compare 
these with barriers cited by women.  
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4.3 Aims and objectives: 
This chapter, draws on the results from two studies; the cross-sectional study 
described in chapter 3, and a separate study of providers of cervical screening in Hong 
Kong. The main questions addressed by this chapter include: 
1. Who are the main current providers of cervical screening services in Hong 
Kong? 
2. What are the characteristics of current providers of cervical screening services 
in Hong Kong? 
3. What are the characteristics of services provided, in terms of waiting time, 
charges, recommended screening interval and provision of other services? 
4. How do women and practitioners‟ views compare in relation to barriers and 
factors influencing uptake of screening? 
 
4.4 Methods: 
The method for the cross-sectional study of women in Hong Kong was described 
previously (chapter 3). In addition, funding was sought for a two-stage study to 
investigate provider characteristics. The first stage involved a survey of practitioners 
in Hong Kong regarding cervical screening. The second stage involved more detailed 
interview with a selection of practitioners, and also focus groups with a sample of 
attendees and non-attendees for screening, identified from the first study. This thesis 
will focus on the quantitative data in the first stage only, and not address the 
qualitative component in the second stage. 
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For stage one, a confidential postal questionnaire was sent to a range of practitioners 
in the private, government and non-government sectors providing preventive health 
screening for women. In order to access relevant practitioners with responsibility for 
cervical screening, the questionnaire was sent to a range of organizations.  These 
included members of the Hong Kong College of Family Physicians, the College of 
Obstetricians and Gynaecologists, the Department of Health, Hospital Authority and 
private Hospitals and Non-Government Organizations (NGOs). NGOs included 
organizations such as the Family Planning Association Hong Kong (FPA), United 
Christian Hospital and Shatin Community Clinical Screening Centre.  The Hong 
Kong Colleges did not allow us access to their list of members, instead sending out 
the questionnaire on our behalf. No reminder letters were allowed.  
4.4.1 The study instrument 
The self-administered questionnaire was developed in consultation with a group of 
expert practitioners, and piloted on a group of five clinicians for content validity. No 
revisions were required following the pilot. The questionnaire consisted of three 
distinct sections (Appendix 3). The first section sought information on the 
practitioner‟s professional background, training and experience. The second, related 
to the administration and management of screening services within the organisation 
where the practitioner worked. This included data related to eligibility criteria for 
women screened, waiting times, charges, screening technique and laboratories used. 
Participants were also asked about how they would manage three types of abnormal 
smears; those with mild, moderate or severe dyskaryosis. For each result, they were 
asked to indicate whether they would repeat the smear or, refer for colposcopy for the 
woman involved. The final section sought information on the individual practitioner‟s 
views and perceptions of women‟s understanding of cervical cancer and factors 
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affecting their uptake of screening. Practitioners were asked to indicate whether they 
believed certain factors would encourage or discourage a woman from attending for a 
smear, and which, in their opinion, was the main reason for non-attendance among 
women who had never had a smear. They were also asked to rank screening locations 
in terms of whether women would find them accessible (cost, appointment system and 
waiting times) and „user friendly‟ for screening. In relation to cervical cancer, they 
were asked whether they believed any of a range of defined behaviours would reduce 
women‟s risk of cervical cancer and to what extent women had discussed their 
attitudes and beliefs about cervical cancer and screening with them. These questions 
were derived from the women‟s telephone survey. The list of behaviours to reduce 
risk included a mixture of well described factors from the literature, and other 
behaviours mentioned by women in an open-ended question in the survey. 
Practitioner responses to section three of the questionnaire were compared with 
responses from the relevant sections of the women‟s survey.  
4.4.2 Analysis 
From the women‟s survey, the sections of the questionnaire related to their current use 
of, experience of and preference for screening services was described. In the 
practitioner survey, descriptive statistics were used to describe the range of provider 
organisations, their characteristics, qualifications and experience. Comparative 
analysis was used to assess the relationship between these characteristics and the way 
services were provided, such as waiting times, charging and use of protocols and 
guidelines. The management of abnormal smears between different providers was 
also compared. Finally, we compared the perceptions of practitioners with those of the 
women surveyed, in relation to cervical cancer and screening. 
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4.5 Results: 
For the practitioner study, a total of 1,759 questionnaires were sent out, and 384 
returned (overall response rate of 22%). However, the response rate varied widely 
according to the organisation (Table 50). The method used for distributing 
questionnaires, meant that many practitioners could have received more than one 
copy. This may have been a contributing factor to the low response rate, the 
implications of which are discussed later (see discussion). Of the questionnaires 
returned, 50 were not completed, as the practitioner was not involved in smear taking. 
There were therefore 334 usable questionnaires. 
Table 50: Response rate by organisation for the practitioner survey 
Organisation Number questionnaires 
sent 
Number (%) returned 
Department of Health 80 16 (20) 
NGO (including FPA) 35 19 (54) 
Private hospitals 84 19 (23) 
Public hospitals  210 36 (17) 
Hong Kong College of Obs & Gynaecologists 325 99 (30) 
Hong Kong College of Family Physicians 1025 195 (19) 
Total 1759 384 (22) 
 
4.5.1 Characteristics of providers of screening services: 
Smear takers responding to the survey come from a range of sectors, the majority 
being from the private sector (n=145, 37.7%) and general practice (n=83, 21.6%). The 
next main group of providers responding to the practitioner survey were those 
working in the Hospital Authority, followed by those working in NGO‟s. This is 
broadly similar to the main providers women reported using (Table 51). However, the 
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FPA, which was reported as the main provider for screening outside the private 
sector, was not as well represented in the practitioner study.  
Table 51: Providers used by women for cervical screening compared with those 
responding to practitioner survey 
 
Screening provider Number (%) women screened at 
organisation (n=741) 
Number (%) responders 
to practitioner survey 
Private sector doctors 300 (40.4) 198 (59.3) 
      Private practitioner      238 (32.1)  
      Private hospital      62 (8.4)  
Hospital Authority 145 (19.5) 78 (23.4) 
     Public hospital     121 (16.3)  
     HA Well Woman clinic     24 (3.2)  
HKFPA (NGO) 165 (22.2) 32 (9.6) 
Department of Health 87 (11.7) 26 (7.8) 
     Maternal Child Health Clinic       65 (8.8)  
     Well Woman clinic      17 (2.3)  
     Family Planning clinic      5 (0.7)  
Overseas 19 (2.6)  
Others  22 (3.0)  
Missing 3  
 
Practitioners providing screening, who responded to our survey, were predominantly 
doctors. However 8 (2.4%) were HMO employees who did not necessarily have a 
registerable medical qualification. One third of responders (n=110) had only a basic 
medical qualification. The rest had post-graduate, including professional 
qualifications (n = 186) and academic degrees at diploma (n=28), bachelors (n=3), 
masters (n=4) or doctorate(n=3) level. Overall there was a higher proportion of males 
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(n= 194, 58%), from a variety of specialties and grades (Table 52). The mean number 
of years they had worked in their current position was 8.6 years (range 0.17 to 40).  
 
Table 52: Grade and post of responders to practitioner survey 
 Position in current post Number (%) 
GP/family practice 97 (29.0)  
Managerial (chief, Chief of Service, director, HMO coordinator) 21 (6.3) 
Specialist (SMO, consultant, O&G specialist, GUM specialist) 94 (28.1)  
Junior (HO, MO) 111 (33.2) 
Academic 11 (3.3)  
 
4.5.2 Screening related activity and formal training of providers 
Practice and frequency of screening 
Most responders (n= 270/329, 82%) reported taking a Pap smear at least once per 
month, and of these, 60% (n=163) took at least one per day. Frequency of smear 
taking was unrelated to duration of experience, but was related to speciality and grade 
(Table 53). Those in primary care generally took smears less frequently than the 
others. 
Table 53: Frequency of smear taking by grade and specialty    
 Frequency of smear taking - Number (%) 
 < 1/month At least 1/month At least 1/week At least 1/day 
GP/family practice 35 (36.5) 23 (24.0) 22 (22.9) 16 (16.7)  
Managerial  3 (14.3) 2 (9.5) 2 (9.5)  14 (66.7)  
Specialist  5 (5.5) 5 (5.5) 13 (14.3) 68 (74.7)  
Junior  15 (13.6) 8 (7.3)  26 (23.6) 61 (55.5)  
Academic 1 (9.1) 2 (18.2)  4 (36.4) 4 (36.4)  
TOTAL 59 (18.0) 40 (12.2) 67 (20.4) 163 (49.5) 
Data missing for 5 practitioners 
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Course attendance 
Less than a quarter of practitioner responders (n = 79/334, 23.7%) had ever attended a 
course on smear taking. The likelihood of having attended a course increased with 
increasing number of years of experience in their current post (χ2 for trend = 7.1, p = 
0.008) [Table 54]. Responders were also more likely to have been on a course with 
increasing years of experience in smear taking, though the trend was not significant 
(χ2 for trend =1.8, p= 0.18). 
Table 54: Relationship between years of work experience and attendance at smear 
taking course  
Years working in current post     Number (%) who had attended a course 
<5 25 (17.6) 
5 - 22 (27.8) 
10 - 7 (17.9) 
15 - 8 (34.8) 
20 - 6 (35.3) 
25 +  10 (38.5) 
Missing data 8 
 
 
Course attendance was related to the frequency of smear taking, with those who were 
taking smears on a weekly or more frequent basis, being more likely to have attended 
(Table 55). However, even among this group, only a minority (n=60, 26%) had ever 
attended a course. 
 
Table 55: Relationship between frequency of smear taking and attendance at a course 
Frequency of smear taking (per year) Number (%) who have attended a course 
(n=76/329) 
Less than one smear done per year 1 (5.3) 
At least one smear done per year 6 (15.0) 
At least one smear done per month 9 (22.5) 
At least one smear done per week 19 (28.4) 
At least one smear done per day 41 (25.2) 
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A higher proportion of those with a post-graduate qualification (n= 58/218, 26.6%) 
had attended a course, compared with those who had just their basic degree (n= 
21/114, 18.4%), though the difference was not significant (χ2=2.8, p = 0.10). The 
proportion who had attended a course was similar in different workplaces (n=79/334,    
24%), although those working in NGO‟s were generally more likely (n=12/38,     
32%) and those working in the HA less likely (n= 9/72,12.5%) to have done so. HMO 
employees were also more likely to have attended a course (n=4/8, 50%). There was 
no difference by gender.  
 
Using a logistic regression model (backward LR), the most important predictors of 
attendance at a course were increased frequency of smear taking, increased number of 
years in current position, having a post basic qualification and not working in the HA 
obstetrics and gynaecology department. The gender of the smear taker and whether 
there was a charge for the service were not predictors of course attendance (Table 56). 
 
Table 56: Results of logistic regression model for factors associated with course 
attendance  
 
Variables included in LR model Odds ratio (95% CI) Statistical significance 
Frequent smear taking (at least once / week) 2.37 (1.19 - 4.73) 0.01 
Years in current position (per increasing year) 1.04 (1.00 - 1.07) 0.03 
Workplace (NGO as reference)  
- GP 
- Private practice  
- HA  
- Department of Health 
 
0.84 (0.32 - 2.19)  
0.41 (0.16 - 1.04)  
0.20 (0.07 - 0.59)  
 0.76 (0.23 - 2.46) 
0.016 
   0.73 
   0.06 
   <0.01 
   0.65 
Post-graduate qualification 1.71 (0.89 - 3.28) 0.10 
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Perceived need for further training  
Perceived need for further training was inversely related to the number of years 
experience in taking pap smears and whether the smear taker had a post-graduate 
qualification. Those with 1 year or less experience were more likely to express a need 
for training compared with those with more experience (OR 2.97, 95% CI 1.14 - 
7.76), and those with no post-graduate qualification perceived a greater need (OR 
1.87, 1.13 - 3.09). Need was also significantly related to current workload (Table 57). 
Those who took smears less than once per week, were 2.5 times as likely to perceive a 
need for training, compared to more frequent smear takers (OR 2.45, 95% CI 1.47 to 
4.1). There was a tendency for those who had already attended a course to perceive 
they need further training (OR 1.6, 95% CI 0.9 to 2.8). 
 
Table 57: Relationship between perceived need for training and frequency of smear 
taking 
Frequency of smear taking (per year) Number (%) who think they need more training 
At least 1 smear done per year 26 (44.1) 
At least 1 smear done per month 13 (32.5) 
At least 1 smear done per week 15 (22.4) 
At least 1 smear done per day 33 (20.4) 
P for trend <0.001 
 
Need for further training was perceived most by those working in community health 
(n=10/14, 71.4%), followed by those working in primary care (n=58/163, 35.6%), and 
was seen as least necessary among those working in Obstetrics and Gynaecology (n= 
18/143,12.6%). When viewed in relation to grade, those in managerial positions were 
more likely to perceive a need for training (n= 36/138, 26%), whilst those in academic 
(n=1/11, 9%) and specialist (n=12/79, 15%) posts were less likely to do so. 
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Using a logistic regression model (backward LR), the most important predictors of 
perceived need for further training were having been to a previous course, being an 
infrequent smear-taker, having no post graduate qualifications and working with an 
NGO (Table 58). Gender of the smear taker, years of experience and whether a charge 
was made for the service, were not predictors of perceived need. 
 
Table 58: Results of logistic regression model of factors related to perceived need for 
further training 
 
Variables included in LR model Odds ratio (95% CI) Statistical significance 
Attendance for previous course    1.99 (1.06 - 3.71)  0.03 
Infrequent smear taking (< once / week)   2.78 (1.49 - 5.21) <0.01 
No post graduate qualification 1.73 (0.97 - 3.08) 0.06 
Workplace (NGO as reference)  
GP  
Private practice  
HA  
Department of Health 
 
0.39 (0.16 - 0.96)  
0.39 (0.16 - 0.91) 
0.21 (0.07 - 0.62)  
0.52 (0.16 - 1.67) 
0.063      
    0.04      
    0.03      
    <0.01     
    0.27  
 
Screening protocol and practices  
Two thirds of responders set no age limit for who they offered a Pap smear to. Those 
working for the DH were more likely to have set criteria for screening, whilst those in 
primary care had the most diverse range of criteria (Table 59). For the majority of 
responders, there was no waiting time for an appointment for screening. However, 
14% (mainly HA and NGOs) had waiting times of up to 3 or more months (Table 59). 
Overall, about two thirds of organisations offered a walk in service for screening, 
whereas others, particularly the HA and NGOs would only take referrals. Most 
allowed less than 10 minutes for a consultation for screening, whereas over 10% 
allowed more than 20 minutes (Table 59). Over half the providers (56.4%) reported 
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giving women the results of their pap smears within one week of taking it. However, 
about one in 12 women would have to wait over one month, with the DH providers 
reporting the longest waiting times.  
Table 59: Screening practice by provider 
 GP 
n=72 
Private 
practice 
n=126 
HA O&G 
n=26 
DH 
n=26 
NGOs 
n=38 
Total (%) 
n= 334 
Age range eligible 
18-64 8 (11.1) 19 (15.1) 7 (9.9) 7 (26.9) 2 (5.3) 43 (12.9) 
30-64 6 (8.3) 10 (7.9)  4 (15.4) 4 (10.5) 24 (7.2) 
18-70 4 (5.6) 10 (7.9) 1 (14.1) 1 (3.8) 9 (23.7) 25 (7.5) 
No limit 53 (73.6) 87 (69.0) 62 (87.3) 1 (3.8) 21 (55.3) 224 (67.3) 
Other variation  1 (1.4)   1 (14.1) 13 (50.0) 2 (5.3) 17 (5.1) 
Missing   1   1 
Average waiting time for an appointment  
None 56 (77.8) 109 (86.5) 8 (12.3) 20 (80.0) 13 (35.1) 206 (63.4) 
Up to 1 week 9 (12.5) 16 (12.7) 3 (4.6)   6 (16.2) 34 (10.5) 
Up to 1 month 5 (6.9) 1 (0.8) 19 (29.3) 5 (20.0) 11 (29.7) 41 (12.6) 
Up to 3 months 1 (1.4)   25 (38.5)   6 (16.2) 32 (9.8) 
Up to 4 months 1 (1.4)   10 (15.4)   1 (2.7) 12 (3.7) 
Missing   7 1 1 9 
Consultation time allocated for screening 
<=10min 17 (23.9) 37 (32.5) 41 (80.4) 21 (80.4) 19 (57.6) 135 (45.9) 
11-20min 46 (64.8) 60 (52.6) 8 (15.7) 3 (12.0) 11 (33.3) 128 (43.5) 
>20min 8 (11.3) 17 (14.9) 2 (3.9) 1 (4.0) 3 (9.1) 31 (10.5) 
Missing 1 12 21 1 5 40 
Time to receive results 
<1week 46 (63.9) 110 (88.0) 15 (22.1) 2 (8.0) 12 (31.6)  185 (56.4) 
1-2 weeks 18 (25.0) 14 (11.2) 34 (50.0) 2 (8.0) 13 (34.2)  81 (24.7) 
>2 to 4 weeks 3 (4.2)  0 13 (19.1) 6 (24.0) 12 (31.6)  34 (10.4) 
>1 to 2 months 5 (6.9) 1 (.8) 6 (8.8) 15 (60.0) 1 (2.6)  28 (8.5) 
Missing  1 4 1  6 
Recommended screening interval 
Yearly 32 (45.1) 91 (74.0) 27 (37.5) 1 (3.8) 14 (38.9) 165 (50.3) 
2 yearly 13 (18.3) 21 (17.1) 16 (22.2) 3 (11.5) 4 (11.1) 57 (17.4) 
3 yearly 16 (22.5) 7 (5.7) 19 (26.4) 4 (15.4) 12 (33.3) 58 (17.7) 
Yearly x 2 then every 3 
years 
10 (14.1) 4 (3.3) 10 (13.9) 18 (69.2) 6 (16.7) 48 (14.6) 
Missing 1 3    4 
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In our telephone survey of women, the reported waiting times for results were 
generally similar to those reported by most providers (Table 60), though there were a 
few exceptions. Women tended to report longer waiting times for the HA and for the 
FPA (an NGO), than the respective responders to the practitioner survey. However, 
the practitioner survey responders were only from the obstetrics and gynaecology 
sector of the HA, whereas the women‟s reports are based on a wider range of 
providers from the HA (including well women‟s clinics). Similarly, the main NGO 
provider reported by women was the FPA, whereas our practitioner study included a 
wider range of NGO providers. 
 
Table 60: Comparison of time taken for reporting results of screening by provider, 
reported by practitioners and by women (numbers and (percentages)) 
 
Time to receive 
results, as 
reported by: 
Private 
practice 
(including 
GP) 
HA DH NGO Others  
P W P W P W P W P W 
< 1 week 156 
(79.2) 
233 
(73.7) 
15 
(22.1) 
22 
(16.7) 
2 
(8.0) 
6 (9.7) 12 
(31.6) 
17 
(15.5) 
 13 
(29.5) 
1-2 weeks 32 
(16.2) 
51 
(16.1) 
34 
(50.0) 
21 
(15.9) 
2 
(8.0) 
4 (6.5) 13 
(34.2) 
25 
(22.7) 
 11 
(25.0)  
2-4 weeks 3 (1.5) 11 
(3.5) 
13 
(19.1) 
24 
(18.2) 
6 
(24.0) 
12 
(19.4) 
12 
(31.6) 
18 
(16.4) 
 8 
(18.2) 
>1-2 months 6 (3.0) 11 
(3.5) 
6 (8.8) 52   
(39.4) 
15 
(60.0) 
33 
(53.2) 
1 (2.6) 36 
(32.7) 
 11 
(25.0) 
Not sure  10 
(3.2) 
 13 
(9.8) 
 7 
(11.3) 
 14 
(12.7) 
 1 (2.3) 
P = practitioners, W = women 
 
Half of all practitioners recommend women to have yearly screening (Table 59). This 
was more conservative than the perception of the women responding to our telephone 
survey. The majority of women who had ever had a screening test (n= 608/706); 
(86%) thought that screening should be performed at least yearly, and only 3.3% (n= 
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23/706) thought that the interval should be 3 or more years (Table 61). Overall, 1% 
(16/1533) suggested that screening should be at least once per month (all had never 
been screened before).  Women with no previous screening test were generally more 
likely to suggest a shorter screening interval. 
 
Table 61: Women’s reported optimal screening interval following a normal smear  
 
Number (%) of women reported screening interval following a normal smear  
Screening interval Previously had screening No previous screening  Total  
Less than yearly 41 (5.8) 121 (15.4) 162 (10.9)  
Yearly 567 (80.3) 513 (65.3) 1080 (72.4)  
2 yearly 57 (8.1) 55 (7.0) 112 (7.5)  
3 yearly 16 (2.3) 18 (2.3) 34 (2.3)  
5 yearly 7 (1.0) 5 (0.6) 12 (0.8)  
Other / not sure 18 (2.5) 74 (9.4) 92 (6.2)  
Non responders 31 258 289 
 
 
Less than half of providers (n= 144/324; 44.4%) claimed to use a protocol for 
screening. There was little difference between organisations, apart from those 
working for the HA, where 92.3% (n= 24/26) reported using one. There was no 
relationship between the use of a protocol and the recommended screening interval. 
 
One third of providers (n = 113) reported a policy of not routinely informing women 
if their smear result was negative, although all notified women when the result was 
positive. This was similar to the 29% (230/792) of women who reported not having 
been informed of their screening results. Most women in this situation had been told 
that they would not be informed of a negative result. The most common method of 
informing women was to invite them back to the clinic (Table 62). However, some 
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used a letter or told women by telephone. There was some discrepancy between 
providers‟ and women‟s reported method of getting the results of smears (Table 62). 
For private practitioners and the HA, providers were more likely to report not 
routinely notifying women, whereas more women reported having had a result from 
these providers. In contrast, more women tended to report not having had a result 
from DH providers and the FPA, compared with that reported by the providers 
themselves. 
 
Table 62: Comparison of reported method for reporting negative screening results by 
provider, reported by practitioners and by women (numbers are percentages) 
 
Method of 
informing 
negative result 
Private 
practice 
HA DH NGO Others  
P W P W P W P W P W 
By letter 2 (1.0) 4 (1.2) 1 (1.4) 11 
(6.6) 
1 
(3.9) 
8 (9.0) 9 
(23.7) 
21 
(12.5) 
 8 
(17.8) 
By phone 63 
(32.1) 
171 
(52.8) 
- 12 
(7.2) 
- 6 (6.7)  12 
(7.1) 
 2 (4.4) 
In clinic 61 
(31.1) 
123 
(38.0) 
8 
(11.1) 
71 
(42.8) 
8 
(30.8) 
29 
(32.6) 
8 
(21.0) 
39 
(23.2) 
 27 
(60.0) 
Combination / 
other 
34 
(17.3) 
4 (1.2) 4 (5.6) 8 (4.8) 9 
(34.6) 
2 (2.2) 11 
(28.9) 
-  4 (8.9) 
Not routinely notify 36 
(18.4) 
22 
(6.8) 
59 
(81.9) 
64 
(38.6) 
8 
(30.8) 
44 
(49.4) 
10 
(26.3) 
96 
(57.1) 
 4 (8.9) 
P = practitioners (10 non-responders), W = women (3 non-responders) 
 
For positive smear results, many providers (41.3% n= 136/329) reported using a 
combination of letter, telephone and/ or clinic visit for informing women. One third 
reported inviting women back to the clinic to inform them of the results. However, 
almost a quarter (23.8%; n=78/329) reported telling women over the telephone, and 
just over 1% (n= 5/329) informed women by letter only.  
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Screening techniques and laboratories used 
The majority of providers (n= 185/320; 57%) exclusively used the Ayre‟s spatula for 
taking smears, whilst a further 25% (n=80) used this and / or the cytobrush. There was 
no relationship between the sampling method used and the charge for taking a pap 
smear (χ2 for trend =0.2; p=0.68). More than half of the providers (186/313; 59.7%) 
reported sending their smears to private laboratories for assessment. These 
laboratories were also most likely to use automated screening instruments for 
screening (Table 63). 
 
Table 63: Type of laboratory cervical smears were sent to, and proportion of those that 
used automated screening methods 
 
Laboratory type (number of providers using) Use of automated screening instruments 
Government laboratories  (n = 36) 1 (2.8) 
Laboratories in HA hospitals  (n = 77) 18 (23.4) 
Private laboratories (n = 186) 83 (44.6) 
University Department of Pathology  (n = 14) 6 (42.9) 
 
 
Charge for cervical screening 
The most frequent charge for a smear test among the provider responders was 
between $100 and $300 (HK). One third of providers ((111/328) had no charge, 
whilst 2.2% (n= 7) charged more than $500. Among women, the reported charge for 
screening varied considerably, ranging from the test being free (n= 164/760; 22%)  to 
one women reporting having paid over $4000 (0.1%). The median charge was $250. 
Most of the women reporting screening had the test as part of a women's check up 
package (n= 415/793; 52.3%), or other health package (n=135, 17%) rather than as a 
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pap smear alone. For the women who had a cervical screening test on its own, the 
median charge was $131.5, with a range from zero to $1,200 (Table 64).  
 
Table 64: Charge for cervical screening, as reported by providers and by women 
PROVIDERS WOMEN* 
Charge for 
Pap smears 
GP Private 
practice 
HA 
O&G 
Dept of 
Health 
NGOs Total (%)  
Free 13 (18.3) 2 (1.6) 63 (91.3) 22 (84.6) 11 (28.9) 111 (33.8) 77 (31.8) 
<$100 4 (5.6) 2 (1.6) 6 (8.7) 4 (14.6) 5 (13.2) 21 (6.4) 43 (17.8) 
$101-300 32 (45.1) 95 (76.6)     16 (42.1) 143 (43.6) 47 (19.4) 
$301-500 19 (26.8) 22 (17.7)     5 (13.2) 46 (14.0) 44 (18.2) 
$501-700 2 (2.8) 2 (1.6)     1 (2.6) 5 (1.5) 19 (7.9) 
$701-1000 1 (1.4) 1 (0.9)       2 (0.6) 11 (4.5) 
>$1000      -  1 (0.4) 
* Only women where the charge was for a cervical screening test alone are included 
Missing data for 6 practitioners 
 
Among providers, there was a significant relationship between the charge for 
screening and waiting times. Those who offered the service for free were more likely 
to have long waiting times, over a third having a waiting time over three months. In 
contrast, the maximum waiting time for those charging over $500 was 1 week (χ2 for 
trend= 99.8; p<0.001). There was also a relationship between allocated time for 
screening and the charge for the service (Table 65), so that those charging more 
tended to spend more time with their patients (χ2 for trend=54.5; p <0.001). 
Table 65: Consultation time allowed for screening according to fee charged 
Charge for 
Pap smear 
Number (%) of providers allowing this amount of time Non-
responders 
<=10min 11 - 20min >20min 
Free 72 (79.10) 16 (17.60) 3 (3.30) 10 
<$100 11 (57.90) 7 (36.80) 1 (5.30) 2 
$101-300 41 (31.10) 73 (55.30) 18 (13.60) 11 
>$300 10 (20.40) 31 (63.30) 8 (16.30) 4 
Non responders 1  1  1   
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Yearly screening tended to be more commonly recommended by those who charged 
more for the service (χ2 for trend= 25.7; p<0.001). Providers using private laboratories 
were likely to charge more for their service; 96.8% (179/185) using a private lab, 
compared with 4.8% (6/125) of those using other laboratories charged over $100. 
However there was no relationship between the charge and whether the laboratory 
used automated screening. 
 
Logistic regression was used to identify factors that were related to providers charging 
$100 or more for a Pap smear (Table 66). After adjusting for other factors, they were 
more likely to charge $100 or more if the smears was sent to a private laboratory and 
they offered a shorter waiting time for an appointment. NGOs were more likely to 
charge than those working in general practice or private practice, though this was of 
borderline statistical significance. Those charging a high fee, were less likely to have 
attended a course for taking smears and there was no relationship with having a 
postgraduate qualification, consultation time or recommended screening interval 
following a smear. 
Table 66: Factors associated with providers charging over $100 for screening 
 Charging $100 or more  OR (95.0% C.I.) Significance 
Private labs 1851.52 (64.90 -52824.34) <0.001 
Consultation time 0.91 (0.26 -3.19) 0.881 
Waiting time for appointment 0.37 (0.15 -0.88) 0.024 
Having post-graduate qualification 1.71 (0.39 - 7.49) 0.474 
Attendance for pap-smear course 0.12 (0.02 - 0.67) 0.015 
Workplace (NGO as reference)  
- General practice / private practice  
- Government funded (HA / DH) 
 
0.08 
0.00 
 
(0.01 – 1.03) 
(0.00 – infinity) 
 
0.05 
0.73 
Recommend one-yearly screening  1.70 (0.71 – 4.06) 0.23 
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4.5.3 Management of abnormal smears 
The reported management of abnormal smears was compared among providers 
(Figure 15 a to c). For mild dyskaryosis, the majority (n=243/312; 77.9%) of 
responders stated they would repeat the smear as the first step. However, over a third 
(n=50/134) of those specialising in obstetrics and gynaecology (O&G) would 
consider colposcopy at this stage; a higher proportion than those in other specialties. 
For moderate dyskaryosis, over two thirds of providers (n=218/314), particularly 
specialists in O&G (n=119/137), would recommend colposcopy. For severe 
dyskaryosis, a minority of providers (n=9/313; 2.9%), predominantly those not 
specialising in O&G, would still consider recommending a repeat smear.  
Figure 15: Reported management strategy for different types of abnormal smear result, 
by specialty 
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b) Moderate Dyskaryosis
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c) Severe Dyskaryosis
0%
20%
40%
60%
80%
100%
O&G Family Medicine /
GP 
Community Health No speciality
identified
Specialty
%
 r
ec
o
m
m
en
d
in
g
 t
h
is
 a
ct
io
n
No fixed policy
Refer to specialist
Colposcopy
Repeat smear within 12 months
Repeat smear within 6 months
 
     n= 137      n= 150  n=14             n=12 
Provider survey 
-157- 
The main difference in management was between specialists in O&G and others. For 
mild and moderate dyskaryosis there was a significant difference between the groups 
in their suggested management strategies (Table 67). In general, O&G specialists 
were more likely to intervene and offer more invasive tests at an earlier stage than 
others reported being prepared to.  
 
Table 67: Comparison of O&G specialists with others in relation to recommendations 
for management of abnormal smear results 
 
 Number (%) recommending colposcopy/ referral rather than repeat smear 
Smear result O&G specialist 
(n=143) 
Other specialist 
(n=191) 
Difference in proportions 
Mild dyskaryosis 50 (37.3) 19 (10.7) P <0.001 
Non responders 9 13  
Moderate dyskaryosis 119 (86.9) 99 (55.9) P <0.001 
Non responders 6 14  
Severe dyskaryosis 134 (97.8) 170 (96.6) P = 0.522 
Non responders 6 15  
 
4.5.4 Practitioners’ perceptions of women’s attendance for Pap smear 
Barriers and factors encouraging uptake of screening 
Among practitioners, the majority thought that if women had knowledge of the reason 
for a Pap smear (n=322/327; 98.5%), or were aware of the need for having a test 
(n=314/327; 96.0%), this would encourage them to attend for a test. These were also 
the most common reasons cited by the 1024 women interviewed, who had not 
previously attended for screening. Nevertheless, among this group, about a third 
(n=343/1024; 33.5%) did not attribute their non-attendance to lack of knowledge and 
a similar proportion (n=173/445; 38.9%) disagreed that they were unaware of the 
need for a pap smear. Practitioners tended to overestimate the role of accessibility as a 
factor in encouraging women to attend (Table 68). The questions are not directly 
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comparable, as the wording was different. However, they explore similar concepts 
and are grouped together for the presentation of results (see discussion). 
Table 68: Comparison of practitioner and women’s views on factors encouraging 
attendance  
Factors affecting 
attendance  
Number/total responding to question (%)  
Practitioners who 
perceive this would 
encourage attendance 
Women who disagree 
with this being a reason 
for non-attendance* 
Women who agree this is 
reason for non-
attendance* 
Knowledge of 
reason for smear 
322/327 (98.5) 343/1024  (33.5) 661/1024 (64.6) 
Awareness of 
need for the test 
314/327 (96.0) 173/445 (38.9) 250/445 (56.2) 
Convenience of 
access to clinic 
288/325 (88.6) 237/436 (54.4) 176/436 (40.4) 
*Women who had not attended for screening before. Those who did not know what a smear test is, 
were excluded from the remaining questions regarding reasons for non-attendance. Hence the smaller 
denominator for the remaining questions. 
 
Practitioners generally recognised anxiety, pain, embarrassment and other medical 
problems as being important barriers to attendance, although fewer women perceived 
them as barriers compared with practitioners (Table 69). Practitioners tended to 
underestimate the discouraging effects of time needed for the test and the anxiety 
related to getting the results, as barriers. 
 
Table 69: Comparison of practitioner and women’s views on factors discouraging 
attendance  
Factors affecting attendance Practitioners who perceive this 
would discourage attendance 
Women who agree with this being 
a reason for non-attendance* 
Anxiety associated with the test 216/322  (67.1) 178/435 (40.9) 
Embarrassment/ humiliation 
associated with test 
251/323 (77.7) 71/436 (16.3) 
Pain associated with the test 211/322 (65.5) 174/436 (39.9) 
Medical problems preventing 
attendance  
135/316 (42.7) 43/434 (9.9) 
Cost of the test 151/324 (46.6) 204/436 (46.8) 
Time needed for the test 92/322 (28.6) 149/434 (34.3) 
Anxiety related to test results 14/318 (4.4) 116/436 (26.6) 
*Women who did not know what the smear test was were not asked the other questions. Therefore the 
denominator is smaller for remaining reasons for non-attendance 
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When comparing women‟s stated main barriers to attending for screening with the 
perceptions of practitioners, they agreed on the major barriers being lack of 
knowledge about the test and unawareness of the need for the test. However there 
were differences in perception between practitioners and women in the importance of 
other barriers. The results are not directly comparable, because in the women‟s 
survey, only one main reason for non-attendance was taken, whereas practitioners 
could give several reasons, and 30% (77 individuals) did so (Table 70). Overall, very 
few women perceived anxiety, embarrassment or pain associated with the test as 
barriers to attendance, whereas relatively more practitioners thought these discourage 
women. Relatively more patients than practitioners felt that time needed for a test, and 
fear of what the results would show, to be important barriers. 
Table 70: Comparison of women and practitioners’ views of the main reasons for non-
attendance at screening 
Main reason for not having a test before Practitioner (1) Practitioner (2) Women 
Knowledge of reason for Pap smear 131 (39.9) 131 (43.0) 340 (33.8)  
Awareness of need for the test  152 (46.3) 95 (31.1) 446 (44.3)  
Convenience of access to clinic  14 (4.3) 7 (2.3) 42 (4.2)  
Anxiety associated with the test  26 (7.9) 13 (4.3) 8 (0.8)  
Embarrassment/ humiliation associated with 
test  
43 (13.1) 30 (9.8) 2 (0.2)  
Pain associated with the test  11 (3.3) 6 (2.0) 4  (0.4)  
Cost of the test  18 (5.5) 11 (3.6) 31 (3.1)  
Time needed for the test  13 (3.9) 9 (3.0) 81 (8.0)  
Other medical problems preventing attendance  1 (0.3) 0    9 (0.9)  
Anxiety related to test results  2 (0.6)  0  17 (1.7)  
Other   8 (2.4) 2 (0.7) 5 (0.5)  
 
Practitioner (1) = all reasons included - % implies proportion who gave this as a reason 
Practitioner (2) = only first reason given is included - % in column adds up to 100% 
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In addition, two thirds of practitioners (n= 216/321; 67.3%) felt that having a female 
practitioner taking a smear would be encouraging, and 58.5%, (n=189/323) that 
having a male practitioner would be discouraging for attendance. They also believed 
that women would prefer the screener to be a doctor. In general, these perceptions 
were in agreement with women‟s stated preferences. However, women, particularly 
those who had never been screened, were more likely to be neutral in their preference 
for type of professional than practitioners expected (Table 71). Women who had 
previously been screened were significantly more likely to state that they wanted their 
screener to be a doctor. 
 
Table 71: Comparison of practitioner perceptions and women’s stated preferences for 
screener 
 
Preferred 
screener  
Number (%) Difference between 
screened and unscreened 
Practitioners 
perception 
(n=334) 
Women’s preference  
Never 
screened 
(n=1098) 
Previously 
screened (n=742) 
χ2 (p value) Total 
Gender  
Male 
Female   
No preference  
NR=11 
1      (0.3) 
243  (75.2)  
79    (24.5) 
NR=25 
6 (0.6)  
647 (62.6)  
380 (36.8) 
NR=10 
10 (1.4)  
473 (64.6)  
249 (34.0) 
5.32 (0.07)  
16     (0.9)  
1120 (63.5)  
629   (35.6) 
Profession  
Doctor  
Nurse  
No preference 
NR=10 
282 (87.0)  
5      (1.5)  
37    (11.4) 
NR=25 
659 (63.7) 
97   (9.4)  
279 (27.0) 
NR=9 
589  (80.4)  
40 (5.5)  
104  (14.2) 
52.50 
(p<0.001) 
 
1248 (70.6)  
137   (7.7)  
383   (21.7) 
 
Familiar person 
Not familiar 
No preference 
 NR=26 
176 (17.5) 
356 (35.4) 
479 (47.2) 
NR=11 
128 (17.5) 
289 (39.6) 
313 (42.9) 
 
3.77 (0.15) 
 
304 (17.5) 
645 (37.1) 
788 (45.4) 
NR= non-responders 
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Perceived accessibility of screening services 
Practitioners were asked to rank their perceived accessibility and “user friendliness” 
of different types of clinic that offer women screening (scale of 1 = most and 5 = least 
favoured). On the whole, practitioners rated their own workplaces as most accessible. 
However, public hospitals had the lowest overall rating and were ranked lowest by all 
groups (Table 72).  For all practitioners combined, the HK FPA was rated as most 
accessible, followed by general practice, maternal and child health clinics and well 
woman clinics. 
 
Table 72: Practitioners’ ranking of screening clinics in terms of perceived accessibility 
for women   
 
Workplace of 
responder 
 Mean Rank for screening clinics (lower rank = more accessible) 
Public 
Hospitals 
MCHC WWC HK FPA GP / private 
practice 
General practice/ 
private practice (n=198) 
4.65 2.99 2.86 2.17 1.85 
HA (O&G) (n=72) 4.15 2.06 3.36 2.15 2.76 
Dept Health (n=26) 4.60 1.44 3.72 2.12 2.80 
NGO (n=38) 4.15 2.50 2.72 1.64 2.72 
Total 4.47 2.56 3.06 2.10 2.24 
MCHC = maternal and child health clinic, WWC = well women’s clinic, HKFPA = Hong Kong Family 
Planning Association 
 
Most practitioners reported that the cost of the service is an influential factor in 
women‟s choice of service provider. Providers charging less than $100 for their 
service (n=105/130; 80.8%) were more likely to feel this was an important factor 
compared with those charging more (n=145/187; 77.5%), but the difference was not 
statistically significant (χ2=0.48; p=0.49).  
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In terms of being “user friendly”, however, almost all groups rated general and private 
practice with the highest score. The only exception was the Department of Health 
responders, who rated the MCHC as best. Overall public hospitals were rated as 
worst, followed by Maternal and Child Health Clinics (MCHC), Well Women‟s 
Clinics (WWC) and the Hong Kong Family Planning Association (HKFPA) (Table 
73). 
Table 73: Practitioners’ ranking of clinics in terms of perceived ‘user-friendliness’ for 
women   
 
Workplace of 
responder 
 Mean Rank for screening clinics (lower rank = more user-friendly) 
Public 
Hospitals 
MCHC WWC HK FPA GP / private 
practice 
General practice/ 
private practice (n=198) 
4.67 3.27 2.63 2.48 1.56 
HA (O&G) (n=72) 4.35 2.82 2.65 2.51 2.16 
Dept Health (n=26) 4.57 1.88 3.17 2.58 2.46 
NGO (n=38) 4.38 2.80 2.35 2.40 2.04 
Total 4.55 2.97 2.66 2.49 1.84 
MCHC = maternal and child health clinic, WWC = well women’s clinic, HKFPA = Hong Kong Family Planning Association 
 
The results were compared with women‟s responses in the telephone survey, about 
where they would prefer to have a screening test. The preferred place for screening, 
overall, was a public hospital, followed by a private practitioner (Table 74). Women 
who had previously had a screening test tended to prefer the provider they had already 
attended. The main exception was women who had attended the Department of Health 
(DH) clinics. Only 36% of these women mentioned these clinics as their choice 
provider. The majority of women who had previously been screened had attended a 
private practitioner, and the largest single provider was the FPA. However, overall, 
women rated private practice as their preferred location, followed by a public hospital, 
with the FPA being the 3
rd
 preferred provider.  
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Table 74: Women’s stated preference for screening provider, according to place of last 
screening 
 
 
Number (%) of women mentioning this as their preferred provider 
Public 
Hospitals 
MCHC WWC HK FPA GP / 
private  
Other  No 
preference 
  
  
  
  
  
 P
ro
v
id
er
 f
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r 
la
st
 s
cr
ee
n
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g
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es
t 
GP/ private 
practice (n=316) 
56 (17.7) 2 (0.6) 9 (2.8) 14 (4.4) 230 (72.8) 2 (0.6) 3 (0.9) 
HA (n=137) 88 (64.2) 6 (4.4) 3 (2.2) 13 (9.5) 17 (12.4) 5 (3.6) 5 (3.6) 
DH WWC or 
FPC (n=47) 
15 (31.9) 4 (8.5) 17 (36.2) 3 (6.4) 7 (14.9) - 1 (2.1) 
FPA (n=165) 43 (26.1) 6 (3.6) 7 (4.2) 82 (49.7) 21 (12.7) 3 (1.8) 3 (1.8) 
MCHC (n=65) 20 (30.8) 28 (43.1) 2 (3.1) 2 (3.1) 12 (18.5) - 1 (1.5) 
Other (n=43) 24 (55.8) - 2 (4.6) 4 (9.3) 8 (18.6) 3 (7.0) 2 (4.6) 
Total for ever 
screened (n=720) 
221 (30.7) 44 (6.1) 37 (5.1) 111 (15.4) 282 (39.2) 11 (1.5) 14 (1.9) 
 Never screened 
(n=992) 
512 (51.6) 40 (4.0) 54 (5.4) 103 (10.4) 195 (19.7) 13 (1.3) 75 (7.6) 
Total (n=1712) 733 (42.8) 84 (4.9) 91 (5.3) 214 (12.5) 477 (27.9) 24 (1.4) 89 (5.2) 
MCHC = maternal and child health clinic, WWC = well women’s clinic, HKFPA = Hong Kong Family Planning Association,  
DH = Department of Health, FPC = Family planning clinic 
 
 
Action to reduce risk of cervical cancer 
Practitioners were asked whether a range of behaviours, in their opinion, could reduce 
the risk of cervical cancer. These were compared with women‟s perceptions of factors 
that would reduce risk. In the women‟s survey, this was an open-ended question and 
only 18% (n= 320) of women suggested any activities that they believed would 
reduce risk (Table 75).  
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Table 75: Protective behaviours mentioned by women and proportion of 
practitioners who believe these behaviours would reduce risk of cervical cancer 
 Number (%) who believe/ mention this  
 Practitioners (n=334) Women (n=320) 
Behaviours where there is reasonable evidence for protection against cervical cancer 
Reduce number of sexual partners 249 (74.6) 61 (19.4) 
Reduce smoking 168 (50.3) 18 (5.7) 
Use condom 232 (69.5) 7 (2.2) 
Medical advice on disease and prevention 195 (58.4) 30 (9.5) 
Behaviours where there is no good evidence for protection against cervical cancer 
Reduce intake of carcinogenic food 84 (25.1) 23 (7.3) 
More exercise / personal hygiene & diet 37 (11.1) 202 (64.1) 
Reduce stress 48 (14.4) 
Reduce alcohol intake 24 (7.4) 8 (2.5) 
Take Chinese medicines 15 (4.5) 7 (2.2) 
Others 8 (2.4) 36 (11.4) 
 
 
Among factors where there is some evidence of benefit, only three quarters of all 
practitioners thought that reducing the number of sexual partners would be effective, 
and over two thirds (69.5%) recommended the use of condoms. Half thought smoking 
reduction was useful and 58.4% thought that seeking medical advice to understand 
more about the disease would be beneficial. In addition, practitioners thought that 
many other factors, where there is no clear research evidence of benefit, would be 
useful for reducing risk. These included diet, exercise and use of Chinese medicines. 
Among women, the most commonly mentioned activity was doing more exercise and 
paying attention to personal hygiene. Reducing the number of sexual partners was 
mentioned by 19% of those responding to this section, and only 5.7% mentioned 
smoking as a risk factor (almost exclusively non-smokers). 
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4.6 Discussion 
Hong Kong has a mixed medical economy and in the absence of any centralised 
screening programme, there was previously no comprehensive documentation of the 
range and type of services provided for cervical screening. This is the first study to 
describe the diversity of providers and to explore the variation in the way screening is 
administered and provided.  
There is great variation in the way that cervical screening is currently provided, both 
between different organisations, and within specific provider groups. There is no 
consensus on who should be offered screening, the recommended screening interval, 
administrative arrangements (waiting times, charge, method of informing women of 
results) or on how to deal with abnormal smears. One of the features of organised 
screening programmes is the agreement of guidelines related to these issues.  
4.6.1 Providers of screening services 
Responders to the practitioner survey were almost exclusively doctors. This may be 
because the study failed to access non-medical screeners. However, the findings agree 
with anecdotal evidence that non-medical personnel are rarely involved in cervical 
screening in Hong Kong. In other countries, nurses have a greater role in smear taking 
in primary care
250
. In Birmingham, UK (see chapter 6), 61% of smear takers were 
nurses, and in Sweden, nurse-midwives have responsibility for smear taking in 
primary care
251
. There is some evidence that involvement of nurses in smear taking 
reduces the cost of the service
252; 253
. Nurses can be successfully trained to take 
cervical smears and their performance is at least as good as doctors in this respect
253; 
254
.  
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However, having the doctor as the smear taker seems to be important for attendance 
for some women. A trial in the UK which compared different invitation letters for 
screening, found that those signed by a doctor resulted in significantly higher 
attendance, than those signed by non-medical personnel
255
. We found that although 
the majority of women did state a preference for a doctor to take smears, those who 
had no prior experience of the system were more likely to accept a nurse. Thus the 
stated preference is likely to be partly influenced by current practice. Also, 
practitioners underestimated women‟s acceptance of a non-medical practitioner taking 
smears. Almost all women, whether they had previously been screened or not, 
preferred a woman as smear taker, and most (>80%) preferred not to know the 
practitioner. Therefore it would seem that having a nurse practitioner taking smears 
would be socially acceptable for at least a proportion of women. Other studies have 
examined women‟s preference for providers of cervical screening. As in the study, 
most suggested that women prefer a female smear taker
244; 256
. Non-availability of a 
female smear-taker has been shown to be one of the reasons for non-attendance for 
screening among women
242
. A survey of 500 women belonging to a Health 
Maintenance Organisation in the USA found that over half had no preference for the 
gender of the clinician taking smears, and almost half was happy to see an unfamiliar 
clinician
257
. In that study, about three quarters of women also were happy to see a 
nurse practitioner rather than a doctor. A much smaller study in the UK, found that 
the most popular choice of health professional for taking the test was a nurse
258
. 
4.6.2 Cervical screening practice 
The age range for which screening is provided in Hong Kong varies according to 
provider. Whilst most of the private providers have no age limit, most of the 
government funded providers do set a limit. In regions with organised screening 
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programmes, the target group for screening and recommended screening interval is 
usually defined. However, there is no consensus on these issues. The age at which 
screening is recommended to start varies, from 18
259
, 20, 23, 25 through to 30 years
260
 
in most developed countries. In general, international experts suggest that screening 
should start at around 30 – 35 years of age261. Although most guidelines recommend a 
screening interval of 3 years, this also varies between countries, from one yearly 
through to 5-yearly
260
. The most common screening interval recommended by 
practitioners in our study was yearly, and fewer than 5% of women thought that a 
screening interval of 3 years or longer was appropriate. This has implications for costs 
and resource use, as well as for increasing anxiety generated as a result of abnormal 
tests.  
4.6.3 Management of abnormal smears 
According to the recommendations from the NHS cervical screening programme
262
, 
patients with their first occurrence of mild dyskaryosis should be managed with a 
repeat smear within 6 months. Anyone with moderate or severe dyskaryosis, or with 
mild dyskaryosis on repeat smear, should be referred and have colposcopy. The 
Canadian National Workshop on cervical screening provided the same 
recommendation for management
259
. A consensus conference of international experts 
in the field, held in 1999, also considered management and concluded with similar 
recommendations
261
. The question used in the study did not make it clear that the test 
results referred to a woman having a first abnormal Pap smear, though this was 
inferred. From the survey, O&G specialists are likely to manage patients more 
invasively than the current guidelines recommend, whilst other specialists are likely to 
be too conservative and not refer women when it would be advisable to do so. In one 
study in the US, researchers examined women‟s own preferences for the management 
Provider survey 
-168- 
of mildly abnormal smears. Among the 136 women with first mildly abnormal smear 
result, the majority preferred an active management strategy (colposcopy and biopsy) 
rather than a passive approach (repeat smear)
263
.  
4.6.4 Comparison of practitioners and women’s perceptions of factors influencing 
screening uptake 
Both women and practitioners cited lack of knowledge or awareness of the need for 
screening as reasons for non-attendance. These have also been shown to be major 
barriers in other studies 
192; 220; 221
.  However, it was found that over a third of women 
who had not attended for screening did not attribute this to either of these factors. The 
questions asked to women and to practitioners were worded slightly differently, 
though they explored the same themes. Women were asked whether they agreed or 
disagreed with certain statements related to screening, whereas providers were asked 
whether they believed each of the factors would encourage or discourage women from 
attending. In terms of planning and encouraging uptake, it is therefore important for 
providers to recognise all potential barriers cited by women. Practitioners were 
generally aware of the role of negative emotional factors, such as anxiety, 
embarrassment and pain associated with the test, in deterring women. However, over 
half did not recognise perceived high cost, lack of time and anxiety related to the 
results as barriers. In relation to the main reason for non-attendance, practitioners 
overestimated the role of anxiety related to the test, embarrassment and pain as 
deterrents. On the other hand, they tended to underestimate the importance of anxiety 
related to test results and the time needed to attend for a test as barriers. 
Few studies have previously examined practitioners‟ views of perceived barriers to 
cervical screening and compared these with women‟s views. One such study in South 
Africa, found that health workers tended to identify structural problems, such as a 
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busy clinic and accessibility as major barriers, whilst women mainly emphasised the 
screening procedure and their understanding of it as barriers
264
. Another study, used 
focus group methodology, to explore perceived barriers among 520 health care 
personnel in the USA
265
. The main barriers perceived by these professionals included 
structural factors (cost, transport, child care, time) emotional factors associated with 
the test (fear, discomfort, embarrassment) and women‟s lack of awareness of the need 
for the test.  
It was found that most women who had previously been screened, and a high 
proportion of practitioners, believed primary care practices to be an appropriate 
setting for screening. Other studies also confirmed this finding
230
, although a hospital 
setting has also been shown to be acceptable
266
.  
4.6.5 Knowledge and beliefs about actions to reduce cervical cancer incidence 
Almost three quarters of all practitioners and one in five women responders 
recognised the importance of sexual activity as a risk factor for cervical cancer. 
However, relatively few recognised smoking as a risk factor, including half the 
practitioners. On the other hand, both practitioners and women mentioned several 
other general health protective measures that are not necessarily related to cervical 
cancer risk, as means of reducing an individual‟s cervical cancer risk. In particular, a 
quarter of practitioners mentioned diet, and almost two thirds of women and a quarter 
of the practitioners mentioned exercise and stress reduction.  
Few studies have previously examined beliefs about cervical cancer risk factors. A 
survey of 72 women in the UK, using a mixture of open and closed ended questions, 
showed that women were aware of sexual activity as a risk factor, particularly among 
younger women
258
. There is no clear agreement on dietary risk factors for cervical 
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cancer. Some studies have suggested low folate as a risk factor, though the evidence 
remains uncertain for this cancer
267
. A high level of serum carotenoids
83; 268; 269
 and 
vitamin C levels
83
 have been shown to be associated with a lower risk of cervical 
lesions in some studies, suggesting that fruit and vegetable consumption may be 
protective.  Another case control study showed that high dietary intake of green-
yellow vegetables was associated with lower rates of cervical cancer, particularly 
among older women 
270
. However, these findings are not confirmed in other studies
89
. 
Exercise and stress reduction are considered to be avoidable risk factors for cancer in 
general, though not specific to cervical cancer
271
. Alcohol consumption, similarly, has 
not been shown to be a risk factor for cervical cancer
270; 272
. 
4.7 Conclusions and implications  
There is much diversity in the way that cervical screening services are provided in 
Hong Kong. The lack of central co-ordination and uniform guidelines are apparent 
from the variability in how often, to whom and how screening is offered, both within 
and between types of service providers. There is also no clear consensus on how 
abnormal smears should be managed. There is some agreement between practitioners 
and women on what the main barriers and promoters of screening are. Nevertheless, 
practitioners need to be more sensitive to the economic and time constraints related to 
screening attendance, and the anxiety related to screening results.  
 
Practitioners play an important role in encouraging screening uptake, and should play 
an active part in promoting appropriate screening. An organised screening programme 
would require consensus to be formed among providers for some of the above issues, 
and for a more consistent message to be given to women regarding health behaviours 
to prevent cervical cancer, and how often they should attend for screening.
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5 MONITORING THE NHS CERVICAL SCREENING 
PROGRAMME – AN EXPLORATORY INVESTIGATION, 
USING INADEQUATE SMEAR RATES AS AN EXAMPLE OF 
A QUALITY INDICATOR  
 
5.1 Summary 
The aim of this study was to demonstrate the use of statistical process control in 
monitoring, using inadequate smear rates as an indicator of quality. 
Methods 
Routine data on inadequate smear rates by general practice were obtained for a 15-
month period for Birmingham. For each practice, the quarterly rates were plotted 
using control charts, and these rates compared with the average from all practices. 
Practices with persistently high or persistently low inadequate rates were identified 
and contacted. A telephone interview was conducted with the practice staff in charge 
of cervical screening in each of these practices. They were asked about the 
characteristics of smear takers in the practice, including the average number of smears 
taken by each smear-taker and their training, their use of protocols or guidelines and 
the laboratory used by the practice. Practices with higher rates were compared with 
those with lower rates to identify any factors that may be contributing to the observed 
variation. 
Results 
Information on inadequate smear rates was available for 237 practices, of which 29 
had persistently low and 8 persistently high rates. The only significant difference 
between the two type of practice was the laboratories they used for analysing smears, 
suggesting that most of the variation was due to differences in laboratory 
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interpretation. In addition, there was some evidence that practices with higher volume 
smear takers, those where staff had attended for training and where protocols were 
used, were more likely to have lower inadequate rates. 
Conclusions 
The study demonstrates an efficient and useful method of monitoring quality, as a 
basis for quality improvement. Further research is needed to see whether adoption of 
the strategies identified in this study by all practices would result in quality 
improvement. 
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5.2 Introduction 
The success of a screening programme in reducing the incidence and mortality from 
cervical cancer depends on several factors. In previous chapters, the importance of 
identifying the target population, ensuring high coverage and selecting an appropriate 
screening interval were emphasised and discussed. However, as reviewed in chapter 
1, the organisation of the programme and implementation of quality control measures 
also contribute to the effectiveness and success of the programme. These include 
ensuring competency of smear takers, having a system for ensuring compliance with, 
and adequate provision for, follow-up and treatment, and quality assurance systems 
within cytology laboratories. An integral aspect of quality control is measurement and 
monitoring. The European Commission developed a set of guidelines for quality 
assurance in cervical cancer screening, which consider all the issues mentioned 
above
273
. These guidelines list parameters to be measured for monitoring and suggest 
targets for programmes. One of the short term measures for monitoring described in 
the guidelines, is the proportion of smears that are inadequate. These are cytology 
smears that are of poor quality and cannot be used by the pathologist.  This chapter, 
will review the methods and principles of quality control and quality improvement, 
focusing on one particular technique; statistical process control (SPC), and will 
demonstrate the use of SPC, by applying it to monitoring of inadequate smear rates 
among different GP practices in Birmingham, UK.  
5.2.1 Implications of inadequate smears 
Inadequate smears are important for several reasons. Given that they are sometimes 
related to underlying pathology, their misinterpretation can contribute to false 
negative results 
274-276
. A study in one region in the UK, estimated that 18% of deaths 
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due to cervical cancer were attributed to inadequate smears
277
. Another audit of deaths 
from cervical cancer over a 2-year period in a district in England, found that 8% of 
such deaths were related to women with previously inadequate smears
278
. On the 
other hand, the majority (over three quarters) of women with persistently inadequate 
smears have a normal outcome at colposcopy
279; 280
. In the UK, women with 3 
consecutive inadequate smears are recommended for referral to colposcopy. Around 
three per 1,000 women screened fall into this category
279
, and there is some evidence 
that the proportion of inadequate smears is increasing
280
.  Therefore minimising the 
rates could contribute substantially to reducing unnecessary colposcopy. This would 
prevent needless anxiety and inconvenience for the women involved and avoid 
excessive waste of NHS resources
281
. 
5.2.2 Inadequate smear rates as a measure of quality within the NHS 
Within the NHS cervical screening programme (NHSCSP), national quality assurance 
guidelines were published in 1996
282
. One aspect of quality assurance is the 
competency of the smear taker and of the laboratory that evaluates the smear. Several 
other authorities recommend audit of inadequate smear rates as a quality control 
measure of smear takers‟ competence273; 283; 284. Inadequate smear rates have also been 
suggested, and used as a performance indicator for general practice
285
. The NHSCSP 
has advised an indicative range for inadequate smears of 7.0± 2.0%
262; 286
. The system 
of quality assurance is co-ordinated and led regionally, and until recently, monitoring 
of the programme was done at health authority level.  
 Inadequate smear rates, like other indicators of performance at health authority level, 
are determined by the combined performance of individual units where smears are 
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taken. Quality control requires standardisation of procedures at all units, so that 
performance monitoring and review should be carried out at this level.  
In the UK, the government outlined a three-part approach to quality improvement for 
health services, in a document called “First class service”, published in 1998287. 
Monitoring and performance assessment are central to this. Consequently, the 
government publish annual data on all hospital trusts, based on agreed measures of 
quality. The aim of this exercise was to ensure that “where there are large and 
unexplained variations in performance, every effort is made to find out why, and work 
is put in train to bring about an early improvement.”288 The traditional approach to 
identifying such variation has been through use of league tables. However, this 
approach has been met with much criticism and resistance, in part, justifiably
289
. 
League tables produce a static snapshot of performance, and ranking of individual 
units is mainly by chance. They contribute to a blame culture, focusing on apparent 
poor performers, rather than taking a systems approach to quality improvement. The 
method is often seen as a way of allocating rewards and punishment. An alternative 
approach to monitoring quality, derived from industrial quality management science 
is the use of statistical process control and control charts
289
.   
5.2.3 Quality improvement methods and principles 
Continuous quality improvement techniques, mainly derived from industry, are 
increasingly being applied to health care
290-292
. These techniques, often referred to as 
total quality management (TQM), are derived from a range of disciplines, including 
statistics, engineering and psychology
292
. Quality improvement models typically use a 
problem solving approach, such as the one in Figure 16. 
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Figure 16: Example of quality improvement model 
 
 
 
  
 
 
 
 
 
 
 
 
Adapted from Plsek
292
 
 
These models are based on the work of the statistician Deming and management 
scientists such as Shewhart and Juran. Juran, a leading expert in the field of quality
292
, 
likened the steps in industrial quality improvement to the scientific method of clinical 
decision-making. He used terms such as “diagnostic journey” and “remedial journey” 
to describe steps 4 to 6, and 7 respectively, in Figure 16. Measurement of 
performance is an integral part of the quality management sciences. Measurement 
provides the feedback loop to allow performance to be maintained at a set level 
(quality control and assurance) and signals the need for change (quality improvement) 
292
.  
5.2.4 Use of statistical process control for quality improvement 
Statistical process control (SPC) was developed in the 1920s as a way of reducing 
defects in the process of manufacturing telephones 
293
. It is a methodology using basic 
graphical and statistical tools to analyse, control and reduce variation within a 
process. This technique has been used to monitor process improvement in industry for 
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many years, and more recently is being applied to health care
294; 295
. It is based on the 
recognition that the outputs of even the most perfectly tuned production system 
inevitably show some variation. This means that even under ideal conditions, similar 
providers (e.g. practices, or individual nurses) will never match each other‟s 
performance exactly, or indeed their own performance from one month to the next.  
The purpose of any monitoring system is to sort out “signals” from background 
“noise”. In industry, it has long been known that most of the variation detected by a 
monitoring system results from “common causes”, which accounts for the noise in a 
stable system. These are factors that are an inherent part of any system or process, and 
affect everyone working in the system at all times. Changing the system cannot 
reduce the noise and must be avoided if the system is to remain stable
296
. On the other 
hand, some of the variation in a system results in a “signal” that a “special cause” is 
operating and its cause should be sought. These causes are not part of the process all 
of the time or do not affect everyone, but arise because of specific circumstances. 
Thus the cycle of quality improvement includes stabilisation of the process by 
identification and elimination of special causes, and then active improvement of the 
process by tackling the common causes of variation. 
5.2.5 Control charts  
One of the tools used in SPC is the control chart. This simple graphical method allows 
us to distinguish between the two sources of variation
297
. The technique allows 
performance data to be plotted, and for statistically derived upper and lower limits of 
common cause variation to be shown as control limits. Several different types of 
control chart are available, depending on the data collected. In general, a control chart 
consists of at least 5 lines (Figure 17), including the mean line, and lines indicating 2 
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and 3 standard deviations (sigma, ) above and below the mean line. The lines 3- 
above and 3- below the mean are called the upper and lower control limits (UCL and 
LCL) respectively.  
 
Figure 17: Basic structure of a control chart 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
In a stable system, all performance measures would be expected to fall within the 3 
control limits. Thus variation that falls within these limits ( in Figure 17) is due to 
common causes. Any unit with a performance measure outside of these limits ( in 
Figure 17) is demonstrating special cause variation. Such units act as signals of 
adverse or positive factors that may be contributing to process variation and thus 
influencing the process outcome. When all special causes have been identified and 
addressed, the system will move to stability. In this state, the only way to improve 
performance is to make a fundamental change to the system (Figure 18). Lessons 
learnt from units showing special cause variation may sometimes be applied to all 
other units, allowing the whole system to improve. This systems approach to quality 
improvement, by reducing variation in quality, avoids focusing on individual 
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components (e.g. individual hospitals, or clinicians), instead encouraging quality 
improvement across all units. 
Figure 18: Approach to quality improvement using control charts  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
(Adapted from Nolan et al
298
) 
 
5.2.6 Inadequate smears as a process 
A process can be defined as a set of causes and conditions that repeatedly come 
together to transform inputs into outcomes
298
. The inputs may include people, 
information or materials. Smear taking can therefore be seen as a process, an outcome 
of which may be an inadequate result; an outcome we want to minimise. To obtain a 
cytology smear competently, the smear taker must ensure that the cervix is fully 
visualised and that sampling includes the whole of the area called the transformation 
zone
299
. Inadequate smears may be attributed to poor smear-taker technique, for 
example by inadequate sampling of material, incompetence in spreading or fixation of 
the smear on a glass slide, or inadequate storage and transfer of specimens
280
. Around 
half to 70% of inadequate smears are attributable to the smear taker
279
. In this case, 
inadequate smear rates can be a useful outcome measure of clinicians‟ competence 
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and technique
299
 and used for quality improvement purposes. Other reasons for 
inadequate smears include excess red or white blood cells in the sample, which may 
be due to cervical pathology (infection or malignancy) 
280
 or physiological changes, 
such as cervical atrophy, pregnancy or use of the oral contraceptive pill
273
. The 
laboratory is also an important potential source of inadequate smear reports.  
Interpretation of smear inadequacy is subjective, and varies from laboratory to 
laboratory
300; 301
.  
The process contributing to inadequate smears therefore includes characteristics of the 
woman‟s cervix, the ability and technique of the smear taker, the organisation within 
the practice to store and transfer slides and the policies and practices of the laboratory 
that analyses them (Figure 19).  
 
Figure 19: The process of smear taking in relation to inadequate results 
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5.2.7 Application of SPC to this study: 
In this study control charts were used to measure inadequate smear rates among GP 
practices in Birmingham, to see if all practices were performing within expected 
control limits. A priori, would have been to expect all GP practices to be part of the 
same system, as components of the NHS cervical screening programme. All were 
NHS practices and had the same regional co-ordinator for screening. Practice 
remuneration for screening is under the same scheme and the same group of NHS 
laboratories, with prescribed quality assurance methods and guideline. There are 
national guidelines for cervical screening and a number of approved training 
programmes. Nevertheless, from a review of the literature, several steps in the process 
of smear taking can contribute to inadequate smears, not all of which are likely to be 
strictly controlled.  Therefore it was sought to identify any practices with performance 
indicating a special cause. The aim was to formulate hypotheses about causal factors 
contributing to unusually lower or higher inadequate smear rates. In the quality 
control model shown in Figure 16, this study follows steps 2 through to 6. 
5.3 Aims and objectives: 
The questions addressed by this study were: 
1) Are all GP practices in Birmingham that performed cervical screening part of 
a system that is in statistical control, in relation to inadequate smear rates? 
2) Are there any practices where a special cause may be operating, leading to 
unusually high or low inadequate rates? 
3) What steps and procedures in the process of smear taking within practices may 
be contributing to special cause variations in inadequate smear rates? 
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4) Is there any evidence to support differences in practice procedures 
contributing to any observed variation?  
 
This study demonstrates the use of control charts in measurement and data analysis, 
and discusses how the information obtained can be used for quality improvement.  
5.4 Methods: 
Routinely published data was obtained on screening within all 238 GP practices in the 
Birmingham area from the Birmingham Health Authority database.  Control charts 
were then used to identify practices whose performance indicated special cause 
variation. All these practices were contacted and interviewed, using a structured 
questionnaire. External factors were sought to be identified that may have contributed 
to special cause variation.   
5.4.1 Inadequate smear rates 
Information on inadequate smear rates by practice has been available at health 
authority level since January 2000. This data is published on a quarterly basis, and we 
obtained data based on 5 quarters (January 2000 to March 2001). This data was 
obtained through the KC53 returns
240
 kept at the Health Authority. These are forms 
that were first introduced at the start of the cervical screening programme in the UK, 
in 1988. The forms are required to be completed as part of the Department of Health‟s 
monitoring of the NHS cervical screening programme. The data come from patient 
information held on the cytology database of each health authority and provide 
information on screening coverage and the outcomes of screening. This is a fairly 
reliable and accurate system, providing good quality data. 
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5.4.2 Statistical Process Control Chart 
The calculation and plotting of control charts was based on the work done by 
Shewhart
302
. The data on inadequate smear rates for 5 quarters for each practice was 
entered onto a spreadsheet (Excel).  
In the case of inadequate smear rates, where the outcome variable is binary, a 
variation on the „P‟-chart was used.  First data was used from all quarters in all 
practices, weighted by the number of smears done at each practice, to obtain a 
weighted mean inadequate rate. This determines the mean line for the control chart. 
Control limits for the rate were also calculated based on the aggregated data.  These 
were based on the calculation of standard deviation for proportions, according to 
binomial theory. The control chart is plotted with the proportion of inadequate smears 
on the y-axis and the total number of smears taken on the x-axis (Figure 20).  A 
control chart was plotted for each practice individually, using the data from each 
quarter separately.  
Figure 20: Example of control chart, based on a typical practice 
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5.4.3 Signals of special cause variation 
A set of rules was developed for detecting the presence of special cause variation on 
the control charts. Those practices where the inadequate rates were either above or 
UCL (+3) 
LCL (-3) 
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below the mean for all 5 quarters, or for 4 quarters with at least one measure outside 
the 2 level, were identified. This finding would rarely be seen by chance, the 
likelihood being less than once in 120 occasions. In a minority of practices, relatively 
few smears were taken overall, and there were extremes of variation in inadequate 
rates. In these cases, practices were categorised separately as no meaningful analysis 
could be performed on a quarterly basis. Each chart was reviewed by myself and 
another colleague independently, and we then compared our results for consistency. 
In the few cases where there were discrepancies, the chart in question was retrieved 
and discussed, and consensus was obtained. All practices were then divided into four 
categories: 
1. Practices with persistently low inadequate rates (Figure 21) 
2. Practices with persistently high inadequate rates (Figure 22) 
3. Practices taking so few smears, that interpretation of performance was not 
possible (Figure 23) 
4. All other practices (Figure 20) 
 
Figure 21: Example of practice with persistently low inadequate smear rates 
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Figure 22: Example of practice with persistently high inadequate smear rates 
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Figure 23: Example of practice with too few smears to analyse 
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5.4.4 Study questionnaire for practices with special cause variation 
All practices contacted were categorised as those with persistently high or low 
inadequate rates and interviewed them based on a short structured questionnaire 
(Appendix 34). The questionnaire contained 6 questions and covered aspects related 
to the number and type of staff involved in smear taking, whether they had attended 
any training courses, use of protocols or guidelines and whether the practice had taken 
part in any audits of cervical screening in the past five years.  Also asked was which 
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Practice 22 
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laboratory was used by the practice for analysing cervical smears. The questions were 
based on the process involved in obtaining an adequate smear (Figure 18). In addition, 
Birmingham Health Authority supplied data on practice cervical screening coverage, 
Townsend score (an indicator of deprivation), list size, and childhood immunisation 
coverage (as an indication of practice organisation) on all practices. 
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5.5 Results: 
Information on inadequate smear rates was available for all quarters for 237 of the 
practices (99.6%) in Birmingham. The mean rate of inadequate smears, pooled over 
the 5-quarters was 12.4%. However there was wide variation between practices, with 
the inadequate rates ranging from 2.2% to 28.1% (Figure 24). The proportion of 
inadequate smears varied in each quarter, ranging by practice from zero to 50%. 
Figure 24: Percentage of smears reported as inadequate by practice (January 2000–
March 01) 
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The quarterly pooled inadequate rate varied little, ranging from 11.2 to 14.2% (Figure 
25).   
 
Figure 25: Variation in mean inadequate rates over five quarters among practices 
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Overall, 37 practices demonstrated special cause variation which was further 
investigated. There were 8 (3.4%) practices identified with persistently high and 29 
(12.2%) with persistently low rates of inadequate smears. In addition, 15 practices 
(6.3%) took very few smears and demonstrated extreme variation in inadequate rates.  
 
A comparison of practices according to their inadequate smear rates is presented in 
Table 76. In general, practices that took very few smears differed from others in 
several respects. Compared with all other practices, they had lower screening 
coverage and tended to be situated in more deprived areas. Practice list size was also 
generally smaller than other practices.  However childhood immunisation rates were 
similar to other practices. 
 
Table 76: Variation in practice characteristics according to cytology inadequate rates 
 Mean (range) for each category of GP practice 
 Persistently low 
inadequate rates 
(n=29) 
Persistently high 
inadequate rates 
(n=8) 
Too few smears  
(n=15) 
All other practices 
(n=185) 
Total number of 
smears  
308 (44 – 1,169) 498 (109 - 857) 52 (12 - 134)  352 (28 – 1557) 
Cervical screening 
coverage (%) 
82 (66 - 99) 84 (74 - 89) 71 (21 – 93) 81 (27 – 95) 
Childhood 
immunisation rates 
(%) 
92 (0 - 100) 81 (0 - 98) 95 (75 – 100) 92 (0 – 100) 
Townsend score* -0.24 (-8.20 to 3.80) -3.11 (-5.50 to -0.30) 3.14 (-1.90 to 5.90) -0.03 (-11.4 to 5.70) 
Practice list size 4,080 (1,141 – 10,647) 4,823 (1,581 – 8,116) 2,702 (779 – 5,008)  4,853 (848 – 24,090) 
*Positive score represents higher level of deprivation 
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5.5.1 Comparison between practices with persistently high or low inadequate 
rates 
Additional data collected on these selected practices was compared in the two groups. 
The laboratory used by practices for analysis of their smears was first compared. 
Other areas of comparison included the characteristics of the practice, as a measure of 
practice organisation, characteristics of the smear takers, and the recorded use of 
quality improvement techniques (guidelines and clinical audit) within practices.  
5.5.2 Laboratory used for analysis of smear 
The most important factor differentiating the two groups of practices was the 
laboratory they used for analysing cervical smears (Table 77). Practices using Good 
Hope Hospital were significantly more likely to be in the persistently high inadequate 
rate group, compared with practices using other laboratories. Nevertheless, there were 
two practices with persistently low inadequate rates also using Good Hope Hospital. 
All practices interviewed that used the City or Heartlands Hospital had persistently 
low inadequate rates. 
 
Table 77: Comparison of practices in relation to the laboratory used for cervical 
cytology 
Laboratory used for cytology Persistently low 
inadequate rate 
Persistently high 
inadequate rate 
Difference 
between groups 
- Heartlands Hospital 
- Birmingham Women‟s Hospital 
- Good Hope Hospital 
- City Hospital 
4 (13.8) 
17 (60.5) 
2 (6.9) 
6 (18.8) 
0 
4 (50.0) 
4 (50.0) 
0 
 
χ2 =10.0 
p = 0.04 
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5.5.3 Practice characteristics: 
Relevant data was not available for one of each category of practice. Practices with 
high inadequate rates tended to be situated in less deprived areas (Table 78).  
However, there was a significant relationship between practice deprivation scores and 
the laboratory used for screening. Practices using Good Hope Hospital were generally 
least deprived, whilst those using Heartlands were most deprived. Practices with high 
inadequate rates also tended to have lower screening coverage and lower 
immunisation rates. These practices also were more likely to have either a very large 
or very small list size, whilst the majority of those with low inadequate rates had 
average sized lists. 
5.5.4 Characteristics of smear takers 
In terms of staff, practices with persistently low inadequate rates tended to have a 
higher proportion of regular (at least once a week) smear takers (Table 79). 
Subsequently, each smear taker in these practices takes more smears on average than 
practices with high inadequate rates. Smear takers in the former practices were more 
likely to be nurses, and to have had specific training. There was high correlation 
between the proportion of nurses in a practice and the proportion who had been 
through training (Pearson‟s r = 0.74, p<0.001).   
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Table 78: Characteristics of practices with persistently high or low inadequate rates 
Practice characteristic Persistently low 
inadequate rate 
(n=28) 
Persistently high 
inadequate rate 
(n=7) 
Difference 
between groups 
Townsend score 
- Lowest deprivation (≤-2.01) 
- Low deprivation (-2.0 to 0) 
- Some deprivation (0.01 to 3.5) 
- Most deprived (≥3.51) 
 
8 (28.6) 
5 (17.9) 
13 (46.4) 
2 (7.1) 
 
5 (71.4) 
2 (28.6) 
0 
0 
 
χ2 for trend = 6.1 
p = 0.014 
Screening coverage 
- <70% 
- 70.1 – 80% 
- 80.1 – 90% 
- >90% 
 
1 (3.6) 
11 (39.3) 
14 (50.0) 
2 (7.1) 
 
0 
1 (14.3) 
6 (85.7) 
0 
 
χ2 for trend = 0.9 
p = 0.35 
Immunisation rate 
- <60% 
- 70.1 – 80% 
- 80.1 – 90% 
- >90% 
 
1 (3.6) 
1 (3.6) 
3 (10.7) 
23 (82.1) 
 
1 (14.3) 
- 
1 (14.3) 
5 (71.4) 
 
χ2 for trend = 0.9 
p = 0.35 
Practice list size 
- <2000 
- 2001 – 6000 
- >6000 
 
3 (10.7) 
21 (75.0) 
4 (14.3) 
 
1 (14.3) 
4 (57.2) 
2 (28.6) 
 
χ2 for trend = 0.2 
p = 0.64 
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Table 79: Characteristics of smear takers in practices with persistently high or low 
inadequate rates 
Characteristics of smear takers Persistently low 
inadequate rate 
(n=29) 
Persistently high 
inadequate rate 
(n=8) 
Difference 
between groups 
% Smear takers taking smears regularly 72.13* 67.81* p = 0.73 
- ≤50 
- 50.1 – 80 
- ≥80.1 
9 (31.0) 
6 (20.7) 
14 (48.3) 
3 (37.5) 
2 (25.0) 
3 (37.5) 
χ2 for trend = 0.2 
p = 0.63 
Number of smear takers/ 1000 smears 10.86* 9.33* p = 0.63 
- ≤5 
- 5.1 – 10 
- ≥10.1 
8 (28.6) 
12 (42.9) 
8 (28.6) 
3 (42.9) 
3 (42.9) 
1 (14.3) 
χ2 for trend = 0.8 
p = 0.38 
% Smear takers that are nurses 
- ≤25 
- 25.1 – 50 
- ≥50.1  
59.93 
8 (27.6) 
7 (24.1) 
14 (48.3) 
51.77 
2 (25.0) 
4 (50.0) 
2 (25.0) 
P = 0.56 
χ2 for trend = 0.4 
p = 0.53 
% Smear takers that had training 56.79* 41.98* 0.31 
- Up to one third 
- One to two thirds 
- > Two thirds 
8 (27.6) 
7 (24.1) 
14 (48.3) 
2 (25.0) 
4 (50.0) 
2 (25.0) 
χ2 for trend = 0.4 
p = 0.53 
Type of training 
- None 
- Marie Curie 
- Palm 
- Other 
 
4 (13.8) 
7 (24.1) 
12 (41.4) 
6 (20.7) 
 
1 (12.5) 
3 (37.5) 
3 (37.5) 
1 (12.5) 
 
χ2 =0.9 
p = 0.92 
Values are number (%), except for values marked *, where the mean is presented 
 
Amongst the training courses, the most commonly attended was the “Palm” training 
course, followed by the Marie Curie Cancer Care training course, whilst others either 
did not specify what training they had (n=3), or mentioned training in family planning 
(n=2) or through the Health Authority (n=2). Although there was no significant 
association between training courses and inadequate rates, a higher proportion of 
practices with staff attending the Palm training course tended to have low inadequate 
rates compared with practices where staff attended other training courses. We did not 
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ask for detailed information on training. However, briefly, the Palm training course 
consists of some theory, visits to the cytology laboratories and a colposcopy clinic, 
and taking a certain number of smears under supervision. The Marie Curie course 
covers breast and cervical screening. For the cervical screening aspect, it includes 
theory and supervised smear taking, but no laboratory or clinic visits. Not all practices 
responded to the question on when staff attended training and there was no clear 
relationship between type of practice and how recently staff had been on a course. 
5.5.5 Use of quality improvement techniques 
In general, practices with persistently high inadequate rates tended to report using 
protocols or guidelines for smear taking, though there was no statistically significant 
difference (Table 80).  
Table 80: Use of protocols and guidelines, and participation in audit among practices 
with persistently high or low inadequate rates 
Practice characteristic Persistently low 
inadequate rate 
Persistently high 
inadequate rate 
Difference 
between groups 
Use of protocols or guidelines for 
cervical screening 
21 (72.4) 7 (87.5) χ2 =0.8 
p = 0.38 
Type of protocol/ guidelines used 
- None 
- Vague description 
- Practice developed 
- Named recognised guideline 
 
8 (27.6) 
3 (10.3) 
13 (44.8) 
5 (17.2) 
 
1 (12.5) 
3 (37.5) 
3 (37.5) 
1 (12.5) 
 
 
χ2 = 3.6 
p = 0.31 
Undertaken audit of cervical screening 7 (24.1) 3 (37.5) χ2 =0.6 
p = 0.45 
Undertaken audit of inadequate smears 3 (10.3) 1 (12.5) χ2 =0.03 
p = 0.86 
 
However, practices with persistently low rates tended to specify a named protocol or 
to have developed their own practice guideline. There was a tendency for more 
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practices with persistently high inadequate rates to have undertaken audit of cervical 
screening, and of inadequate smears in particular.  
5.5.6 Predictors of persistently high inadequate rates  
A logistic regression model was developed to examine characteristics related to 
persistently high or low inadequate rates, adjusting for other factors (Table 81). In the 
adjusted model, being a practice with persistently high inadequate rates was 
associated with using Good Hope Hospital, having no protocol or guideline for 
screening, having more low volume smear takers, having taken part in audit of 
cervical cytology and having fewer staff trained in screening. None of these factors 
were statistically significant, apart from the laboratory used. However, the confidence 
intervals for all odds ratios were very wide, suggesting that the lack of statistical 
significance was related to the small sample size. 
Table 81: Factors associated with having a persistently high inadequate rate, based on 
logistic regression 
 
Characteristic OR (95% CI) for having 
persistently high inadequate rates 
P value 
Laboratory used for cytology analysis 
- Good Hope Hospital 
- Heartlands 
- Women‟s  
- City  
 
1.00 
<0.01 (<0.001 to 6x10
48
) 
0.01 (<0.001 to 1.05) 
<0.01 (<0.001 to 1x10
47
) 
 
 
0.81 
0.05 
0.79 
Type of guideline or protocol used for cervical screening 
- None 
- Vague 
- Practice developed 
- Named recognised guideline 
 
1.00  
0.08 (<0.001 to 20.33) 
0.01 (<0.001 to 4.95) 
<0.01 (<0.001 to 18.07) 
 
 
0.37 
0.16 
0.18 
Increasing proportion of staff attended for training 0.98 (0.94 to 1.01) 0.18 
Increasing number of smear takers / 1000 smears done 1.19 (0.93 – 1.53) 0.16 
Taken part in cervical screening audit in past year 82.52 (0.31 to 21,791) 0.11 
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5.6 Discussion 
5.6.1 Summary of findings  
This is the first study demonstrating the use control charts in identifying variations in 
the processes of care, in relation to cervical smear taking and inadequate smear rates. 
We identified practices with persistently high or low inadequate rates and compared 
them in relation to general characteristics and modifiable processes contributing to 
smear quality. Because of the small number of practices, particularly those with high 
inadequate rates, most comparisons were not statistically significant. Nevertheless 
there were some important trends that may suggest strategies for quality 
improvement. The only significant difference between the two types of practice was 
the laboratory they used, suggesting that much of the variation in inadequate rates was 
due to differences in laboratory interpretation. However, even within laboratories 
there was some variation in practice inadequate rates. The findings suggest that 
inadequate rates may be reduced by rearrangements of staff, organisation and training 
within practices. Practices where smear takers take a higher volume of smears and do 
so on a regular basis were more likely to have low inadequate rates. These practices 
also tended to be more likely to have nurses being involved in smear taking, and for 
the nurses to have had specific training in cytology techniques. They were more likely 
to have guidelines or protocols for screening, particularly ones adapted for the 
practice or those developed by a recognised source. Participation in audit of cervical 
screening in the past year was generally low, but more common among practices with 
high inadequate rates.  Because of the cross-sectional design of our study, we cannot 
assess whether this was in fact a consequence of their high inadequate rates. 
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5.6.2 Use of quality improvement methods for reducing inadequate cervical 
smears 
TQM methods have been previously used for improving the quality of cervical 
smears. A project in the USA used various industrial management tools to examine 
the role of methods used for collecting cervical smears, in relation to inadequate 
smears
303
. The team identified the collection method as a key factor, and 
demonstrated that after introducing the use of a combined smear collection method 
(spatula and Cytobrush) inadequate smear rates fell from around 25% to 10% in their 
region. However, the focus of that study was the link between individual smear results 
and the collection method used, rather than the more global approach we used with 
primary care practices as the unit of analysis. In another US study, quality assurance 
methods were used to increase adequate smear rates from 82 to 91%
304; 305
. This 
improvement was mainly attributed to monitoring and feedback of performance to 
individual clinicians. However, none of these studies had used control charts as the 
main tool for quality improvement. 
5.6.3 Use of control charts for quality improvement 
Application of control chart technology for improving health care has been 
demonstrated in several clinical disciplines. This includes the use of control charts for 
monitoring and guiding asthma care
306-308
, in monitoring and reducing mortality 
among trauma and intensive care unit patients in hospital
309; 310
, for surveillance of 
infectious diseases
311
 and in reducing peri- and post-operative adverse events
312; 313
. 
These methods have also been used to improve the quality of operational and 
administrative arrangements 
314; 315
, and to monitor quality indicators
316
in clinical 
settings. In addition, the Joint Commission on Accreditation of Health Care 
Organizations (JCAHO)
317
, a major independent organization for standard setting and 
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accrediting body in the USA, uses control charts as one of its tools for measuring 
clinical performance of health care organizations. 
5.6.4 Implications of this study for practice 
There is some evidence that inadequate smear rates in the UK are increasing
240; 280
. 
One review to investigate the reasons for this rising trend, suggests that the main 
reason was deterioration in the quality of smears received
279
. Therefore attempts to 
improve quality can contribute to reversing this trend, in addition to reducing 
unnecessary anxiety among women and saving resource costs for the NHS.  
Use of control charts provides an efficient means for developing hypotheses for care 
processes that affect quality. In this study only a relatively small number of practices 
whose performance signalled special cause variation needed to be approached for our 
questionnaire. This meant that the information obtained could be maximised by 
targeting those with extremes of performance, whilst minimising the time spent by 
practices and ourselves. The results of the study can be used to form hypotheses about 
factors that may be affecting quality and to develop a strategy for quality 
improvement. The approach avoids practices being stigmatised for their performance, 
instead allowing a systems approach to be taken in improving quality across all 
practices. After confirming which factors contribute to special cause variation, the 
lessons learnt can be applied to all practices, irrespective of their current performance. 
The results of this study have implications for laboratories involved in analysing 
smears. Practices using one particular laboratory were more likely to have high 
inadequate rates. Introduction of external quality assurance for laboratories, by the 
NHS cervical screening programme, has been shown to reduce inadequate smear 
reporting among participating practices
318
. Another study comparing assessment in 
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different laboratories found fairly high reproducibility of assessment among those 
who strictly followed the Bethesda System criteria
319
. A review of the external quality 
assurance system of the laboratories involved would therefore seem reasonable. In the 
UK, if the smear is considered inadequate, the laboratory is required to differentiate 
between those where the cause is attributable to the smear-taker, and others. It would 
therefore be useful to assess the proportion of inadequate results that are attributable 
to the smear-taker in each laboratory.  
In addition, pursuing the other strategies suggested by this study could improve the 
system and reduce overall inadequate rates. Practices where a higher proportion of 
smear takers had specific training tended to have lower inadequate rates. Thus 
training seems to be an important contributor to smear quality. A study in the US 
showed a negative linear relationship between clinician experience (measured by 
years of practice) and inadequate rates
320
. Physicians with more years of experience in 
smear taking had the lowest inadequate rates, suggesting a role for increased training. 
Several studies have reported on systems for providing feedback to clinicians 
regarding their individual or group cervical cytology inadequate rates
299; 305; 321; 322
. 
One of these studies, based in the US, showed that such feedback alone led to a 
sustained improvement in the quality of cervical smears
305
. In other studies, a 
programme of training or update training was arranged as part of the audit.  
No previous study has specifically examined the relationship between use of 
guidelines or protocols for smear-taking and inadequate smear rates. However 
systematic reviews of the effects of introducing guidelines in general, have shown 
beneficial effects on the process of care 
323
, but minimal effect on clinical outcomes in 
primary care
324
. This study showed that practices with high inadequate rates were less 
likely to have guidelines or protocols for smear taking, suggesting that their use may 
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reduce inadequate rates. However, having guidelines may also be an indicator of other 
practice characteristics and organisation. It is not known whether having guidelines 
per se would contribute to quality improvement. 
5.6.5 Statistical control and clinical control  
Control charts examined show whether a system is in statistical control. That is, 
where the system seems free of special causes. When special cause variations are 
found, identifying and altering the process can bring the system back in control. 
However, statistical control is not the same as clinical control and it does not mean 
that a system is organised or implemented in an optimal manner. It would be of little 
use to have a controlled system, where the lower or upper control limits are 
considered clinically unacceptable. In this case, intervention should be aimed at 
altering the entire system. For example, in one study where control charts were used 
to monitor asthma care for individual patients
306, one patient‟s daily peak flow 
readings all fell within control limits over 14 days. This suggested that no special 
events had occurred in her process of care, or the environment that she was exposed 
to. However, the lower control limit based on her readings, was well below what 
would be considered clinically safe.  The intervention in this case was therefore to 
change her treatment plan. On the other hand, another patient‟s control chart showed a 
special cause signal, where her peak flow readings were persistently above the control 
limits for a period of 4 days in the middle of the 14 day observation. On further 
enquiry, this observation was related to a period when she had visited a relative and 
been away from her home environment and pets. Thus use of control charts allowed 
both special cause variation and poor clinical management to be identified.  
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In this study, the mean inadequate rate for all practices (12.4%) is above the upper 
level of the indicative range suggested by the NHSCSP (9%).  For the period 
1999/2000 in England, out of 4.3 million smear tests, 9.8%were inadequate, with a 
range of 4% to 20.0% 
240. The upper 3σ limit on the control chart is 25% or higher for 
practices taking fewer than 100 smears per quarter (about two thirds of all practices). 
This is clearly not an acceptable level for inadequate smear rates, and implies that a 
systems approach is required to improve the quality of smears in all practices.  It was 
found that practices where few smears were taken were not easy to monitor. 
Furthermore, practices with lower volume smear takers, or those with fewer staff 
taking smears on a regular basis, tended to have higher inadequate rates. This suggests 
that encouraging a few practices or practitioners to take more smears, rather than 
allowing all to take a few, would be a better strategy for quality improvement. This is 
supported by a study of 4,000 cervical smears in Israel, which found a direct 
relationship between the volume of smears taken by an individual and their 
inadequate rates
325
. In that study, 90% of the inadequate smears (rate of 16.5% 
overall) were attributed to clinician error, and the findings suggested a threshold for 
the minimum number of smears to minimise inadequate rates. This association 
between high volume of work and better outcomes has been shown in several clinical 
specialties, particularly surgery. Improving the system could also be achieved by 
applying more widely any interventions found to reduce special cause variation. 
5.6.6 Methodological issues 
The use of control charts in health care is still relatively new, and there are some 
methodological issues that need to be considered
326
. The assumption that GP practices 
in Birmingham were all part of a single “system” in relation to smear taking may have 
been incorrect. If, for example, single-handed GP practices followed a different 
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system to other practices, the two types of practices would have had to be plotted on 
different charts. A priori, there was no reason to believe that there would be different 
types of practice, and they therefore were analysed all together.  
There are also many different type of control chart, depending on the data collected. 
Outliers based on their pattern of performance over five quarters were chosen to be 
identified. On the other hand, a single control chart could have been plotted for all 
practices, comparing the inadequate rates over the total time period. This would have 
allowed practices based on a larger number of smears to be examined and reduced the 
range of common cause variation one would have expected. However, this latter 
approach would have ignored information based on variation over time.  This 
approach allowed real time data to be used as it would normally be generated, and 
would be a useful way of monitoring practices in the longer term. Practices were 
identified with rates persistently above or below the average, but where the 
aggregated average would not have reached outside the control limits.  
A pragmatic rule was used for identifying special cause variation. Other rules for 
detecting special cause variation do exist. The original rules set by Shewhart, were to 
take action when data fall outside of the 3σ limit327. Another statistician suggested 
additional signals, including 9 successive points on one side of the central line, or 6 
points rising or falling in sequence. Another often quoted rule is based on eight 
signals of special cause variation (Figure 26)
306
. None of these rules are necessarily 
always right
327
. The different rules increase the sensitivity of the control chart in 
detecting signals, whilst at the same time increasing the proportion of “false alarms” 
of detecting a signal, when there is no special cause variation.  
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Figure 26: The 8 signals of special cause variation 
1 point above 3σ 
2 or 3 points above 2σ 
4 or 5 points above 1σ 
8 points in a row above the mean 
8 points in a row below the mean  
4 or 5 points below 1σ 
2 or 3 points below 2σ 
1 point below 3σ 
 
Given that there were only five data points per practice, the rules were a variation of 
those mentioned above. Nevertheless,  practices may have been mistakenly identified 
as signalling special cause variation, or missed some, where a special cause did in fact 
exist.  
Another drawback to this approach was that because of the small number of practices 
interviewed, the results were necessarily descriptive, without demonstrating statistical 
significance. There are also potential problems with the method used for identifying 
outliers. Practice inadequate rates are based on an aggregate of performance by 
different smear takers in the practice. This has been shown to mask variation in 
inadequate rates between smear takers within a single practice
299
. Therefore it could 
be argued that individual smear-takers whose techniques need improving may have 
been missed. However, the systems approach is concerned with identifying processes 
and practices that could be applied across all units, irrespective of their current 
performance. The method does not replace the need for audit of individual smear-
takers, which could be done within practices, so that interventions such as training 
could be targeted.  
Having identified outliers, information was obtained from practices based on self-
report.  Information was not verified for attendance of training and use of guidelines 
+3σ 
+2σ 
+1σ 
-1σ 
-2σ 
-3σ 
Mean 
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or protocols. However, practices where such information was vague, or they could not 
give the name of the training course or guidelines used were differentiated from 
others.  It was not known  whether smear-takers in practices reported owning a 
guideline, or actually using them. One study which explored the extent to which 
Dutch GPs adhered to guidelines on cervical cancer screening, including those related 
to the organisation of smear taking, found poor adherence
328
. 
Finally, modifiable steps may have been missed in the process of smear taking that 
could have given rise to variation. In retrospect, a key question that could have been 
addressed, would have been the method of specimen collection used in practices
303
. 
5.6.7 Conclusions and recommendations 
This study demonstrates an efficient and useful method of monitoring quality, as a 
basis for a programme of quality improvement. A number of modifiable factors have 
been identified, which could be introduced across practices to improve the quality of 
smears taken. Most of the factors identified are supported by previous research 
findings. Nevertheless, further research is needed to see whether feedback of the 
findings to practices does lead to changes in procedures and practice. Also there is a 
need to assess whether implementation of the changes recommended by this study 
lead to continuous quality improvement, using a system of audit. 
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6 A RANDOMISED CONTROLLED TRIAL OF THE EFFECT 
OF EVIDENCE BASED INFORMATION ON WOMEN’S 
WILLINGNESS TO PARTICIPATE IN SCREENING 
6.1 Summary 
The aim of this study was to assess whether providing women with additional 
information on the pros and cons of screening, compared with information currently 
offered by the NHS, affects their intention to attend for screening.  
Methods 
This was a randomised controlled trial. Participants were randomly assigned to 
receive either the control, (based on an NHS Cervical Screening Programme leaflet 
currently used), or the intervention leaflet (containing additional information on risks 
and uncertainties). Participants were selected from three general practices in 
Birmingham and the aim was to include 300 women aged 20 to 64 attending the 
practices during a one-month period. The main outcome measure was intention to 
attend for screening. 
Results 
283 women (94.3%) completed the study. Fewer women in the intervention (79%) 
than the control group (88%) expressed an intention to have screening after reading 
the information leaflet (difference between groups 9.2%, 95% confidence interval 
(CI) 3.2% to 21.7%). The crude odds ratio (OR) and 95% CI was 0.50 (0.26 – 0.97). 
After adjusting for other factors, the trend persisted (OR 0.60, 95% CI 0.28 – 1.29). 
Having a previous Pap smear was the only significant predictor of intention to have 
screening (adjusted OR 2.54, 95% CI 1.03 to 6.21). Subgroup analysis showed no 
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intervention effect on intended uptake between women at higher and lower risk of 
cervical cancer (p=0.59). 
Conclusions  
Providing women with evidence-based information on the risks, uncertainties and the 
benefits of screening, is unlikely to deter many, including those at higher risk, from 
undergoing screening.  
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6.2 Introduction 
Most researchers agree that organised population screening has contributed to a 
reduction in the incidence and mortality from invasive cervical cancer
5; 329; 330
. It has 
been estimated that about 800
331
 cases in England and 1,300 cases in England and 
Wales
330
 per year are prevented as a result of screening. However, this has been 
achieved at high cost. Approximately 3.8 million women in England had a cervical 
screening test in the year 1999-2000. 
240
, at a cost of £132 million to the NHS, or £34 
per patient screened 
332
. Each year, about 10% of women have an inadequate smear, 
which needs to be repeated. Of the remainder, between 7% and 8% have an abnormal 
result
17; 240
 and overall about 3% are referred for colposcopy
17
. The number of 
abnormalities detected and referrals for colposcopy far exceed the number of invasive 
malignancies that could be prevented
17
.  A woman with average risk for cervical 
cancer (less than one in 10,000), and who has seven pap smears during her lifetime, 
has a one in two chance of having an abnormal test result
17; 240
, and one in five chance 
of having colposcopy
17
. Furthermore, the test has a false negative rate, estimated by 
some studies to be around 15 to 25%
20
. For every one woman whose life is saved by 
the screening programme, over 300 women are called back for further tests, and about 
54 would have a colposcopy.  Over 10 years, between one and seven women per 
10,000 (depending on their age) will live longer as a result of cervical screening
333
.  
Many people misunderstand the purpose of screening and the accuracy of screening 
tests
334
. In a survey of 300 women attending a colposcopy clinic following an 
abnormal smear result, 42% reported that the smear taker had not discussed the reason 
for having a cervical smear with them, and almost three quarters of had not been told 
that the test is not 100% accurate
335
. The purpose of information given on cervical 
screening has tended to be to increase coverage, rather than to promote informed 
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choice
336
. The NHS Cervical Screening Programme (NHSCSP) and Cancer Research 
Campaign have jointly produced an information leaflet, and this, or something 
similar, is sent to all women with their first invitation for cervical screening 
337
. 
Whilst leaflets are an important source of patient information
338
, current leaflets on 
cervical screening have been criticised for over-emphasising the benefits of 
interventions, and rarely mentioning the risks and side-effects 
339
. Such 
overestimation of the benefits of screening prevents women from making an informed 
choice, and may contribute to accusations of negligence when screening has 
“failed”340. The General Medical Council in the UK has issued guidance on informed 
choice for all medical procedures, including screening
341
 and has outlined what 
information should be given. This includes information on the purpose of screening, 
the likelihood of positive and negative findings and the possibility of false positive/ 
negative results, the uncertainties and risks attached to the screening process, any 
significant medical, social or financial implications of screening, and follow up plans.  
The importance of providing full information and getting informed consent for 
cervical screening has been highlighted in recent years 
342
, 
343
, 
344
, 
333
. In its report of 
the first 5 years of the programme in 1994, the NHSCSP acknowledged that women 
were less aware of the limitations of screening than its benefits, but did not feel that 
addressing this problem was a priority 
345
. There may be several reasons for this 
reluctance. Firstly paternalistic attitudes within part of the medical community 
promote the idea that patients cannot cope with bad news or uncertainties
338
. 
Secondly, within the NHS, health professionals (GPs) are financially rewarded for 
achieving targets for high screening coverage, rather than on the quality of 
information that they give 
339; 346
. It is therefore not in their interest to give women 
more information, if it may discourage them from attending 
347
 and result in their 
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losing their target payments. A less cynical view is that if a high proportion of women 
are discouraged from attending, the programme would fail to have a significant 
population impact on reducing cervical cancer incidence and mortality. Thus there is a 
tension between achieving high coverage, and promoting informed choice, if this 
results in individuals choosing not to undertake screening
348
. All these arguments 
assume that providing more information will affect screening uptake. No previous 
study has assessed whether giving women more information on cervical screening 
would have an effect on screening coverage, particularly among those at higher risk. 
In this study, the main objective was to estimate the effect on expressed uptake, of 
providing more information on the risks and uncertainties associated with cervical 
screening, compared with the information previously provided by the NHS
337
. A 
secondary objective was to examine the effects of any difference in intended uptake 
between women at higher and lower risk for cervical cancer.  
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6.3 Methods: 
6.3.1 Study design and population 
The study was a randomised controlled trial undertaken at three general practices in 
Birmingham.  
Three members of the team (medical students) made visits to the participating 
practices on several occasions between April and May 2001. Women between the 
ages of 20 and 64 attending the practices for any reason were invited to participate in 
the study.  Participants were given a questionnaire (Appendix 35) together with either 
the control, or intervention information leaflet, at the end of which they were asked to 
indicate whether they would be willing to attend for screening.  
Permission for the trial was obtained from South Birmingham Research Ethics 
Committee and all participants were provided with information on the study before 
being asked to give written consent.  
6.3.2 Intervention 
We devised two types of information leaflet on screening. The first (the control 
leaflet) was based on the NHSCSP leaflet
337
, which women received when they were 
first invited for cervical screening. This includes information on: 
 the preventive nature of screening,  
 the purpose of the test in detecting pre-cancer,  
 what the test involved,  
 who it was for,  
 the screening interval,  
 choice of venue for the test,  
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 how results would be obtained,  
 possible reasons for further tests and 
 what to expect if the results were abnormal 
In addition the leaflet briefly mentions that screening is not 100% perfect. 
The other (the intervention leaflet), in addition to this, contained information on the 
absolute individual risk for cervical cancer, likelihood of positive and negative 
findings, the possibility of false positive/ negative results, the uncertainties attached to 
the screening process, the absolute benefit associated with screening and the cost of 
the process to the NHS (Appendix 6). 
 
As the NHS cervical screening programme is now well established, and in order to 
gain the co-operation of participating practices with minimal disruption, all reference 
to “cervical” cancer, “cervical” screening or “smear test” were removed from the 
leaflets. Nevertheless, all the facts presented were related to cervical screening and 
referred to “a cancer” affecting women, and “a screening test”.  
 
6.3.3 Protocol and random assignment 
A structured questionnaire was developed and piloted on 20 women.  A computer-
generated list of random numbers, was used to sequence questionnaires to contain 
either the control or intervention leaflet. Participating general practices were visited 
on several occasions between April and May 2001 and questionnaires were 
distributed in random order. Both patients and those distributing questionnaires were 
blinded as to which information sheet was received. Participants were asked to leave 
completed questionnaires with the reception before leaving the practice.  
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6.3.4 Outcome measures 
The main outcome measure was expressed willingness to have the “study screening 
test”. In addition, women were asked whether they thought the Government should set 
up a national programme using this test, irrespective of whether they would attend.  
 
6.3.5 Other measures 
The structured questionnaire was piloted on approximately 20 women before being 
used in the study.  Information was collected on socio-demographic factors (including 
age, marital status, social class and ethnicity), health related behaviours (including 
smoking, attendance for cervical screening and dental check ups) and whether they 
had any family or close friends with cancer. In addition, a risk score for cervical 
cancer was calculated, based on the woman‟s age, social class, and smoking status. 
The score increased with increasing age (20 – 35, 36 – 45, 46 – 64 years), lower social 
class (I & II, III, IV & V) and smoking status (never smoker, former smoker, current 
smoker). Those with scores below the median were labelled as “lower risk”, and the 
rest as “higher risk”.  
 
6.3.6 Sample size 
The 5-year uptake of cervical screening in the UK is estimated to be around 80%
240
. It 
was calculated that in order to detect a difference in intended uptake between groups 
of 15% or more with 95% confidence and 80% power, a minimal sample size of 276 
(138 in each group) was required.   
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6.3.7 Statistical analysis 
 The overall current uptake of cervical screening among the study population was 
assessed. The intended uptake of the study screening test among the intervention and 
control groups were then compared.  Bivariate analysis was used to compare those 
who intended to have screening, with those who did not, in terms of risk, socio-
demographic factors, other health related behaviours and whether they had personal 
contact with someone with cancer. Any characteristic that was associated with 
intended uptake at a level of significance of 10% or less was entered in a logistic 
regression model, to obtain an adjusted odds ratio for the intervention compared with 
the control group. Subgroup analysis was performed using interaction terms in the 
logistic regression model, to compare women at higher and lower risk of cervical 
cancer. All statistical analyses were performed with SPSS (version 10).  
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6.4 Results 
6.4.1 Participant flow and follow-up  
During the study period, about 7% of those approached (n =23/329) refused to 
participate, and were not given a questionnaire. Of the 300 questionnaires distributed 
to women who had given consent, 283 (94.3%) were returned; 141 (49.8%) from the 
control arm and 142 (50.2%) from the intervention arm (Figure 27). Overall, 43 
questionnaires (15.2%) were only partially completed and these were evenly 
distributed between the control and intervention groups. 
 
6.4.2 General description 
The mean age of responders was 39.4 years (range 20 to 64). A sizeable minority 
(17.3%) were non-Caucasian, reflecting the population in Birmingham and the 
practices participating in the study. There were no significant difference between 
control and intervention group in terms of age, health and health related behaviours, 
though there was a higher proportion of non-Caucasians in the intervention (23.0%) 
compared with the control (12.6%) group (Table 82). 
 
6.4.3 Characteristics of attendance for cervical screening  
A high proportion of responders (90.5%, n = 256) had attended for a Pap smear in the 
past, 71.4% (n=202) within the last 3 years, and 80.6% (n=228) within the last 5 
years. None of the socio-demographic or behavioural factors enquired about were 
significantly associated with having had a Pap smear within the last 5 years. 
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Figure 27: Flowchart of recruitment and participants in trial 
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Table 82: Comparison of intervention and control groups at baseline  
(Values are numbers and (percentages) unless otherwise stated) 
 Participant characteristics Control (n=141) Intervention (n=142) 
Socio-demographic characteristics 
Age*  39.3 (20 – 64) 39.5 (20 –64) 
Marital status 
Single / divorced / widowed 
Married / living with partner 
 
54 (39.1) 
84 (60.9) 
 
50 (36.0) 
89 (64.0) 
Social class 
I & II 
III 
IV & V 
 
35 (31.3) 
58 (51.8) 
19 (17.0) 
 
37 (32.7) 
60 (53.1) 
16 (14.2) 
Ethnicity 
Caucasian 
Non-Caucasian 
 
118 (87.4) 
17 (12.6) 
 
107 (77.0) 
32 (23.0) 
Personal contact with someone with cancer 
Having family or close friends with cancer  
Yes 
No 
 
64 (45.4) 
77 (54.6) 
 
57 (40.1) 
85 (59.9) 
Health related behaviour 
Pap smear within last 5 years 
Yes 
No 
 
110 (79.7) 
28 (20.3) 
 
118 (84.9) 
21 (15.1) 
Make regular visits to dentist 
Yes 
No 
 
120 (85.7) 
20 (14.3) 
 
117 (83.6)  
23 (16.4) 
Smoking status 
Never smoker 
Former smoker 
Current smoker 
 
68 (48.2) 
36 (25.5) 
37 (26.2) 
 
70 (49.3) 
41 (28.9) 
31 (21.8) 
Risk for cervical cancer 
Risk score*  
(based on age, social class and smoking status) 
5.5 (3 – 9) 5.4 (3 – 9) 
* Values are mean (range) 
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6.4.4 Intended uptake of screening test 
The majority of responders (229/274, 83.6%) expressed their willingness to attend for 
the study screening test.  However, those in the intervention group were significantly 
less likely to want the test (109/138, 79.0%) compared with the control group 
(120/136, 88.2%) [χ2 for difference between groups = 4.3; p=0.04] (Table 83).  
Table 83: Factors associated with current and intended uptake of screening  
 Intended screening uptake Pap smear within last 5 years 
Number (%)  OR (95% CI)  Number (%)  OR (95% CI)  
Information sheet 
Control 
Intervention  
 
120 (88.2) 
109 (79.0) 
 
2.00 (1.03 - 3.87)* 
 
110 (79.7) 
118 (84.9) 
 
0.70 (0.37 – 1.49) 
Dentist visits 
Regularly 
Not regularly 
 
198 (86.5) 
28   (66.7) 
 
3.19 (1.52 - 6.73)* 
 
194 (84.0) 
32 (74.4) 
 
1.80 (0.83 – 3.89) 
Family/friends with cancer 
Yes 
No 
 
102 (88.7) 
127 (79.9) 
 
1.98 (0.99 - 3.96) 
 
99 (81.8) 
129 (82.7) 
 
0.94 (0.51 – 1.75) 
Self-rated health status 
Very good/good 
Poor/very poor  
 
187 (83.1) 
39   (84.8) 
 
1.13 (0.47 – 2.72) 
 
186 (81.6) 
40 (87.0) 
 
1.50 (0.60 – 3.78) 
Marital status  
Married/ living with partner 
Single 
 
146 (85.4)  
83 (81.4) 
 
1.28 (0.67 – 2.46) 
 
144 (85.2) 
81 (79.4) 
 
1.49 (0.79 – 2.83) 
Social class 
I, II and III 
IV and V 
 
161 (85.2) 
26   (76.5) 
 
1.75 (0.73 – 4.35) 
 
160 (86.0) 
26 (74.3) 
 
2.13 (0.90 – 5.00) 
Smoking status 
Current smoker 
Current non-smoker 
 
55   (82.1) 
174 (84.1) 
 
0.87 (0.42 – 2.00) 
 
587 (86.6) 
170 (81.0) 
 
3.40 (0.69 – 3.33) 
Ethnicity  
Caucasian 
Non-Caucasian 
 
187 (83.9) 
39   (81.3) 
 
1.12 (0.53 - 2.69)  
 
184 (82.1) 
38 (86.4) 
 
0.72 (0.29 – 1.85) 
Risk            
Higher risk 
Lower risk  
 
93   (82.3)  
93   (85.3) 
 
0.80 (0.39 – 1.64) 
 
88  (79.3)  
97  (89.0) 
 
0.47 (0.22 – 1.01)* 
* p <0.05 
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Women who had previously attended for cervical screening were significantly more 
likely to say they would attend for the study screening test (OR 2.3, 95% CI 1.1 – 
4.8). Other factors associated with intention to take up the study screening test 
included attending regularly for dental check-ups (OR 3.19, 95% CI 1.52 - 6.73) and 
having close friends or family with cancer (OR 1.98, 95% CI 0.99 - 3.96).  
 
After adjusting for these other variables using logistic regression, exposure to the 
intervention leaflet was still associated with reduced expressed willingness to have the 
study screening test, but the association was no longer statistically significant (Table 
84).  Having had a Pap smear in the past was a significant predictor of intention to 
have screening. However, having more risk factors for cervical cancer was not related 
to screening intention. Repeating the logistic regression model with an interaction 
term between the intervention effect and level of risk showed no significant 
interaction (p=0.59).  
Table 84: Results of logistic regression model assessing the factors associated with 
women’s expressed intention to have the study screening test 
Intention to have study screening test Adjusted OR (95% CI)  Level of significance 
Exposure to intervention 0.60 (0.28 – 1.29) 0.191 
Previous Pap smear within last 5 years 2.54 (1.03 – 6.21) 0.042 
Regular dentist attendee 2.26 (0.96 – 5.29) 0.062 
Having family/friends with cancer 1.99 (0.89 - 4.48) 0.096 
Higher risk for cervical cancer  0.94 (0.44 - 2.02) 0.871 
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Overall 87.6% (240/274) thought the Government should set up a national screening 
programme, including 59% (n=26/44) of those who did not want to attend themselves.  
Those in the intervention group were less likely to think such a programme should be 
implemented compared with the control group, though the difference was not 
statistically significant (Table 85). 
 
Table 85: Expressed willingness to attend, and support for national screening 
programme, in control and intervention groups  
 % Control 
(n = 136) 
% Intervention 
(n = 138) 
Difference  
(95% CI) 
Unadjusted OR  
(95% CI) 
P value 
Expressed willingness to attend for screening 
 88.2 79.0 9.2 (3.2 – 21.7) 0.50 (0.26 – 0.97) 0.039 
Government should set up national screening programme 
 89.8 85.4 4.38 (-0.35 – 12.2) 1.50 (0.72 – 3.11) 0.273 
 
 
Clinical trial 
-219- 
6.5 Discussion 
Providing women with more information about the risks and uncertainties of 
screening, as well as the benefits, resulted in a small reduction in expressed 
willingness to attend for screening. However, even among women who were given 
more information, intended screening rates were nearly 80%. Furthermore, there was 
no evidence that providing women with more information adversely affected those at 
higher risk. 
 
6.5.1 Strengths and weaknesses of the study  
This is the first trial to assess the effect of giving evidence-based information on 
women‟s expressed willingness to attend for a screening test that is already well 
established. The 5-year coverage for screening within the study population was the 
same as that for Birmingham generally (80.6%)
240
 and this, together with the high 
response rate suggests that the samples were fairly representative of the target group.  
 
The study attempted to blind participants to what the study test was, and the condition 
to which screening referred. The aim was to limit interference with their current 
understanding and beliefs about the Pap smear. On the other hand, decisions may 
have differed had women known that we were referring to cervical screening. As in 
some other studies
349
,
350
 the principal outcome was expressed willingness to have 
screening, which may differ from actual attendance. This may partly explain the 
higher proportion of women who said they would attend, compared with those that 
currently have Pap smears. Knowledge could not be compared between the two 
groups, and could not directly infer that women in the intervention group had a better 
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understanding of the pros and cons of the test. Also, the sample size did not allow 
sufficient power to detect a difference in intended uptake of less than 15% between 
groups.  
 
6.5.2 Findings in relation to other studies 
A few studies have investigated the effects of offering different types of information 
on intended
350; 351
 or actual uptake
352; 353
 of screening. Providing more information 
increases knowledge and assists in decision-making
354
, but has an unpredictable effect 
on uptake
355
. In three studies assessing the effect of information giving on decisions to 
undergo screening for prostate cancer, two found that intervention reduced uptake, 
whilst in the other there was no effect
354
. In a study to assess willingness to undergo 
screening for pancreatic cancer, participants who were given extended information 
were significantly less likely to accept the test compared with those given basic 
information
350
. However, in a trial of women at low to moderate risk of breast cancer, 
better information had no effect on wanting to have genetic screening
352
.   Decisions 
on screening are not just influenced by the information provided, but also by other 
factors, such as values, cultural beliefs and personal experiences
355
. There was a 
tendency for women who had personal contact with someone with cancer to be more 
likely to want to undergo screening. 
 
6.5.3 Implications  
The GMC guidelines, the National Screening Committee and various researchers all 
emphasise the importance of informed decision making for people undergoing 
screening. In cervical screening where a programme is now well established, the 
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tension is between maintaining a high enough coverage, particularly among women at 
high risk, to have a population impact, and ensuring that women given informed 
consent. This study has shown that providing women with a more balanced and 
honest appraisal of the pros and cons of screening does not have a major impact on 
decisions to have the test. Furthermore, such information is not likely to differentially 
deter women at high risk. Fears that providing more information would make the 
programme unviable appear unfounded. 
 
6.5.4 Unanswered questions and future research  
The intervention leaflet offered evidence based information related to the topics 
emphasised by the GMC. However, it is not known whether this contained sufficient 
information for decision making and whether it included messages, that women who 
have been through the process themselves, would feel are important. Furthermore, 
although there is some evidence that the medium used to convey information has little 
effect on knowledge, understanding or decision making
355
, little is known about the 
most effective form of presentation. 
 
6.5.5 Conclusions  
The findings suggest that providing women with a more balanced appraisal of the 
pros and cons of screening, as well as being more ethical, would not have a major 
impact on uptake and would not adversely affect women at higher risk.  
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7 Concluding Remarks 
When considering screening, it is important to note that it is more than the application 
of a single test. Screening consists of a series of steps, from the identification of the 
population at risk, who are offered the initial test, through to the diagnosis of disease 
or its precursors in some individuals, and subsequent treatment. The principles
2; 3
 that 
need to be considered before setting up such a programme were briefly discussed in 
the introduction to this thesis and those related to the programme are outlined in box 
3. The studies reported here will now be discussed in relation to these principles and 
to issues that need to be considered by policy makers in Hong Kong before deciding 
on setting up a cervical screening programme.  
 
Box 3: Principles to be considered for a screening programme
3
  
 There should be evidence from high quality randomised controlled trials that 
the screening programme is effective in reducing mortality or morbidity. 
 There should be evidence that the complete screening programme (test, 
diagnostic procedures, treatment/ intervention) is clinically, socially and 
ethically acceptable to health professionals and the public. 
 The benefit from the screening programme should outweigh the physical and 
psychological harm (caused by the test, diagnostic procedures and treatment). 
 The opportunity cost of the screening programme (including testing, diagnosis 
and treatment) should be economically balanced in relation to expenditure on 
medical care as a whole. 
 There should be a plan for managing and monitoring the screening programme 
and an agreed set of quality assurance standards. 
 Adequate staffing and facilities for testing, diagnosis, treatment and 
programme management should be available prior to the commencement of 
the screening programme. 
 All other options for managing the condition should have been considered 
(e.g. improving treatment, providing other services). 
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7.1 Arguments for developing a screening programme 
In chapter 1, the epidemiology of cervical cancer was discussed. Based on this 
information, it is known that cervical cancer is an important health problem, 
particularly given the higher incidence rates in Hong Kong relative to many other 
countries. The disease has a recognisable pre-invasive stage that can be identified 
through application of a relatively simple test (cervical smear test). Treatment of this 
early stage has been shown to prevent progression to invasive disease, and evidence 
from countries with screening programmes suggests that both incidence and mortality 
can be reduced. In chapter 2, it was found that screening is also effective in the Hong 
Kong population, particularly in relation to squamous cell carcinomas. Therefore, the 
levels of benefit observed in other countries with organised screening programmes are 
likely to occur in this population as well.  
 
Uptake rates for screening in countries with an organised programme are high, 
suggesting that such a programme is acceptable to the population. However, in 
chapter 3 it showed that in Hong Kong a large proportion of women do not attend for 
cervical screening. Those who are being screened have lower risk, and are screened 
more frequently than necessary. Furthermore, the study reported in chapter 4 
demonstrated that currently there is great diversity in the way screening is provided, 
managed and organised in Hong Kong. An organised centrally co-ordinated screening 
programme would require a uniform plan for programme management and based on 
the model developed in chapter 3, it would have been expected to prevent more 
deaths, at a lower cost. It therefore seems reasonable to consider setting up such a 
programme. 
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7.2 Some considerations against a programme 
It is also important to consider the other principles suggested by Wilson and Jungner 
and the National Screening Committee in the UK. First, although much is known 
about the natural history of the disease, the nature of pre-invasive disease is not fully 
understood. The incidence of pre-invasive disease is far higher than expected, and the 
factors that result in progression and regression are not known. This has implications 
for how information is conveyed to participants in the screening programme. Many 
positive smears occur in women who, untreated, would not have progressed to 
developing invasive disease. This means that the programme generates unnecessary 
anxiety related to false positive results and there is a degree of waste in resources.  
 
There have been no randomised controlled trials to assess the effectiveness of cervical 
screening. Although the weight of evidence from observational studies is strong and 
convincing, it is likely that the magnitude of benefit achievable by a programme will 
be lower
138
. This will need to be taken into account when considering the economic 
benefits of a screening programme.   
 
It is also relevant that compared with other major health problems in the region – such 
as vascular disease, and cancers of the lung, breast and gastrointestinal system, the 
incidence of cervical cancer is relatively low. Therefore it is important to consider the 
opportunity cost of setting up a cervical screening programme against other 
interventions.  From a public health perspective, screening is only one contributor to 
reducing cancer deaths in the population. A study of the likely contribution of various 
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preventive interventions to overall cancer mortality reduction in the USA
356
, 
estimated that screening would contribute about 3% (Table 86). 
 
Table 86: Estimated cancer death reduction (all cancers) in USA by the year 2000 
Type of prevention Percentage reduction 
Diet 8 
Smoking reduction 8 – 15  
Improvements in treatment 10 – 26  
Screening 3 
Total 29 – 52 
Source: reference
356
 
 
Primary prevention measures should therefore be considered and implemented where 
possible. For example, given the important role of HPV in the aetiology of cervical 
cancer, effective health promotion interventions aimed at reducing other sexually 
transmitted diseases should contribute to reducing cancer incidence. Both active and 
passive smoking are also important risk factors for cervical cancer, particularly 
squamous carcinoma (as discussed in chapter 2). Smoking control and prevention 
interventions are therefore important for preventing this, as well as other smoking related 
diseases.  
 
7.2.1 Challenges to setting up an organised screening programme in Hong Kong 
7.2.2 Programme organisation 
The study of practitioners reported in chapter 4, shows the great range of current 
providers for screening, as well as diversity of screening arrangements and follow-up. 
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The first challenge to setting up an organised programme would therefore be 
standardisation of the various components in the system. Unless there are set criteria 
and guidelines for quality assurance and programme delivery, the programme and its 
effectiveness cannot be monitored. This would require consensus being reached on 
defining the target population, specification of the screening interval and quality 
assurance standards.  
 
There is no worldwide consensus on issues such as age at which screening should 
start and end or screening intervals
210
. In Hong Kong, the incidence of cervical cancer 
starts to rise from the mid-30‟s to a peak in the late 50‟s age group. However, 
incidence remains high well into the mid-70‟s. Given that pre-invasive lesions usually 
pre-date invasive disease by about 10 years, this suggests that screening should start 
in the 20‟s and continue at least to the late 60‟s. However, other considerations 
include the cost-effectiveness ratios of screening at different ages. For example, a 
study examining the effect of extending screening up to age 74 rather than 65, showed 
that this would result in a reduction in risk of death from cervical cancer by about 18 
in 10,000 and increase life expectancy by 3 days. This would be achieved at a 
marginal cost per life year of £52,241
100
.   
 
Similarly, screening intervals suggested in different programmes vary from yearly to 
5-yearly. In the UK, a review of the literature was undertaken to consider the effects 
of reducing the screening interval from 5- to 3-yearly
357
. The review concluded that 
the additional cost of 3-year policy would be £200,000 per year per 100,000 eligible 
women (1995 prices). This was equivalent to £143,000 per extra case prevented. In 
chapter 3, the effect of various policies on effectiveness and estimated efficiency are 
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discussed. In general, little would be gained by having a screening interval lower than 
3-yearly, and a 5-yearly programme would result in similar benefit at much lower 
cost.  
 
The telephone survey reported in chapter 3 suggests that women at highest risk of 
cervical cancer tend not to attend for screening. Lack of knowledge about screening 
was the main reason for non-attendance. Therefore another important challenge to 
setting up a screening programme is invitation of the target group for screening. In the 
absence of population registers and with the diversity of providers, this would require 
a combination of approaches including the use of the media and health care providers.  
 
Although uptake rates for screening are high in many countries with organised 
programmes, this is achieved by conveying information that emphasises the benefits 
of screening to the public. In chapter 6, the ethics of informed consent in screening 
was discussed. The pilot trial reported here suggests that providing more full 
information on the benefits and harms of screening may deter some women. However, 
a larger trial would be needed to assess the full impact on uptake. Also, more research 
is needed on they type of information and method of delivery that would enable 
participants to make an informed choice about participation.  
 
Another important consideration is the extent to which the current health care system 
would have the capacity to expand to allow a greater proportion of women to 
participate in the screening programme. Whilst facilities for screening may be found, 
resources required for analysing smears (timely reporting from laboratories), testing 
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and diagnosing those with abnormalities and treatment facilities should also be taken 
into account.  
 
7.2.3 Screening methods and management of abnormal smears 
The practitioner study also showed that there is no recognised basic training for smear 
takers, the equipment for taking smears varies and the type of labarotories involved in 
analysing smears are diverse.  Standardisation of procedures with the introduction of 
guidelines is therefore an important aspect of an organised programme. Given that 
practitioners and laboratories are in both the public and private sector, it would be 
reasonable to set up a system of accreditation for providers eligible to participate in 
the organised programme.   
 
Currently providers for screening services do not necessarily have a direct link with 
diagnostic and treatment services, to which women with abnormal smears would be 
referred. Most providers would be unaware of whether women identified with an 
abnormality actually attend for subsequent follow-up. Compliance is a key factor in 
determining the success of a screening programme, yet studies even in countries with 
organised programmes have shown that non-adherence following screening is not 
uncommon, and can be as high as 40%
17; 358; 359
. Therefore it is important to identify 
lines of responsibility to ensure follow-up and treatment of individuals identified with 
an abnormality through screening. There also needs to be an agreed policy on both the 
reporting of smear results, and the subsequent management plan. 
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7.2.4 Monitoring the programme and use of resources 
In chapter 6, one approach to monitoring was discussed. Use of TQM techniques is 
useful for monitoring and improving an organised programme. However, this requires 
agreed data collection procedures and a system for collating and analysing such data. 
Standards and targets for the programme would also have to be agreed in advance. 
These have to be carefully thought through, so as to reflect the screening process and 
be good indicators of screening effectiveness. For example, a target for coverage set 
in many countries, may be inappropriate if the emphasis of the programme is to offer 
informed choice. 
 
7.3 Conclusions 
The current system of screening in Hong Kong achieves poor coverage, is inequitable, 
wastes resources unnecessarily and may be resulting in more harm as a result of over-
screening low risk women. Introduction of an organised cervical screening 
programme could contribute to a reduction in mortality and morbidity from this 
important disease. However, this would be achieved at high initial and ongoing costs. 
Introducing such a programme would require commitment to adequate long term 
resources, and development of agreed policies for screening methods, programme 
organisation and monitoring. 
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Appendix 1: Questionnaires used for case control study and for cross-sectional study 
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 Appendix 2: Calculation of potential number of cases prevented by screening  
 
Firstly,  information was obtained regarding the average number of incident cases of 
cervical cancer observed per year (Oa) in Hong Kong for each age group (a), based on 
a 5-year average (from latest available period 1988-1992). For each age group (a), the 
average proportion reduction (Ra) for cumulative incidence was calculated as:  
Ra =  ∑ Sai * Ri 
where  Sai =  the proportion of women screened at each interval 
and   Ri =  the interval specific proportional reduction in incidence  
(from Table 21, assuming this to be the same for all age groups) 
 
For each age group, the number of new cases of cervical cancer expected if there were 
no screening (Ea) is then given by Ea = Oa / (1 - Ra) 
The potential number of cases prevented for each age group (Pa) is then: 
Pa = Ea - Oa 
The total number of cases potentially prevented (P) is given by: 
P = ∑ Pa 
 
For example, for a = 20 to 39 age group: 
Screening interval 
(months) 
(i) 
Proportion screened  
(Sai) 
Expected 
proportional 
reduction (Ri) 
 Number of cases 
/ year (1990-
1994) (Oa) 
0-11 0.280 0.935 72.5 
12-23 0.147 0.925  
24-35 0.046 0.908  
36-47 0.022 0.871  
48-71 0.024 0.836  
72-119 0.014 0.713  
120 0.000 0.641  
120+ 0.022 0.375  
Never 0.445 0  
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Ra =  ∑ Sai * Ri = 0.497 
Ea = Oa / (1 - Ra) = 146 
Therefore Pa = Ea - Oa = 73 
 
For estimating the interval-specific screening coverage in each age group, those that 
were included only had at least two previous screening tests, or women who had only 
one test, but intended to return for further screening. Women, who had only one 
screening test and were not intending to have any more, were assumed to have the 
same benefit as those who were screened over 10 years ago.  
 
Appendices 
-234- 
Appendix 3: Questionnaire used for practitioner study
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Appendix 4: Questionnaire used for practices with high or low inadequate smear rates
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Appendix 5: Questionnaire used for randomised controlled trial (chapter 6) 
 
First, we want to know something about your general health: 
1. In the recent months, do you think your health is: 
 Very good 
 Good 
 Poor 
 Very poor 
 
2. On average, how often do you visit your GP? 
 Weekly 
 Fortnightly 
 Monthly 
 Once every 3 months 
 Twice yearly 
 Yearly 
 Other, please specify . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
3. Do you visit your Dentist regularly? 
 Yes:  
 Every 6 months 
 Yearly 
 Other, please specify . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   
 
 No 
 
4. Do you smoke currently? 
 Yes 
 No 
If no, have you ever smoked? 
 Yes 
 No 
 
5. Have you had any major illnesses in the past 10 years or suffer from any chronic disease? 
 Yes 
 No 
 
If yes, please would you say: 
 
what the problem was/is . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
and approximately what year the problem first started . . . . . . . . . . . . . . . . . . . . . . . .   
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6. Has anyone in your family or among your close friends had any one of the following 
conditions? 
 Diabetes 
 Heart disease 
 Psychiatric disorders 
 Asthma 
 Epilepsy 
 Cancer, if so please specify what type . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . . .  
 
7. Have you ever had a smear (cervical smear) in your lifetime? 
 Yes 
Please state when the last test you had was: 
 Within the last 3 years 
 Within the last 5 years 
 More than 5 years ago 
 
 No 
Please state your main reason for not having the test: 
 I don‟t know what it‟s for 
 It‟s inconvenient to get to a clinic 
 The test is humiliating 
 The test will be painful 
 I don‟t have time to attend for a test 
 Other medical problems prevent me from going 
 I don‟t want to have a test 
 I‟m scared of what the test will show 
 Other reason, please specify . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
.   
8. Have you ever had a mammogram in your lifetime? 
 Yes 
Please state when the last test you had was: 
 Within the last 5 years 
 More than 5 years ago 
 
 No 
Please state your main reason for not having the test: 
 I‟m too young to have one 
 I don‟t know what it‟s for 
 It‟s inconvenient to get to a clinic 
 The test will be humiliating 
 The test will be painful 
 I don‟t have time to attend for a test 
 Other medical problems prevent me from going 
 I don‟t want to have a test 
 I‟m scared of what the test will show 
 Other reason, please specify . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
 
We would now like to give you some information about an important cancer in the UK, for which 
screening is possible. 
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We would now like to know; 
 
9. Given this information, do you think the Government should implement a National 
Programme for this condition? 
 Yes 
 No 
 Don‟t know 
 
10. Would you have the screening test yourself? 
 Yes  
 No  
 Don‟t know 
 
Finally, we would like some personal information about you.  We would be grateful if you would 
complete this last section of the questionnaire: 
11. Please would you write down how old you are now 
. . . . . . . . . . . . . . .  years old 
 
12. What is your marital status? 
 Single (never married) 
 Married or living with a partner 
 Separated or divorced 
 Widowed 
 
13. The main wage earner in the household is usually described as the head.  From this list 
below, please describe the occupation of the head of your household. (If presently retired or 
unemployed, please give information about the last job, or choose the ‘never worked’ box) 
Non-manual occupation: 
 Professional occupations (e.g. doctor, lawyer) 
 Managerial and lower professional (e.g. sales managers, teachers) 
 Non-manual skilled occupations (e.g. clerk, shop assistant) 
Manual occupations: 
 Skilled manual occupations (e.g. bricklayer, engineering trades) 
 Partly skilled manual occupations (e.g. farm worker, postman) 
 Unskilled occupation (e.g. general labourer, cleaner) 
Other: 
 Member of armed forces 
 Student 
 Never worked 
 Other: please briefly describe the occupation of the head of the household . . . . . . . . . . . . . . . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
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14. Which ethnic group best describes you? 
 White 
 Asian (including Indian, Bangladeshi, Pakistani) 
 Black (including Caribbean, African) 
 Chinese 
 Other, please specify . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . 
 
 
THANK YOU FOR YOUR HELP!                                            
            Please return this questionnaire to the receptionists before you leave the surgery. 
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Appendix 6: Information in intervention Leaflet 
Cancer Screening Test  
Introduction: 
We would like to tell you about a test that is now available to detect the early signs of cancer. The sign 
that cancer may develop can be spotted in advance, and it can be prevented even before the cancer has 
started.  
 
On average, around 10 out of every 100,000 (or 1500 women) die from this cancer in the UK each 
year. The risk is lower in younger women. Yet a quick, simple and painless test is available, that might 
have saved their lives. We would like to tell you more about this test. 
 
What is the test? 
The test can pick up abnormalities, which are the warning signs that cancer may develop if no 
treatment is given. As with all medical tests, this is not 100% perfect. There is approximately 10% 
chance that the test report will be normal, even when there is an abnormality. If you have any 
problems between tests, you should still consult your GP. 
 
The test takes a few minutes and is painless, although slight discomfort may be felt occasionally. You 
could have the test at your GP surgery, or at a family planning clinic. You will be asked to undress 
from the waist down, and the test involves a vaginal examination. 
 
What happens next? 
After the test you will be told how, where and approximately when you will get the results. Each time 
you have a test, there is a bout 7% chance that you will be called back for further tests. This may be 
because the test didn‟t show up clearly and another test is needed. In 3% of tests, slight changes are 
detected in the cells that were tested. In this case, the test result is abnormal.  
 
What happens if I have an abnormal result? 
You may be asked to have another test. Sometimes the abnormal changes return to normal by 
themselves. But if the repeat test still shows abnormal cells, you may need to have more extensive 
tests. You will be asked to go to a hospital for a closer examination and treatment. The treatment is a 
minor procedure done on an out-patient basis. 
 
Not all people with abnormal results actually have any disease – in fact about 2000 women will be 
recalled for further tests for every 1 woman who has early cancer. 
 
How often would I be tested? 
You are recommended to have the test at least once every 5 years, from when you are 20 years old. If 
you have the test regularly, the risk of you having this cancer will reduce to 1 per 100,000. 
 
What is the cost of this test? 
Each time you have a test, this will cost the NHS about £35. 
 
In summary, what are the benefits and possible problems of having this test for me? 
Your risk of dying from this cancer without the test is about 10 in a 100,000. Your risk is lower if you 
are younger (below 45 years old). By having the test regularly (at least every 5 years), you could 
reduce your chances of dying from this cancer to 1 in 100,000.  
 
However, every time you have a test, you have 7% chance of being called back, and 3% chance that the 
test shows an abnormality that needs more extensive assessment. To put it another way, if you have 7 
tests in your lifetime, you have a 1 in 2 chance that you will be called back, and 1 in 5 chance that you 
will need more tests at least once. If you are called back and need more tests, there is 1 in 2000 chance 
that you actually have serious disease that needed treatment.  
 
On the other hand, even if your test result is normal, you have 1 in 10 chance that you have an 
abnormality that wasn’t spotted by the test. 
Sections in italics are additional information that was not in the control leaflet. 
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Appendix 7: CONSORT details 
Paper section and 
topic 
Item Description 
TITLE & ABSTRACT  1 One of us (PA) prepared a computer-generated list of random numbers, which 
was used to sequence questionnaires to contain either the control or intervention 
leaflet. 
INTRODUCTION                  
        Background                         2
 
Scientific background and explanation of rationale- see paragraphs 1 and 2. 
METHODS                                 
   Participants                                                                                             3 Eligibility – women aged 20 to 64 (based on NHS cervical screening 
programme age criteria) who visited their GPs during a one-month period. 
Setting – 3 general practices in Birmingham 
   Interventions 4 Information in the control and intervention leaflets is attached 
Leaflets given out at randomisation within general practices, and read at the 
practice  
   Objectives 5 Specific objectives: to assess the effects of giving additional information on the 
pros and cons of screening on intended uptake  
   Outcomes 6 Outcome measures: 
- Primary – “expressed willingness to have screening test” 
   Sample size 7 How sample size was determined  
- Based on detecting a difference in intended uptake between groups of 15% or 
more  
   Randomisation          
Sequence generation 
 
8 Method used to generate the random allocation sequence – computer generated 
list of random numbers 
Allocation concealment 
 
9 Questionnaires were previously stacked in random sequence, and distributed in 
order, without researcher‟s knowledge of which had been assigned 
Implementation 10 The main author generated the allocation sequence, and the 3 last authors 
enrolled and assigned participants to their groups. 
   Blinding (masking)  11 Participants and those administering questionnaires were blinded to group 
assignment. 
 
   Statistical methods  12 Analysis: Bivariate analysis was used to compare intended screening in relation 
to other factors. Any characteristic that was associated with intended uptake at a 
level of significance of 10% or less was entered in a logistic regression model, 
to obtain an adjusted odds ratio for the intervention compared with the control 
group. All statistical analyses were performed with SPSS (version 10).  
RESULTS   
   Participant flow 13 Flow of participants through each stage – Figure 27 
   Recruitment 14 Dates defining the periods of recruitment – April to May 2001 
   Baseline data  15 Baseline demographic and clinical characteristics of each group. The two 
groups did not differ significantly in terms of sociodemographic factors (except 
ethnicity), past cervical screening history, smoking status and dentist visits. 
  Numbers analysed 16 Number of participants (denominator) in each group included in each analysis  
See report 
    Outcomes and 
estimation  
17 Odds ratios and 95% confidence intervals are stated where relevant. 
   Ancillary analyses  18 Subgroup analyses – none reported. 
   Adverse events  19 Adverse events – not relevant. 
DISCUSSION                             
  Interpretation                              20 Interpretation of the results, taking into account study hypotheses, sources of 
potential bias or imprecision: final two paragraphs. 
   Generalizability  21 Generalizability (external validity) of the trial findings: The 5-year coverage for 
screening within the study population was the same as that for Birmingham 
generally. However, the trial was based on women attending their GPs and 
would not be representative of those who do not visit their practice. 
   Overall evidence  22 General interpretation of the results in the context of current evidence: final two 
paragraphs. 
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